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Abstract 
Many of the challenges in supply chains have been traced to emanate from a misalignment between 
the type of product, together with its attributes, and the strategy according to which the supply chain 
of the product is managed. Several frameworks, incorporating a diverse set of product attributes, have 
been recommended to enable this alignment between product attributes and supply chain strategies 
in various sectors. The priorities that are typically pursued in public healthcare pharmaceutical supply 
chains, differ from those that are typically pursued in the commercial sector in a number of ways. 
Despite this, a structured search of literature did not uncover any framework that incorporates the 
distinct critical attributes to be used in describing product categorization in public healthcare 
pharmaceutical supply chains specifically.  
A review of literature on product categorization as it has been applied in various industries, indicates 
that it is reasonable to conclude that tailoring supply chain management practices and policies to the 
attributes of the products being supplied in the public healthcare pharmaceutical supply chain sector 
is likely to be beneficial. The South African National Department of Health is in the process of rolling 
out the Visibility and Analytics Network reference framework, with the aim of ensuring the sustained 
availability of and access to medicine. At present, the Visibility and Analytics Network strategy does 
not incorporate the product categorization concept. In this study, a product categorization framework 
is developed specifically for use in the contemporary South African public healthcare pharmaceutical 
supply chain. The framework is intended to provide guidance to supply chain managers on aligning 
pharmaceutical products with appropriate supply chain strategies, thereby formulating different 
supply pipelines in line with the relevant attributes of the products. 
It is envisioned that the framework will be used by the provincial supply chain managers in the 
Visibility and Analytics Network strategy informed push model as they: analyze and optimize 
complex links in the public healthcare pharmaceutical supply chain; and make inventory planning 
and management recommendations to primary healthcare facilities. The product categorization 
framework that is developed in this research is expected to aid in enhancing sustainable availability 
and access to medicines in the South African public healthcare supply chain.   
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Opsomming 
 
‘n Groot aantal van die uitdagings in voorsieningskettings ontstaan vanweë ‘n wanbelyning tussen 
die tipe produk, tesame met die eienskappe daarvan, en die strategie waarvolgens die 
voorsieningsketting van die produk bestuur word. Verskeie raamwerke, wat 'n uiteenlopende reeks 
produkeienskappe insluit, word aanbeveel om hierdie belyning tussen produkeienskappe en 
voorsieningskettingstrategieë in verskillende sektore te bewerkstellig. Die prioriteite wat tipies in 
farmaseutiese voorsieningskettings vir openbare gesondheidsorg nagestreef word, verskil van dié wat 
tipies in die kommersiële sektor nagestreef word. Ten spyte hiervan het 'n gestruktureerde 
literatuursoektog geen raamwerk ontbloot wat die onderskeie kritieke eienskappe bevat wat gebruik 
moet word om, spesifiek in openbare gesondheidsorgvoorsieningskettings vir farmaseutiese 
produkte, die kategorisering van produkte te bewerkstellig nie. 
'n Oorsig van die literatuur wat handel oor die toepassing van produk-kategorisering in verskillende 
industrieë, dui aan dat dit redelik is om tot die gevolgtrekking te kom dat hierdie praktyk ook in 
openbare gesondheidsorgvoorsieningskettings vir farmaseutiese produkte voordeel sal inhou. Die 
Suid-Afrikaanse Nasionale Departement van Gesondheid implementeer tans ‘n 
verwysingsraamwerk, naamlik die Sigbaarheid- en Analitiese Netwerk, wat ten doel het om 
volgehoue beskikbaarheid van- en toegang tot medisyne te verseker. Die produkkategorisering 
konsep word nie tans in hierdie verwysingsraamwerk ingesluit nie. In hierdie navorsing word 'n 
raamwerk vir produkkategorisering spesifiek ontwikkel vir gebruik in die kontemporêre Suid-
Afrikaanse openbare gesondheidsorgvoorsieningsketting vir farmaseutiese produkte. Die raamwerk 
is ontwerp om aan bestuurders in die voorsieningsketting leiding te gee oor hoe om toepaslike 
voorsieningskettingstrategieë, vir verskillende farmaseutiese produkte te identifiseer om sodoende 
verskillende aanbodpyplyne daar te stel, in ooreenstemming met die toepaslike eienskappe van die 
produkte. 
Daar word voorsien dat, binne die konteks van die Sigbaarheid- en Analitiese Netwerk, provinsiale 
voorsieningskettingbestuurders die raamwerk sal gebruik soos wat hul: komplekse skakels in die 
farmaseutiese voorsieningsketting vir openbare gesondheidsorg analiseer en optimeer; en 
aanbevelings rakende voorraadbeplanning en -bestuur by primêre gesondheidsorgfasiliteite maak. 
Die raamwerk vir produkkategorisering wat in hierdie navorsing ontwikkel is, sal na verwagting 
bydra tot volhoubare beskikbaarheid van- en toegang tot medisyne in die Suid-Afrikaanse openbare 
gesondheidsorgvoorsieningsketting.  
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Introduction 
Supply chains incorporate the end-to-end streaming of information, products, and money (Perez, 
2013) and supply chain management (SCM) has been defined as: “The management of upstream and 
downstream relationships with suppliers and customers in order to deliver superior customer value 
at less cost to the supply chain as a whole” (Christopher, 2011). This definition describes supply 
chain management as a function that incorporates a wide variety of activities, and a function that has 
a far-reaching impact on an organization. Consequently, how supply chains are managed has 
significant implications for an organization's product cost, working capital requirements, lead time to 
market, and service delivery, amongst others. 
In an influential paper that pioneered the concept of product categorization, Fisher (1997) proposed 
that the reason why supply chains do not perform as expected despite increased investments in effort 
and resources, is an improper alignment of product attributes and supply chain strategies. Similarly, 
Harris, Componation, & Farrington (2010) stated that a product with steady demand and dependable 
supply cannot be managed similarly as a product with unpredictable demand and inconsistent supply.  
Applying the concept of product categorization in the healthcare sector is expected to offer benefits 
in terms of the sustainable availability of medicines and a reduction in healthcare expenditure 
(Mapowo, Bam, de Kock, & van Eeden, 2018). Researchers have highlighted that product 
categorization makes a vital contribution to business attributes such as spend analysis, financial 
analysis, strategic sourcing, tendering, enterprise resource planning, and merchandising in healthcare 
(Fisher, 1997; Harris et al., 2010). The concept of product categorization has been employed in 
conjunction with robust Information Technology (IT) systems for better use in scientific warehousing 
and inventory management, transparent integrated procurement, real-time stock monitoring, and 
decentralized distribution methodologies (Prinja, Bahuguna, Tripathy, & Kumar, 2015). 
This research project is concerned with developing a framework for incorporating the principle of 
product categorization into the management of the public healthcare pharmaceutical supply chain in 
South Africa. This first chapter provides background on the research problem before formally 
defining the aim and objectives of the research. The scope of the study is also defined, and key 
assumptions, limitations, and delimitations are articulated. The research design and validation 
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strategy are also described before the chapter concludes with an overview of the content of each 
chapter of the thesis. 
 Background 
The South African National Department of Health (NDoH) is in the process of rolling out the 
Visibility and Analytics Network (VAN) reference framework, with the aim of ensuring the sustained 
availability of and access to medicines (Llewellyn, 2017). One of the objectives of the VAN strategy 
is to transform South Africa’s public healthcare pharmaceutical supply chain from an ‘uninformed 
pull’ system to an ‘informed push’ system (Llewellyn, 2017). The distinction between these two 
systems being that specialized supply chain management professionals will be utilized in each 
province. These professionals will analyze and optimize complex links in the public healthcare 
pharmaceutical supply chain and make inventory planning and management recommendations to 
primary healthcare facilities (PHCFs), rather than the PHCFs doing so on their own (Llewellyn, 
2016). An informed push model will relieve the PHCFs’ staff of sophisticated and time-consuming 
supply chain planning work and enable them to focus more exclusively on healthcare delivery.  
At present, the VAN strategy does not incorporate product categorization—which entails the 
organization of products into categories according to shared attributes; more specifically, when 
supply chains are considered, attributes that are related to or could influence the best supply chain 
management strategy for respective products (Qi, Boyer, & Zhao, 2009). Simchi-Levi, Clayton, and 
Raven (2013) reasoned that “one size does not fit all” in the formulation of a supply chain strategy, 
highlighting the fact that different supply chain management strategies may be needed for products 
that differ in terms of attributes such as variability, volume, lead-time, lifecycle, etc.  
Findings from a nationwide survey conducted by the Stop Stock-outs Projects (SSP)1 stated that in 
2013, 21% of South African public healthcare facilities experienced a stock out or shortage of a 
Tuberculosis (TB) or Human Immunodeficiency Virus (HIV) medicine within three months prior to 
SSP conducting the survey (Stop Stock-outs Projects, 2013). In 2014, a second national SSP survey 
exposed that the abovementioned metric further increased to 25%, meaning that a quarter of PHCFs 
in South Africa experienced HIV and TB medicine stock-outs at least once in the year prior to the 
SSP survey. In 2015, the status quo remained unchanged at 25% (2015 Stock Outs National Survey 
 
 
1
 SSP is a consortium made up of six civil society organizations established in 2013 to monitor the availability of: medicines for TB; 
antiretroviral (ARV) medicines for HIV; and childhood vaccines; amongst others. 
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Third Annual Report – South Africa, 2016). Medicine stock-outs pose a danger to people’s health by 
leading to interrupted treatment, the taking of partial doses, or defaulting on treatment. In turn, these 
eventualities lead to increased cost, loss of confidence in the health system, decreased immunity of 
patients, drug resistance, and increased risk of opportunistic infections leading to more illness, new 
infections and ultimately death (2015 Stock Outs National Survey Third Annual Report – South 
Africa, 2016). It can be reasoned that, due to differences in the therapeutic nature of pharmaceuticals 
and differences in performance of these products in the supply chain, various pharmaceutical products 
(e.g. anti-hypertensive, anti-viral, thrombolytic, and anti-cancer medicines) require different supply 
chain management strategies (e.g. continuous-flow, efficient, fast, and agile supply chains) depending 
on the product attributes (e.g. demand volume, lead-time, uncertainty, and lifecycle). Such an 
approach of managing the supply chain of pharmaceutical products in line with the product attributes 
is expected to improve the performance of the supply chain, thereby decreasing the occurrence of 
stock-outs. 
Product categorization has been conceptualized in diverse ways and has been envisioned to be 
substantial in effective supply chain strategies for improving performance efficiency in a wide range 
of sectors (Harris et al., 2010; Mapowo et al., 2018; Sullivan, Harris, Farrington, & Componation, 
2007). In the South African public healthcare pharmaceutical supply chain, segmenting products into 
clusters according to shared attributes and oriented management ideologies is potentially a valuable 
strategy for improving performance. Ways in which the management approaches for various 
categories can differ include: what and how key performance indicators (KPIs) and performance 
levels are defined; applied inventory management policies; and how and why replenishment and 
procurement decisions are taken.  
This research focuses on proposing an approach for applying the principle of product categorization 
to the South African public healthcare pharmaceutical supply chain. The research is provided within 
the reference framework of the VAN strategy of the South African public healthcare pharmaceutical 
supply chain. 
 Research aim and objectives 
In order to propose an approach for applying the principle of product categorization in the South 
African public healthcare pharmaceutical supply chain, the main question which guided the research 
is: What is the best approach to match pharmaceutical products and their attributes with supply chain 
strategies in the South African public healthcare pharmaceutical supply chain to enhance sustainable 
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availability of medicines based on the VAN strategy? Thus, the following research aim and objectives 
are pursued. 
1.2.1. Research aim 
The aim of this research inquiry is to contribute towards improving the sustainable availability of 
medicines in the South African public healthcare pharmaceutical supply chain by proposing a suitable 
framework for the application of the concept of product categorization under the VAN strategy. 
1.2.2. Research objectives 
In order to pursue the stated research aim, four research objectives, as well as a number of sub-
objectives, are defined: 
✓ Research objective 1: To develop the rationale for the research by investigating the expected 
benefit of incorporating product categorization into the South African public healthcare 
pharmaceutical supply chain. The sub-objectives associated with research objective 1 are: 
a) Provide an overview of the concept of product categorization based on literature; 
b) Provide an overview of the contemporary application of product categorization to various 
industries, including a summary of the impact of product categorization in these industries, 
based on a systematic literature review; 
c) Provide an overview of the operation and management of the South African public healthcare 
pharmaceutical supply chain; 
d) Provide an overview of supply planning in line with the VAN principles in the South African 
public healthcare pharmaceutical supply chain; and 
e) Articulate the rationale for expecting product categorization to hold benefit for the South 
African public healthcare pharmaceutical supply chain.  
✓ Research objective 2: To investigate a number of operational aspects that are critical to informing 
the development of the framework design requirements. The sub-objectives associated with 
research objective 2 are: 
a) Determine and identify a set of product attributes critical for matching pharmaceutical product 
categories with supply chain strategies in public healthcare pharmaceutical supply chains 
using a triangulation method; 
b) Identify pharmaceutical product bundles based on existing classification and nomenclature 
systems used in healthcare; 
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c) Provide an understanding of supply chain focus points which product categorization can 
target; 
d) Examine supply chain strategies and contextualize the product categorization framework 
development consistent with: the VAN supply chain; VAN service supply planning; and the 
South African public healthcare pharmaceutical supply chain; and 
e) Determine and tailor to the VAN strategy, the specific levers to control in product 
categorization and supply chain strategy implementation in the South African public 
healthcare pharmaceutical supply chain.  
✓ Research objective 3: To develop a framework, drawing from the findings of the first and second 
objectives, for the incorporation of product categorization into the South African public healthcare 
pharmaceutical supply chain, providing detail on: 
a) The basis for categorization—i.e. aligning and matching pharmaceutical product categories 
with appropriate supply chain strategies coupled with respective decoupling points and thus 
formulate different supply pipelines for different products; and 
b) The implication of categorization—i.e. what aspects of the South African public healthcare 
pharmaceutical supply chain would be implicated based on the product categorization 
framework. 
✓ Research objective 4: To verify and validate the framework using subject matter experts (SMEs) 
validation interviews and a case study application. The sub-objectives associated with research 
objective 4 are: 
a) Validation interviews and iterative improvement of the framework—from preliminary to final 
product categorization framework—based on subject matter expert (SME) feedback; and 
b) To validate the final framework using a case study application and establish recommendations 
for future research. 
 Scope of study 
In SCM, the term ‘planning’ can be used to refer to supply planning, demand planning or distribution 
planning (Harris et al., 2010; Llewellyn, 2017). The focus of this research is limited to product 
categorization for supply planning in the South African public healthcare pharmaceutical supply 
chain under the context of the VAN reference framework. Thus, product categorization for demand 
and distribution planning is outside the scope of this project, except in cases of overlaps with supply 
planning. Furthermore, only supply planning activities that occur at the national and provincial levels 
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of the South African healthcare system will be considered, thus supply planning activities that relate 
to the actual manufacturing of pharmaceuticals is outside of the scope of the study.  
The motivation for focusing on supply planning specifically is that, under the VAN strategy, supply 
planning will be used to develop sourcing and replenishment plans within the supply chain, which is 
considered to have a significant, direct impact on product categorization for sustainable availability 
of medicines (Llewellyn, 2017). Therefore, the output of this research inquiry (i.e. the product 
categorization framework) will be used to facilitate decision making in sourcing and replenishment 
of pharmaceuticals in a bid to ensure sustainable availability of medicines to end-users.  
The US Department of Health and Human Services (2017) defined drugs as “articles intended for use 
in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals” and 
a device as “an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, 
or other similar or related article, including any component, part, or accessory” used in achieving 
the same purpose as a drug. The scope of this study is limited to the categorization of drugs or 
pharmaceuticals and excludes devices. 
 Assumptions, limitations, and delimitations 
This thesis is limited to the pharmaceutical supply chain in the South African public healthcare sector. 
The focus will be on developing product-driven supply chain sourcing and replenishment strategies 
for VAN in the context of supply planning (thus excluding demand or distribution planning) and will 
be limited to two tiers, namely national and provincial supply planning.  
Service SCM has two categories of supply chain systems, i.e. Product Service Supply Chains (PSSCs) 
and the Service Only Supply Chains (SOSCs) (Wang, Wallace, Shen, & Choi, 2015). PSSCs have 
both physical products and services, for example, restaurants and food retail supply chains, while in 
SOSCs the ‘products’ offered are pure services for example financial consultancy and psychology 
advice (Wang, Wallace, Shen, & Choi, 2015). This research, however, will be limited to the PSSCs 
as this goes along with the South African public healthcare supply chain in that the delivery of 
healthcare by practitioners is deemed to be the service while the medication/pharmaceuticals are the 
products. 
 Research design and methodology 
According to Bryman and Bell (2014), a quantitative research approach tends to adopt the norms and 
practices of a model and extensively emphasizes deduction and quantification when collecting and 
analyzing data. In contrast, Bryman and Bell (2014) posited that a qualitative research approach is 
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principally inductive in the linkage of theory and research, with the emphasis being placed on 
generation rather than testing of theory. Qualitative and quantitative research approaches can also be 
combined to aid the researcher in capitalizing on the strengths and counterbalancing the weaknesses 
of each method, using a mixed-method research approach (Bryman & Bell, 2014). 
For this thesis, a mixed-method research approach will be employed where secondary quantified data 
sources on the South African public healthcare pharmaceutical supply chain are utilized to determine 
and resolve the research problem. To address the multifaceted research problem, an inductive 
approach—where theory is an outcome of the research—is used and systems thinking is applied to 
analyze and synthesize literature and determine the multiple variables and parameters in developing 
a strategic input-output framework. The proposed framework is verified and validated to confirm the 
solution. The basic systems engineering approach which will be employed is shown in Figure 1.1.  
Figure 1.1: A basic systems engineering approach for framework development (adapted from Mouton (2013) and van 
Aken, Berends, and van der Bij (2007)) 
Van Aken et al. (2007) posited five categories of requirements to enable a balanced approach in the 
design and development of a framework, namely: user requirements (U); functional requirements (F); 
design restrictions (R); boundary conditions (B); and attention points (A). In line with this 
recommendation, the ‘design requirements’ element in Figure 1.1 will consist of these five categories 
of requirements. Van Aken et al. (2007) definition of each of the five categories of requirements is 
given in Table 1.1.  
 
Systems 
engineering 
approach 
Framework 
validation 
Framework 
verification 
Framework 
development 
Design 
requirements: 
• User 
requirements 
• Functional 
requirements 
• Design 
restrictions 
• Boundary 
conditions 
• Attention 
points 
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Table 1.1:  Framework design requirement categories employed in this research (adapted from van Aken et al. (2007)) 
Framework design 
requirement category 
The generic definition of the requirement category 
User requirements (U) 
These are the critical and distinct requirements, as deemed by the framework user, 
which are used to define the constraints in framework development. 
Functional requirements (F) 
These are the fundamental enablers which facilitate the functionality, performance or 
result of the framework’s design and use. 
Design restrictions (R) 
These are the scope, exclusions, limits, and elements of the framework design’s 
preferred solution space. 
Boundary conditions (B) 
These are the categorical design requirements or rules that cannot be altered and must 
be met e.g. ethics, code of conduct and legislation 
Attention points (A) 
These are the desirable and relevant requirements of the framework design though they 
are not binding nor restrictive. 
 
The synthesis of these requirements to develop the framework will follow a basic input-output 
categorization process, as in Figure 1.2: 
 
Figure 1.2: Input-output transformation process (adapted from The US Department of Defense Systems Management 
College (2001)) 
 Validation strategy 
The product categorization framework intended to aid the VAN supply chain professionals, the South 
African NDoH, and ultimately the government in enhancing sustainable availability of medicines, is 
expected to be useful as a decision tool for VAN professionals to decide on ‘what’ product categories 
can be appropriately matched to ‘which’ supply chain strategies by considering ‘which’ product 
attributes. In establishing such a framework, it follows that principles of validity and reliability are 
fundamental in ensuring that the research product is valuable and useful (Jabareen, 2009).  
Reliability is considered to be the extent to which the results of a study are consistent over time and 
whether they are an accurate representation of the total population under study (Bryman & Bell, 
2014). Reliability of the findings is evaluated by verification of the study which entails the assessment 
Categorization 
process 
Attention 
points 
Design 
restrictions 
Boundary 
conditions 
Functional 
requirements 
Framework 
user 
requirements 
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of whether the solution was developed in the correct manner. Verification refers to mechanisms that 
are employed in the framework development process to incrementally contribute to reliability and 
validity, and thus, demonstrate the thoroughness of the study (Srai, Alinaghian, & Kirkwood, 2013). 
Srai et al. (2013) further assert that verification will aid in determining whether the solution is of a 
high quality and complete, though it will not necessarily ensure that the solution is useful in 
addressing the original problem.  
Validity addresses the aforementioned gap by demonstrating the integrity of the solutions from the 
study and ensuring that the research output truly addresses the investigated concept, providing the 
appropriate answers (Kothari, 2004). Srai et al. (2013) posited that the focus of validation is on the 
link between the purpose and the context of the research study and conclusions, thus assessing 
whether the developed solution addresses the defined problem. Kothari (2004) defines two forms of 
validity, namely external validity, which focuses on the extent to which a solution can be generalized 
from the view of its relevance to a larger population, and internal validation, which comprises the 
following three distinct concepts: 
❖ Criterion validity—which evaluates the extent to which applicable features of the solution can 
be precisely forecasted by the theoretical concept;  
❖ Face validity (also referred to as content validity)—which assesses the extent to which a 
solution provides adequate coverage of the topic under study; and  
❖ Construct validity—which tests whether the solution addresses what it claims to solve and 
that the solution does not assess irrelevant attributes. 
1.6.1. Applicable validation routes 
Validation is commonly achieved via three main approaches, namely: 1) interviews with subject 
matter experts (SMEs); 2) implementation and 3) case study application (Mouton, 2001). Each of 
these approaches has its own advantages and disadvantages as given below, based on Mouton (2001): 
• Interviews with SMEs 
Definition: These are interviews where the interviewer gathers knowledge from the 
interviewee to disprove or validate claims made by the researcher. These 
interviews can be structured, semi-structured or unstructured interviews. 
Advantages: It provides a platform for obtaining knowledge from experts who can either 
contest or support the research findings.  
Stellenbosch University https://scholar.sun.ac.za
 Page | 10  
 
Disadvantages: The interviewees can only respond within their circumstances based on their 
personal experiences and knowledge hence the need for special consideration 
in interviewee selection. 
• Implementation 
Definition: This denotes the full practical application of a framework in a given setting to 
review and validate its correctness. 
Advantages: The results of the implementation are definitive and holistic.  
Disadvantages: The full implementation of the framework is resource-intensive and time-
consuming. 
• Case studies 
 Definition: This is a detailed examination of an already existing case with the aim of 
providing descriptive, explanatory and exploratory findings. 
Advantages: It provides a different perspective from which practical challenges and 
requirements are better understood due to similarities between case studies and 
reality. 
Disadvantages: It is susceptible to manipulation and strongly rooted in the setting/context in 
which it is applied. 
This study will employ interviews with SMEs—using semi-structured interviews and Likert scale 
rankings—followed by a case study to obtain detailed and practical insight into the validity of the 
framework. An overview of the validation process and roadmap is provided in the succeeding section. 
1.6.2. Validation roadmap overview 
A summary of the validation strategy that will be employed in this research is provided in Figure 1.3. 
As discussed, this study will take a mixed methods research approach and semi-structured interviews 
with SMEs and a case study application will be employed as validation methods.  
A triangulation approach based on three sourced of input, namely findings based on a systematic 
literature review, SME inputs, and the application of logical arguments and reasoning based on an 
understanding of SCM in public healthcare, will be used to determine the product attributes 
taxonomy. Using the same findings and inputs, a supply chain strategies taxonomy will be developed. 
Framework design requirements specifications which describe user requirements, functional 
requirements, design restrictions, boundary conditions and attention points, will be identified based 
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on the literature reviews and SME inputs (derived from semi-structured interviews) presented in 
Chapters 2 and 3. 
Chapter          
 
Input data  Framework 
development  
Formal outcome
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Validation process overview 
The preliminary product categorization framework will be developed based on this set of design requirements. 
Feedback on both the set of design requirements and the preliminary product categorization framework will 
then be gathered from SMEs using semi-structured interviews. This feedback will be incorporated to develop 
the final product categorization framework. For the purpose of maintaining the flow of the narrative and not 
duplicating the framework within the main document, the preliminary framework is given in Appendix D 
while the validated final framework (with SME feedback incorporated) is given in the main body of the thesis 
in Chapter 4.  
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The final product categorization framework presented in Chapter 4 will then be used to conduct a case study 
workshop with the main purpose of evaluating the applicability and operability of the framework.  
 Thesis outline 
The outline and sequence of this study is summarized in Figure 1.4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1 
Introduction 
 
Chapter 2 
Rationale: Product categorization 
and the South African public 
healthcare pharmaceutical supply 
chain  
Chapter 3 
Solution Development: Product 
Attributes and Supply Chain 
Strategies Taxonomy  
 
Chapter 4 
Product categorization framework 
development 
Chapter 5  
Validation of the Product 
categorization framework 
Chapter 6 
Conclusions and recommendations 
Figure 1.4: Thesis overview 
              Chapter :     Research objective met :  Description:                                                             
1a. b. 
c. d. e. 
2a. b. 
c. d. 
e. 
3a. b. 
4a. b. 
Provides the introduction; background; aim and 
objectives; scope of study; limitations and delimitations; 
research design and validation strategy. 
Conceptualizes product categorization and its use in 
various industries and the impacts thereof; possible 
impacts in the public healthcare pharmaceutical supply 
chain; describes the South African public healthcare 
pharmaceutical supply planning overview in the context 
of the VAN strategy; and postulate the potential impact 
of product categorization in SA’s public healthcare 
pharmaceutical supply chain. 
Solution development: discusses available product 
categorization methods and product attributes to 
determine salient product attributes critical to public 
healthcare pharmaceutical supply chain; discuss which 
focus points of the supply chain should product 
categorization target; examine available nomenclature 
and classification in healthcare to identify salient 
pharmaceutical bundles; discuss generic supply chain 
strategies to determine salient supply chain strategies for 
the study; levers to control in supply chain strategy 
implementation tailored to the VAN strategy and the 
South African public healthcare pharmaceutical supply 
planning.  
Aligning and matching pharmaceutical product 
bundles/categories with appropriate supply chain 
strategies based on their various product attributes. 
Establishment of special cases index of the framework. 
Demonstration of the framework’s decision-making 
philosophy.  
Use of subject matter experts (SMEs) interviews to 
validate the preliminary product categorization 
framework’s construct. Develop the final framework 
and apply it to a case study to validate operability and 
applicability of the framework. 
Drawing of conclusions, recommendations and future 
study from the research findings. 
Stellenbosch University https://scholar.sun.ac.za
  
  
Rationale: Product categorization and the 
South African public healthcare 
pharmaceutical supply chain2  
 Introduction to literature 
This chapter presents relevant literature on the concept of product categorization—its application in 
various industries, evidence on its impact, and concepts used in its application. The chapter further 
investigates the product categorization methods that have been used in relation to SCM in the various 
industries. This chapter seeks to address the first objective of this thesis: 
 
 
 
2 A significant portion of the text in Sections 2.2 and 2.3 has been reproduced from a conference article that was published as part of 
this research. The article citation is: Mapowo, N., Bam, L., de Kock, I., & van Eeden, J. (2018). “Incorporating Product 
Categorization to improve the performance of SA’s public healthcare supply chain: A research agenda.” In SAIIE29 Proceedings, 
24th – 26th of October 2018, Spier, Stellenbosch, South Africa (pp. 391–404). 
Research objective 1: To develop the rationale for the research by investigating the expected 
benefit of incorporating product categorization into the South African public healthcare 
pharmaceutical supply chain. The sub-objectives associated with research objective 1 are: 
a) Provide an overview of the concept of product categorization based on literature; 
b) Provide an overview of the contemporary application of product categorization to 
various industries, including a summary of the impact of product categorization in 
these industries, based on a systematic literature review; 
c) Provide an overview of the operation and management of the South African public 
healthcare pharmaceutical supply chain; 
d) Provide an overview of supply planning in line with the VAN principles in the South 
African public healthcare pharmaceutical supply chain; and 
e) Articulate the rationale for expecting product categorization to hold benefit for the 
South African public healthcare pharmaceutical supply chain.  
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The intended outcome of this chapter is to derive concepts from the literature that potentially drive 
the feasibility and applicability of the product categorization dimensions in the South African public 
healthcare pharmaceutical supply chain. The chapter ends with a summary of the set of framework 
design requirements that are derived from the work presented.  
 The concept of product categorization 
Fisher (1997), an acknowledged pioneer of the concept of product categorization, proposed that if 
products are classified based on their demand configurations, they fall into one of two categories: 
they are either primarily functional or primarily innovative. Furthermore, Fisher (1997) proposed that 
supply chains can either be physically efficient or market responsive based on the stated product 
distinction. He then posited a generic framework to match the product type to the appropriate supply 
chain strategy with functional products being matched to efficient supply chains and innovative 
products matched to responsive supply chains, while the converse results in a mismatch as shown in 
Figure 2.1 
 
Functional Products Innovative Products 
Efficient Supply Chain Match Mismatch 
Responsive Supply Chain Mismatch Match 
Figure 2.1: Fisher's framework, matching supply chains with products. (adapted from Fisher (1997)) 
Fisher (1997) asserted that functional products are the widely available products which satisfy basic 
needs. They are characterized by a relatively extensive lifecycle, with little change over time and little 
variance in their offerings. Demand for functional products is typically predictable and stable, and 
they tend to possess low-profit margins because of the many competitors in the market (Christopher, 
2011). Inventory is used to buffer demand because the cost of functional products obsolescence is 
low (Harris et al., 2010).  
Sullivan, Harris, Farrington, and Componation (2007) underlined that innovative products are 
typically distinguished as trendy and have highly volatile demand that is difficult to predict. They are 
associated with significantly more uncertainty than functional products. Innovative products have 
larger product variety and short life-cycles, but the profit margin is high, therefore lost sales 
(opportunity cost) exert a significant effect on company performance (Harris et al., 2010). Table 2.1 
shows the demand aspects for the classification of products as either functional or innovative. 
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Table 2.1: Product demand aspects versus functional or innovative (adapted from Fisher (1997)) 
Demand Aspects Functional (Predictable Demand) Innovative (Unpredictable Demand) 
Average stock-out rate 1% to 2% 10% to 40% 
Product Variety Low (10 to 20 variants per category) High (often millions of variants per category) 
Contribution to Margin 5% to 20% 20% to 60% 
Product Life Cycle More than 2 years 3 months to 1 year 
If products are not aligned with their appropriate supply chain strategies, this can result in overserving 
and overcharging functional products’ customers, and underserving and undercharging innovative 
products’ customers (Sullivan et al., 2007). Translating this to the public healthcare pharmaceutical 
supply chain, various products from the pharmaceutical product portfolio can probably be determined 
and categorized according to either being functional or innovative. This, as established by Fisher 
(1997) in Table 2.1, would be dependent on the pharmaceuticals demand aspects (e.g. average stock-
out rates, product life cycle, and product variety, etc.) of each product. It can then be reasoned that 
chronic medication which, in the South African pharmaceutical supply chain, has been exposed to 
have a stock-out rate of 25% as established in Section 1.1, will possibly not be considered the same 
as other medication with little or no stock-outs. Chronic medication stock-outs can probably be argued 
to be in the innovative products category since their stock-out rate is between 10% and 40% as 
identified in Table 2.1. However, it can contrarily be argued that since normally chronic patients are 
registered and known, then chronic medication should have predictable demand and thus should be 
categorized as functional. This uncertainty in categorization brings the need to consider all product 
attributes and determine which ones are critical for matching product categories to appropriate supply 
chain strategies, and this is the partial aim of this thesis. 
 Applications of product categorization 
A systematic literature review was conducted to determine previous applications of product 
categorization as well as the documented impacts of product categorization. 
2.3.1. Literature analysis approach 
To understand the trends in research, the current applications of product categorization, and how 
product categorization relates to supply chain strategies, a systematic literature review was conducted. 
Tranfield, Denyer, and Smart (2003) posited that a systematic literature review is a scientific, 
transparent and replicable approach “that aims to minimize bias through exhaustive literature searches 
of published and unpublished studies by providing an audit trail of the reviewer’s decisions, 
procedures, and conclusions”. Tranfield et al. (2003) further highlighted that a systematic literature 
review process involves three main steps, namely: i) identifying the research questions and planning 
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the review, ii) conducting the review, and iii) reporting and dissemination. The procedure is shown 
in Figure 2.2: 
Systematic 
Literature Review
1st Step
Specifying the research 
question(s) and planning the 
review
2nd Step
Conducting the 
review
3rd Step
Reporting and 
Dissemination
 
Figure 2.2: Systematic literature review procedure (adapted from Tranfield et al. (2003)) 
2.3.2. Step 1: Specifying and planning the review 
The systematic literature review consisted of firstly gathering and then analyzing research studies and 
publications concerning product categorization and supply chain strategies that incorporated the 
practice of product categorization. An overview of the application of product categorization 
dimensions across industries and more specifically the healthcare sector is subsequently provided. 
The literature review was conducted using the Scopus3 database to identify the application trends of 
product categorization. The literature review thus sought to address the following two research 
questions (RQ): 
 
 
 
 
Both research questions are considered within the SCM context. Keywords from the research 
questions were derived and the following search line was developed: 
 
 
 
3
 Scopus is a large abstract and citation database of peer-reviewed literature: books, scientific journals and conference proceedings. 
 
❖ RQ 1: For the past decade (2007 to 2017), what have been the trends and concepts employed 
in applying the product categorization dimensions?  
❖ RQ 2: What are the impacts of incorporating product categorization in the various 
industries?  
 
(((categori* OR segment* OR classif*) W/5 (demand* OR supply* OR distrib*)) AND 
("supply chain" OR "value chain")). 
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The search line took word variations into consideration, for instance, the terms product categorization, 
segmentation or classification are used interchangeably in the literature. The search line also catered 
for variations between American English and British English. Since the aim is to consider product 
categorization within the context of SCM, the terms supply chain and value chain are also included 
as search terms as well as demand, supply, and distribution. Supply chain and value chain do not 
necessarily mean the same in literature, but the two terms encompass various aspects that intersect, 
hence both terms were incorporated into the search line.  
2.3.3. Step 2: Conducting the review 
The search field included title, abstract, and keywords of items in the Scopus database and the initial 
search yielded 792 documents. Since the focus of the structured literature review is on contemporary 
applications of the concept of product categorization, the results were filtered to include only 
literature published over the past decade (2007-2017). This reduced the number of documents to 636. 
The abstracts of the 636 documents were screened for relevancy based on the following two criteria: 
i. Documents that addressed the development of frameworks and models of product 
categorization dimensions and/or supply chain strategies were accepted; and 
ii. Documents that did not describe the development of a framework or model but that did detail 
how and why product categorization should be applied in any setting were included too. 
The screening yielded 61 documents that were concerned with detailing and/or development of 
frameworks, models, and impacts of product categorization and/or supply chain strategies. Care was 
taken not to overly filter documents during the screening phase, lest important documents might be 
left out.  
Of the 61 documents identified through the screening process, four documents were found to be 
inaccessible, thus reducing the number of documents included in the dataset for analysis to 57. A 
further seven documents were added to the dataset for analysis, based on serendipitous discovery. 
These documents all satisfied the screening criteria. The final dataset for analysis, therefore, consisted 
of 64 relevant documents. A summary of the approach followed is provided in Figure 2.3. 
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Figure 2.3: Scopus database search methodology (reproduced from Mapowo et al. (2018)) 
2.3.4. Step 3: Reporting and dissemination of the systematic review 
This section provides an overview from the systematic literature review of the application of the 
product categorization concept, firstly in other industries which are not healthcare (18 documents in 
the dataset document instances of industry application in general), then secondly in the healthcare 
industry itself (three documents in the dataset document instances of application to the healthcare 
industry specifically).  
(((categori* OR segment* OR classif*) W/5 (demand* OR 
supply* OR distrib*)) AND ("supply chain" OR "value chain")) 
Search line in Scopus 
Total number of possible relevant documents,  
n=792 
Search field: Article title, 
abstract and key words 
 n= 64 
Inaccessible documents,  
n= 4 
Accessible documents,  
n= 57 
Accessible and inaccessible 
documents from the documents 
set, n= 61 
Relevant documents added, n=7  
Total number of relevant documents, n= 61 
Screen documents for relevancy 
using title and abstract 
simultaneously 
Total relevant documents 
Relevant documents added to the 
documents set from the 
references of the accessible ones   
Limit documents to: Publication 
years 2007-2017 
Total number of possible relevant documents,  
n= 636 
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Figure 2.4: Percentage distribution of industry-specific documents pool 
The industries that are covered in the dataset are summarized in Figure 2.4. As shown, the majority 
of industry-specific research has been directed at the manufacturing industry (33%) followed by e-
commerce (24%). Healthcare is one of the five industries that are explicitly included in the dataset.  
2.3.4.1. Application of product categorization in other industries (excluding healthcare) 
The four industries (excluding healthcare) to which concept of product categorization has been 
applied in that dataset, share certain characteristics with the healthcare supply chain, including:  
✓ Agility to seasonal and demographic variations, in the case of the fashion and retail industry; 
✓ The visibility, variability, analytics and categorization of a large innovative product portfolio and 
how they are supplied that underscores the need for continuous improvement, in the case of the 
e-commerce industry;  
✓ Responsiveness to high demand, especially in the case of the wine industry; and 
✓ Combination of lean and agile principles, in the manufacturing industry.  
Table 2.2 below details the concepts of product categorization application in the industries and the 
impacts thereof. As summarized in the table, product categorization has been applied to demand 
planning, distribution planning, and supply planning functions in the supply chain. As stated in 
Section 1.3, the scope of this research is specifically focused on supply planning. The aspects of the 
supply chain that have been impacted include product availability, product shelf space, order cycle 
time, lead time to delivery, and demand variability.  
 
Healthcare industry
14%
E-commerce 
industry
24%
Manufacturing 
industry
33%
Wine industry
10%
Fasion industry
19%
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Table 2.2: Impacts of application of product categorization in industries (reproduced from Mapowo et al. (2018)) 
Industry Literature Concepts in application Impacts 
W
in
e 
in
d
u
st
r
y
 Wen, Tong, and Yao 
(2010) 
Quality Function 
Deployment (QFD) 
Optimal determination of delivery frequencies 
and minimum lot sizes. Improved product and 
packaging management. Enhanced marketing 
and responsiveness to high demand peaks. 
 
M
a
n
u
fa
c
tu
r
in
g
 i
n
d
u
st
r
y
 
Nagashima, Wehrle, 
Kerbache, and Lassagne 
(2015) 
Ordered feature evaluation 
analysis (OFEA); and 
Collaboration intensity 
Enhanced demand forecasting accuracy. 
Naim and Gosling (2011) Lean and agile ('Leagile') 
manufacturing paradigms 
Optimal determination of decoupling point. 
Ramkumar, Subramanian, 
Narendran, and Ganesh 
(2013) 
Vendor Managed 
Inventory (VMI) 
Reduction in lead time and demand variability. 
Optimal stocking quantities at warehouses. 
Ervolina, Ettl, Lee, and 
Peters (2009) 
Available-To-Sell (ATS) Optimal demand forecasting. Profitable demand 
response. Profitable product portfolio.  
Hiremath, Sahu, and 
Tiwari (2013) 
Outbound logistics 
network (OLN). Multi-
objective genetic algorithm 
(MOGA) 
Minimize the total network cost. Maximize 
resource utilization. 
Taylor, Gan, Grunow, 
Gan, and Grunow (2015) 
concurrent product and 
supply chain design (CP-
SCD) 
Provide managerial insights in design trade-off 
analysis. 
Fichtinger, Chan, and 
Yates (2017) 
Two-Echelon Dual-
Channel Supply Chain 
Development of profitable market segments. 
Micieta, Lieskovsky, and 
Binasova (2016) 
Group technology Improvement in quality, productivity and 
inventory management. Increase costing 
accuracy. Increase customer service. A gain in 
sustainable competitive advantage. 
Rajan and Wang (2016) Hierarchical clustering Obsolescence reduction. 
 
F
a
sh
io
n
 a
n
d
 r
e
ta
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n
d
u
st
r
y
 
Şen (2008) Efficient supply chain 
management practices 
Production of a variety of sizes, styles, and colors 
in shorter lead-time. Agility to changing demand 
requirements. Ability to better forecast and plan 
future production needs. 
Roscoe and Baker (2014) Supply chain segmentation Aligning of demand planning, marketing, sales, 
and supply chain functions. 
Martínez, Errasti, and 
Rudberg (2015) 
Pronto Moda or Rapid-Fire 
Fulfilment 
Reduction of variety and a wide range of 
garments per collection. Standardizing fabrics 
and product platforms. Introduction of mini 
collections. 
Sardar, Lee, and Memon 
(2016) 
Outsourcing strategies. 
Goal programming 
Cost-saving. Capacity flexibility. 
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Rofin and Mahanty (2017) Cournot model Determination of product categories' optimal 
dual-channel supply chain configuration for 
different customer online channels preference. 
Hofbauer, Withalm, and 
Wölfel (2007) 
Ontology Derivation of web ontologies. Efficient and 
reliable electronic product data exchange across 
organizations. 
Liao, Chen, and Yang 
(2013); Murray, Agard, 
and Barajas (2015);  
Cooke (2014); and 
Two-step data mining 
approach 
Mining customer knowledge on online channels 
and product segments preferred. Better market 
segmentation. 
Li and Huang (2012) Two-Echelon Dual-
Channel Supply Chain 
Development of profitable market segments. 
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Considering the literature on the wine industry specifically, the incorporation of product 
categorization facilitates responsiveness to high demand peaks. Product categorization in the wine 
industry has also shown that, with delivery frequencies and minimum lot sizes determined, the cost 
of inbound and outbound transportation can potentially be reduced (Wen et al., 2010). 
Examples from the manufacturing industry show that potential impacts of the incorporation of 
product categorization include determining the optimal decoupling point, reducing lead time and 
demand variability, optimizing stock quantities at depots, and improving the accuracy of demand 
forecasting. As seen in the fashion industry, a reduction of variety and a wide range of garments per 
delivery as well as standardizing product platforms is potentially possible through the incorporation 
of product categorization. The E-commerce industry shows that visibility, analytics, and 
categorization of a large product portfolio is likely feasible through the incorporation of product 
categorization. Determination of product categories' optimal multi-channel supply chain 
configuration for products is potentially possible too.  
As discussed previously, there are shared characteristics between the four industries discussed here 
and the healthcare industry. It is therefore plausible that some of the same impacts that have been 
discussed here can potentially be reaped from incorporating product categorization in the healthcare 
supply chain. The expected benefit of applying product categorization to the South African public 
healthcare pharmaceutical supply chain is discussed in Section 2.6. 
2.3.4.2. Application of product categorization in healthcare 
Unlike in the commercial sector where the focus is largely on profit and competitive advantage, the 
focus in the public healthcare sector is on effective and sustainable availability and administration of 
healthcare (Abdulsalam, Gopalakrishnan, Maltz, & Schneller, 2015). The dimensions of product 
categorization have been used in the healthcare sector by Yadav, Lydon, Oswald, Dicko, and Zaffran 
(2014) in developing a framework for decision making in the integration of vaccine supply chains 
with other health commodity supply chains. The framework enabled the optimization of 
immunization supply chains as vaccines were delivered to the end recipients efficiently, effectively 
and sustainably. Optimal product categories which aided in aligning of demand planning and supply 
chain functions were determined. Hua, Tang, and Wu (2016) employed the product categorization 
dimensions in developing an integrated reverse supply chain model. The model was meant to 
investigate the impact of various unwanted medications categories and government’s publicity and 
penalty investment on the reverse supply chain profit as well as the collection rate of expired 
medications. The findings showed that as the percentage of unexpired medications grew, the rate of 
expired medications collection remained the same, but the profit of the whole reverse supply chain 
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increased (Hua et al., 2016). Finally, Kritchanchai and Meesamut (2015) employed the dimensions 
of product categorization in developing an inventory management model for a hospital in Thailand. 
They argued that a single inventory management system cannot be used on all medicines effectively. 
The inventory management system they developed enabled the hospital to minimize the total 
inventory costs while maintaining patient drug administration safety levels. Provision for demand 
forecasting accuracy was made as well as a reduction in demand variability (Kritchanchai & 
Meesamut, 2015). The application of product categorization in healthcare according to the systematic 
literature review is summarized in Table 2.3. 
Table 2.3: Impacts of application of product categorization in healthcare (reproduced from Mapowo et al. (2018)) 
Industry Literature Concepts in 
application  
Impacts 
 
 
 
 
 
Healthcare 
 
 
  
 (Yadav et al., 
2014) 
Vaccines supply chain 
generic map. 
Efficient, effective and sustainable delivery of vaccines 
to end recipients. 
(Hua et al., 
2016) 
Integrated reverse 
supply chain model. 
Increase in percentage of unexpired medications grew, 
the rate of expired medications collection remained the 
same, but the profit of the whole reverse supply chain 
increased. Cost reduction. 
(Kritchanchai & 
Meesamut, 
2015) 
Inventory management 
model. 
Minimized total inventory costs while maintaining drug 
administration safety levels. Reduction in demand 
variability. Increase in demand forecasting accuracy. 
 
Similar to the comment made at the end of the previous section, the examples of previous applications 
of product categorization to the healthcare industry, as well as the documented benefits from these 
applications, can be used to determine potential applications of product categorization to the South 
African public healthcare pharmaceutical supply chain. In the two sections that follow, a general 
introduction to the South African public healthcare pharmaceutical supply chain (Section 2.4) as well 
as an overview of supply planning in this supply chain (Section 2.5) is presented. This is followed by 
a discussion of the expected benefit of applying product categorization to the South African public 
healthcare pharmaceutical supply chain in Section 2.6. 
 The South African public healthcare pharmaceutical 
supply chain 
Raja and Mohammad (2004) asserted that a public healthcare pharmaceutical supply chain mainly 
comprises of four operational functions, namely product selection; quantification and procurement; 
inventory and distribution; and product use. They further posited that these operational functions exist 
within an enabling environment of policy and legal framework which governs the core management 
supporting elements. There is limited literature available on the description of exact operations within 
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the South African public healthcare pharmaceutical supply chain system, however, the work of Zuma 
(2016) will be largely referred to, coupled with some available additional contemporary resources. 
As shown in the pharmaceutical logistics framework in Figure 2.5, the South African public 
healthcare pharmaceutical supply chain can be conceptualized as consisting of four operational 
functions, supportive elements, and an enabling environment. Each of these components will be 
discussed in the succeeding sections. 
 
 
 
 
 
 
 
 
Figure 2.5: Pharmaceutical logistics framework (adapted from Raja and Mohammad (2004)) 
2.4.1. Operational functions 
Each of the four operational elements depicted in Figure 2.5 is briefly discussed in the following 
subsections. 
2.4.1.1. Pharmaceuticals selection 
The public healthcare pharmaceutical supply chain sector consists of three levels of care i.e. PHCFs, 
secondary hospital, and tertiary/quaternary hospital (Perumal-Pillay & Suleman, 2017). The South 
African NDoH in particular, comprises of a sector-wide Procurement Division mainly responsible for 
Policy, Law and Regulation 
Enabling 
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Pharmaceuticals 
use 
Quantification and 
procurement 
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the essential medicines selection; the standard treatment guidelines (STGs) and essential medicines 
lists (EMLs) development for each health system level; the administration of health tenders and 
contracts; and finally, the licensing of the individuals and facilities involved in the pharmaceutical 
products delivery (Perumal-Pillay & Suleman, 2017).  
The South African NDoH has the responsibility for ensuring safe, affordable and equitable access to 
medicines. The Affordable Medicines Directorate (AMD), a subset of the NDoH, is also responsible 
for “getting pharmaceuticals to the point of need" (Llewellyn, 2016). The AMD governs, from the 
national level, the operations and processes of the public healthcare pharmaceutical supply chain to 
ensure medicine availability across all tiers. The NDoH stipulates the AMD to focus on the Essential 
Drugs Program (EDP)4, tender and contract management, and pharmacists’ and pharmacies’ licensing 
(Zuma, 2016).  
The national EML is utilized by all provinces, with a National Essential Medicines List Committee 
(NEMLC) and provincial, district and facility-based Pharmaceutical Therapeutic Committees (PTCs) 
facilitating medicine selection (Zuma, 2016). Zuma (2016) further states that the provincial PTCs 
known as (PPTCs) have the self-governance to select medicines appropriate for their provincial EML 
needs, though they are guided by the national EML and funded by the provincial budgets. Literature 
describing the medicine selection processes in South Africa is not readily available in the public 
domain, but what is known is that the decisions of the NEMLC guide and drive the procurement of 
medicines in the public healthcare pharmaceutical supply chain and form the basis for medicine 
tender processes (National Department of Health, 2017). The NEMLC’s decisions at the provincial 
level are binding even in donor-funded programs such as the ARV program (Pharasi & Miot, 2012). 
According to Perumal-Pillay and Suleman (2017), the NEMLC often select medicine based on cost 
and efficacy oblivious of the product availability for procurement. This lack of alignment between 
the medicine selection and procurement processes is therefore potentially a contributing factor to 
stock-outs at the facility level. 
2.4.1.2. Essential medicines procurement 
The South African public healthcare pharmaceutical supply chain uses a closed system for medicine 
procurement where the central national tier superintends procurement processes with the active 
 
 
4
 Essential Drugs Program (EDP) promotes the establishment of the Standard Treatment Guidelines (STGs) and Essential Medicines 
List (EML) for PHCFs at hospital level to ensure the availability of safe, affordable and quality medicines (Gray & Vawda, 2018)  
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involvement of various provinces (Zuma, 2016). Once the national tier awards the tenders to selected 
suppliers, provinces are informed and will procure pharmaceuticals from these specific suppliers. 
Provinces have the mandate of quantifying their pharmaceutical requirements advised by the EML 
including other pharmaceuticals as per need (Patel, Norris, Gauld, & Rades, 2009). Most of the 
pharmaceuticals in the public healthcare pharmaceutical supply chain are procured via national 
tenders and are managed by the AMD in conjunction with the provisions of the National Treasury 
allocations (Patel et al., 2009).  
However, Zuma (2016) argued that provinces do not entirely depend on national contracts since in 
some cases suppliers fail to meet the service levels, and in such cases, provinces use buy-outs to 
ensure continuous replenishment of stock. A quotation system where quotes are requested from pre-
qualified suppliers before contracting them is used to procure pharmaceuticals that are not on 
contract—this is termed buyouts. The NDoH pays the deficit from the buy-outs and policy dictates 
that buy-outs should not exceed 10% of the budget (Berger et al., 2010).  
2.4.1.3. Essential medicines inventory and distribution management  
The South African pharmaceutical distribution network involves the central medicine stores, regional 
depots, hospital facilities and PHCFs (Berger et al., 2010; Zuma, 2016). Zuma (2016) posited that 
provinces employ various distribution methods with third-party logistics (3PL) services being mostly 
used between the regional/district depots and PHCFs. Figure 2.6 provides a representation of the 
pharmaceutical distribution network. 
Some provinces, for example, the Free State province, pay contractors based on weight consignment 
so that deliveries cannot take place until the accumulation of stock reaches a certain threshold for 
dispatch (Berger et al., 2010). Few of the provinces employ a direct delivery system where medicines 
are directly distributed from the depots to the PHCFs, whereas with the rest of the provinces, stock 
flows through all the levels downstream (Zuma, 2016).   
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Figure 2.6: Product flows in the South African public healthcare pharmaceutical distribution network (adapted from 
Zuma (2016)) 
The distribution of medicine downstream through all the levels, i.e. from provincial depot to district 
depot to hospital facilities to PHCFs, can affect the lead-times to deliver pharmaceuticals which 
consequently may shorten medicine lifecycle (shelf life and lifetime). Furthermore, this can 
complicate the tracking of medicine expiry dates and makes stock prone to being lost in transit 
between the levels (Zuma, 2016). 
2.4.1.4. Pharmaceuticals use 
Provinces utilize different approaches to promote rational use of different medicines, with some using 
the activity-based costing (ABC) analysis—a method used to classify items according to their relative 
importance—to determine any irrational use of medicine within the province. Other provinces use 
district pharmacists to conduct training sessions to equip health professionals and inhibit the irrational 
use of medicines (Zuma, 2016). Zuma (2016) concluded from his study that there is limited capacity 
building in the South African public healthcare sector for the rational use of medicine.  
2.4.2. Management support 
As shown in Figure 2.5, Raja & Mohammad (2004) define four supportive elements, namely the 
information system, organizational support/human resources, monitoring and evaluation, and 
Provincial Depots/Central Medicines Store  
District/Regional Depots 
Hospital Facilities 
Public Healthcare Facilities (PHCFs) 
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financial and donor coordination. These are grouped together and collectively labeled management 
support. Each of the four elements of management support is subsequently discussed. 
2.4.2.1. Information systems 
Technological systems like the Stock Visibility System (SVS) and the RxSolution software 
implementation are underway across provinces’ PHCFs to enhance the visibility of stock within the 
supply chain (Berger et al., 2010). The NDoH is currently using the Contract Management System to 
manage tenders; administering tender item specification and tender lifecycle in conjunction with the 
MEDSAS system which manages storage and distribution of products at depots. The National 
Treasury uses the Rfx system to administer tender processes at the provincial level and the Western 
Cape province uses the Sourcelink system instead (Berger et al., 2010). Information on what other 
provinces use is not readily available. This fragmentation of the information landscape possibly 
complicates medicine stock visibility across the pharmaceutical supply chain. 
2.4.2.2. Organizational support/human resources 
The NDoH’s AMD manages tenders in collaboration with the National Treasury, with three 
responsibilities (Berger et al., 2010): (i) identifying and selecting medicines for the EML and 
promoting rational use; (ii) facilitating and coordinating operations and processes for procurement 
and distribution of pharmaceuticals; and (iii) licensing pharmacy infrastructure and issuing licenses 
to dispense medicines.   
2.4.2.3. Financial coordination 
Government financing, e.g. taxes, donor financing, and health insurance schemes, are the primary 
source of funds for public healthcare pharmaceutical supply chains (Patel et al., 2009; Zuma, 2016). 
Various provinces and local governments are accountable and responsible for the management of the 
allocated funds and oversee how these funds are spent on healthcare provision within the 
province/local government (Berger et al., 2010).  
2.4.2.4. Monitoring and evaluation  
Within the monitoring and evaluation component, all supporting elements of the operational elements 
are interlinked with the aim of ensuring that activities and processes adhere to SOPs and best practices 
within the public healthcare pharmaceutical supply chain (Berger et al., 2010).  
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2.4.3. Law, policy and legal framework 
As shown in Figure 2.5, the enabling environment within which the South African public healthcare 
pharmaceutical supply chain operates is governed by a legal framework consisting of policies, 
legislations, guidelines, and SOPs.  
The National Department of Health (1996) defined the South African national drug policy to consist 
of: (i) medicine selection; (ii) traditional medicines; (iii) medicine pricing; (iv) procurement and 
distribution; (v) rational use of medicines; (vi) human resource management; (vii) research and 
development; (viii) technical cooperation; (ix) monitoring and evaluation; and (x) regulations and 
legislations. These elements govern the legislation relevant to medicine supply within the South 
African public healthcare pharmaceutical supply chain (Zuma, 2016).  
In summary of the discussed elements in this section, it is clear that the bundling up of 
pharmaceuticals is potentially important for monitoring and evaluation of the pharmaceutical supply 
chain as consumption data and demand trend analysis of pharmaceuticals can be analyzed. This can 
potentially enhance the rational use of medicines cost-effectively. Provinces can possibly analyze 
these trends within their specific context i.e. market environment, ease of doing business, 
demographics, etc. Analyzing service supply planning and service provision in the South African 
public healthcare pharmaceutical supply chain in the context of VAN—which the NDoH is rolling 
out—will provide a further understanding of the gaps in the supply chain, and this is discussed in the 
succeeding section. 
 The VAN strategy in the South African public healthcare 
pharmaceutical supply chain 
In a typical supply chain system, there exists a ‘product’ that is processed and delivered from a point 
of origin to a point of consumption. Wang et.al (2015) posit that the ‘product’ can be either a tangible 
physical product or an intangible service product. As stated in Section 1.4, Wang et.al (2015) further 
suggest that in the context of service supply chain management, two categories of supply chain 
systems exist, namely PSSCs and SOSCs. PSSCs have both physical products and services, for 
example, restaurants and food retail supply chains, while in SOSCs the ‘products’ offered are pure 
services for example financial consultancy and psychology advice (Wang et al., 2015). As discussed 
in Section 1.4, this study is limited to PSSCs. 
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 Figure 2.7: Service supply chain planning in VAN (adapted from Llewellyn (2017)) 
PSSCs entail various overlapping phenomena, which include demand planning, supply planning, and 
distribution planning as shown in Figure 2.7, which have been defined by Llewellyn (2017), in the 
context of VAN, as: 
1. Demand planning: A combination of statistical forecasting techniques using historical data (e.g. 
consumption data, historical campaigns, availability to consumers and epidemiology) and, anticipated 
trends and constraints (e.g. available supply, budget and product changes) to develop demand 
estimates for products and/or services in order to meet patients’ demand (Llewellyn, 2016).   
2. Supply planning: The coordination of inventory and orders to optimize the delivery of products to 
meet the patients’ needs—i.e. to provide sufficient products at the right place and at the right time in 
order to fulfill the demand plan. The outputs from a supply plan are replenishment orders and 
purchase orders with supply planning variables such as lead time, safety stock, stock on hand, 
minimum order quantities and delivery channel costs (Llewellyn, 2017). 
3. Distribution planning: This is a schedule of shipments of products between warehouse/depots, sub-
depots and PHCFs in order to fulfill a supply plan. A distribution plan takes into consideration the 
constraints of transport capacity and storage capacity in order to determine bottlenecks and optimize 
asset utilization (Llewellyn, 2017). 
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As stated in Section 1.3, this study is limited to supply planning. 
2.5.1. Transitioning to an ‘informed push’ approach 
The South African public healthcare pharmaceutical supply chain intends to transition from the use 
of an ‘uninformed pull system’—where stock orders are placed as per need by healthcare staff—to 
an ‘informed push system’ by the implementation of the VAN initiative (briefly introduced in Section 
1.1) (Llewellyn, 2017). The difference being that specialized supply chain management professionals 
will be utilized in each province and will make recommendations to PHCFs, rather than PHCFs doing 
their own ordering (Llewellyn, 2017). Llewellyn (2017) highlighted that the VAN model has been 
established based on the key features of: 
➢ Visibility: Specialized supply chain planners will make use of visibility on the consumption data 
and stock on hand. 
➢ Analytics: Analytical processes and Information Technology (IT) will be used to make ordering 
recommendations and optimization decisions 
➢ Network: The network of interlocking roles and responsibilities will link at national, provincial, 
district and PHCF level, offering clear definitions on what individuals are responsible for, and 
what technology links support them.  
An informed push model, which the VAN advocates for, will relieve the facility staff of supply chain 
planning and management, which they do not necessarily possess the expertise to perform (Llewellyn, 
2017). Specialists who have received the necessary training and have access to the required 
information technology tools and visibility will perform this work instead. The approach pursues an 
economy of skill. The transitioning of the supply chain will proceed in four stages, as depicted in 
Figure 2.8. Stage 3 represents the status quo when VAN is fully operationalized and Stage 4 represents 
the ideal futuristic state (Llewellyn, 2017):  
  
  
Figure 2.8: The scope of VAN (adapted from Llewellyn (2017)) 
(4) Informed Pull (3) Informed Push/ 
Advised Pull 
(2) Uninformed 
Pull 
(1) Uninformed 
Push 
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Stage 1 represents the status quo prior to the implementation of VAN, where the stock is sent to 
PHCFs based on assumptions and rough calculations from the higher levels of the supply chain. This 
stage utilizes no supply chain training. Stage 2 is when recipients make orders on their own. 
Demanders (recipients) are trained to calculate orders, though there is no analysis and upstream 
visibility. Stage 3 utilizes trained and informed planners. The planners use technology to make order 
recommendations based on visible sock levels and consumption data. Stage 4 employs a highly 
automated ordering. In this final stage, technology is used to make order recommendations to 
demanders who will only be required to authorize spend (Llewellyn, 2017). 
 The potential impact of product categorization in the South 
African public healthcare pharmaceutical supply chain 
As mentioned previously, it is reasonable to expect that some of the benefits that have been derived 
from implementing the concept of product categorization in other industries or in the healthcare sector 
outside of South Africa, could also be achieved if product categorization is applied to the South 
African public healthcare pharmaceutical supply chain. This section starts with a generalized 
discussion on the potential positive impact of implementing product categorization in this supply 
chain before proceeding to a discussion of the potential benefit within the context of the VAN service 
supply planning approach specifically. 
2.6.1. General comments on potential benefits 
Based on the findings presented in Section 2.3.4.1 and 2.3.4.2, product categorization can be 
postulated to potentially enable determination of optimal lot sizes for various pharmaceutical 
products, as well as replenishment frequency and safety stock levels for different product categories. 
Literature has suggested the possibility that the lower the replenishment lead time from the provincial 
depots, as an example, the lower the amount of safety stock that needs to be held by the PHCFs 
(Kritchanchai & Meesamut, 2015; Yadav, 2015).  
Within the South African public healthcare pharmaceutical supply chain, some products are highly 
sensitive to shortages and stock-outs and, as described in Chapter 1, these pose a high cost to both the 
healthcare system and its patients. In the wake of the extensive stock outs reported in South Africa, 
the Health Minister Aaron Motsoaledi in 2013 announced that: “A decision has been taken to 
implement a direct delivery system to certain categories of hospitals…” (Brand South Africa, 2013). 
The Minister mentioned this in a bid to curb stock-outs, enhance stock supply to hospitals, and free 
up depots so that deliveries can be made from suppliers directly to district hospitals and PHCFs more 
efficiently. However, it can be argued that not all pharmaceuticals need a direct delivery system nor 
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the conventional approach that has been there—the depot system because different products require 
different supply chain strategies since they have different products attributes and ‘one size does not 
fit all’ in terms of supply chain strategy. Therefore, it can be reasoned that a supply/replenishment 
plan should be developed to facilitate determination of replenishment and purchase orders required 
as well as stock transfers required where products in the product portfolio will have different supply 
chain pipelines/strategies according to their attributes e.g. demand, lead time to delivery and cost, etc. 
By incorporating product categorization, an on-time performance which also affects the variability of 
lead time has the potential to be optimized. Furthermore, literature has suggested that product 
categorization in a public healthcare pharmaceutical supply chain has the capability of increasing 
supply flexibility of various pharmaceuticals—the more flexible the supply is; the less lead time 
variability will potentially be displayed in order quantities. Product categorization based on product 
attributes (demand, value volatility, etc.) will possibly enable a better match between demanded 
products and supply chain strategies (continuous-flow, efficient, fast, and agile supply chains, etc.) 
which will potentially aid in enhancing the sustainable availability of medicines and a better 
performing public healthcare supply chain.  
2.6.2. Potential benefits within the VAN service supply planning approach 
specifically 
As discussed, the focus of this research is specifically on supply planning. Demand planning and 
distribution planning are generally well understood and well defined, but it can be less clear what 
supply planning comprises because it can have many overlaps with demand and distribution planning. 
Llewellyn (2017) posited that for VAN, supply planning is distinctly considered to pursue the 
following arithmetic:  
𝐷𝑒𝑚𝑎𝑛𝑑 𝑝𝑙𝑎𝑛 (𝑓𝑜𝑟𝑒𝑐𝑎𝑠𝑡 𝑐𝑜𝑛𝑠𝑢𝑚𝑝𝑡𝑖𝑜𝑛 𝑓𝑜𝑟 𝑡ℎ𝑒 𝑚𝑜𝑛𝑡ℎ)
− 𝐵𝑒𝑔𝑖𝑛𝑛𝑖𝑛𝑔 𝑜𝑓 𝑡ℎ𝑒 𝑚𝑜𝑛𝑡ℎ 𝑠𝑡𝑜𝑐𝑘 𝑜𝑛 ℎ𝑎𝑛𝑑 (𝑖𝑛𝑐𝑙𝑢𝑠𝑖𝑣𝑒 𝑜𝑓 𝑠𝑎𝑓𝑒𝑡𝑦 𝑠𝑡𝑜𝑐𝑘)
+ 𝑠𝑎𝑓𝑒𝑡𝑦 𝑠𝑡𝑜𝑐𝑘 (𝑓𝑢𝑛𝑐𝑡𝑖𝑜𝑛 𝑜𝑓 𝑑𝑒𝑚𝑎𝑛𝑑 𝑓𝑜𝑟𝑒𝑐𝑎𝑠𝑡 𝑎𝑐𝑐𝑢𝑟𝑎𝑐𝑦)
= 𝑹𝒆𝒒𝒖𝒊𝒓𝒆𝒅 𝒔𝒕𝒐𝒄𝒌 𝒇𝒐𝒓 𝒕𝒉𝒆 𝒎𝒐𝒏𝒕𝒉
− 𝑖𝑛𝑏𝑜𝑢𝑛𝑑 𝑜𝑟𝑑𝑒𝑟𝑠 𝑎𝑙𝑟𝑒𝑎𝑑𝑦 𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝑖𝑛 𝑡ℎ𝑒 𝑚𝑜𝑛𝑡ℎ
= 𝑵𝒆𝒘 𝒔𝒖𝒑𝒑𝒍𝒊𝒆𝒓 𝒐𝒓 𝒓𝒆𝒑𝒍𝒆𝒏𝒊𝒔𝒉𝒎𝒆𝒏𝒕 𝒐𝒓𝒅𝒆𝒓𝒔 𝒓𝒆𝒒𝒖𝒊𝒓𝒆𝒅 
It, therefore, implies that to determine the new supplier or replenishment orders required, constraints 
and decision points to be taken into account are: combined order and delivery lead time, stock on 
hand at the depot, delivery channel costs and the minimum order quantity (Llewellyn, 2017). After 
taking into consideration these constraints and decision points, the outputs are: a supply plan (i.e. 
supplier orders required) and a replenishment plan (i.e. stock transfers required), which all endeavor 
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to meet a demand plan (Llewellyn, 2016). With reference to the concept of product categorization, 
these outputs can be best determined upon selection of the appropriate supply chain strategy for each 
product category, cognizant of the product attributes.  
This study, as highlighted in Section 1.3, focuses on product categorization from the view of the two 
tiers of administration of the South African public healthcare pharmaceutical supply chain i.e. the 
national and provincial levels. The current national role in planning involves: coordinating product 
selection and demand forecasting for cross contracting; and overseeing in-contract compliance of 
demanders and suppliers with stock availability and ordering guidelines (Llewellyn, 2016). However, 
the new activities in the context of VAN will be: establishing and coordinating nationwide planning 
processes to ease communication along the supply chain; promoting the optimization and continuous 
improvement; and managing national health budget allocation and resolving supplier issues 
(Llewellyn, 2017). It follows that, with the establishment of a framework that enables the appropriate 
matching of product attributes and supply chain strategies, the national level will potentially be able 
to facilitate sufficient health budget allocation to assist and enable the various supply chain strategies. 
Moreover, the national level will likely be able to resolve and optimize supplier tendering and 
contracting issues, including upholding legislation and guidelines, to ensure various supply chain 
strategies offer the ‘right’ products at the ‘right’ time in the ‘right’ quantities. This will potentially 
pave the way for an improved pharmaceutical supply chain and enhance the sustainable availability 
of medicines.  
Consequently, a product categorization framework that matches product bundles, attributes and 
supply chain strategies will potentially smooth the supply-demand malfunctions and mitigate 
bullwhip effects. Moreover, product-driven supply chain sourcing and replenishment strategies i.e. 
supply chain strategies developed from the framework, will likely aid in stock (pharmaceuticals) 
availability and potentially contribute as input to the development of an appropriate distribution plan. 
Continuous improvement in national aggregation, issue resolution, and budget alignment can thus 
potentially be facilitated from the provincial level to the national level and vice versa. The Provincial 
Medicine Procurement Units (PMPUs) will thus likely be capacitated, through VAN, to create plans 
for their provincial districts and facilities. Such capacity building seeks to pursue the enactment of 
the Affordable Medicines Directorate (AMD) strategy where the short-term focus (1-3 years) is on 
three pillars—i.e. contracting, supply chain and contract management—in order to ‘get the right 
pharmaceuticals to the point of need’ and beyond three years the focus will be on ‘selecting the right 
pharmaceuticals’ (Llewellyn, 2017).   
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 Framework design requirements identified in Chapter 2 
Aspects discussed in this chapter can be used to deduce design requirements as defined by van Aken 
et al. (2007) which are detailed in Table 2.4. The table format will be used in the succeeding chapters 
to identify and describe design requirements discussed in each chapter. The table details the selected 
design requirement as discussed in the chapter and the corresponding requirement ID.  
Table 2.4: Framework design requirements identified in Chapter 2 
Requirement Req. 
ID 
User requirements (U) 
Not applicable (none identified) 
Functional requirements (F) 
Not applicable (none identified) 
Design restrictions (R) 
Not applicable (none identified) 
Boundary conditions (B) 
The framework’s output, in the form of recommendations for managing the public healthcare pharmaceutical 
supply chain, must align with the principles that underpin the Visibility and Analytics Network strategy, most 
importantly the concept of informed push. 
B1 
The framework’s output, in the form of recommendations for determining supply planning’s sourcing and 
replenishment plans, must contribute to the determination of supplier collaboration constraints (contracts and 
tenders) within the funding limitations. 
B2 
The framework’s output, in the form of recommendations for managing the public healthcare pharmaceutical 
supply chain, must align with the principles that underpin the South African Constitution. 
B3 
Attention points (A) 
The framework’s recommendation for managing supply chain strategies should ideally incorporate the direct 
delivery and depot system that are already operational in the South African public healthcare pharmaceutical 
supply chain 
A1 
 
 Conclusion 
In this chapter, consistent with Objective 1 of this research, a rationale for the research has been 
developed and Sections 2.3.4.1; 2.3.4.2; and 2.6 have detailed the impacts of the concept of product 
categorization when applied in various industries including the potential benefits product 
categorization can have in the South African public healthcare pharmaceutical supply chain.  An 
overview of the operation and management of the South African public healthcare pharmaceutical 
supply chain was detailed together with an overview of supply planning in line with the VAN 
principles in the South African public healthcare pharmaceutical supply chain. 
Chapter 3 will conceptualize product categorization methods together with generic product attributes 
to ensure the determination of critical product attributes specific for public healthcare pharmaceutical 
supply chains. Pharmaceutical product bundles will be identified as an essential element of the 
product categorization framework development. Supply chain strategies in SCM will be 
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conceptualized and contextualized to the South African public healthcare pharmaceutical supply 
chain in the scope of the VAN. To provide perspective, the supply chain goals which product 
categorization can target will also be discussed. Levers to control in supply chain strategy 
implementation, enabled through the VAN strategy, will also be established.  
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Solution development: Product attributes 
and supply chain strategies taxonomy  
 Introduction 
The findings of literature reviews as well as information gathered from SMEs, on a number of topics 
that are relevant to the development of a framework are presented in this chapter. Information is also 
synthesized in order to formulate interim solutions that are necessary inputs to the framework 
development presented in the following chapter. This chapter is consistent with this study’s second 
objective: 
Research objective 2: To investigate a number of operational aspects that are critical to 
informing the development of the framework design requirements. The sub-objectives 
associated with research objective 2 are: 
a) Determine and identify a set of product attributes critical for matching 
pharmaceutical product categories with supply chain strategies in public 
healthcare pharmaceutical supply chains using a triangulation method; 
b) Identify pharmaceutical product bundles based on existing classification and 
nomenclature systems used in healthcare; 
c) Provide an understanding of supply chain focus points which product 
categorization can target; 
d) Examine supply chain strategies and contextualize the product categorization 
framework development consistent with: the VAN supply chain; VAN service 
supply planning; and the South African public healthcare pharmaceutical supply 
chain; and 
e) Determine and tailor to the VAN strategy, the specific levers to control in product 
categorization and supply chain strategy implementation in the South African 
public healthcare pharmaceutical supply chain.  
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The chapter ends with a summary of the set of framework design requirements that are derived from 
the work presented.  
A significant portion of the text in Sections 3.2 and 3.3 has been reproduced from a conference article 
that was presented as part of this research. The full article citation is as follows: Mapowo, N., Bam, 
L., de Kock, I., & van Eeden, J. (2019). “Enabling product categorisation in a public healthcare 
pharmaceutical supply chain by underscoring the product attributes taxonomy”. Accepted for 
publication in: Proceedings of the 25th ICE/IEEE International Technology Management Conference, 
17th – 19th of June 2019, Sophia Antipolis, Nice, France. © 2019 IEEE. 
 Product categorization methods 
This section details the generic product categorization methods that have been established in the 
literature. The product attributes that are identified for use in matching product categories with 
appropriate supply chain strategies in these established categorization methods are presented. Finally, 
the most salient characteristics that differentiate public healthcare supply chains from commercial 
supply chains, in general, are briefly discussed. 
As briefly introduced in Section 2.2 and as a reminder to the reader, Fisher (1997) proposed that if 
products are classified based on their demand configurations, they fall into one of two categories: 
they are either primarily functional or primarily innovative—with functional products being 
characterized by the low profit-margins and predictable demand whereas innovative products are 
characterized by short lifecycles, high-profit margins, and volatile demand. Furthermore, Fisher 
(1997) posited that these product categories can be matched to supply chains which can either be 
physically efficient or market responsive. According to Fisher (1997), functional products are 
matched to efficient supply chains and mismatched to responsive supply chains, while the opposite 
holds true for innovative products. If products are not aligned with their appropriate supply chain 
strategies, this can result in overserving and overcharging functional products’ customers and 
underserving and undercharging innovative products’ customers. 
Various researchers have premised on Fisher’s pioneering framework to develop product 
categorization methods using diverse product attributes. Three such well-documented methods that 
can address SCM product categorization selection are: the DWV³ by Christopher and Towill (2000), 
the three-dimensional global classification system by Christopher and Towill (2002) and the Product 
Supply Characterization (PSC) model by Payne and Peters (2004). 
Stellenbosch University https://scholar.sun.ac.za
 Page | 38  
 
3.2.1. The DWV3 classification 
The DWV³ classification system utilizes five product attributes, namely the Duration of the product 
lifecycle, the time Window for delivery, the Volume, the Variety, and the Variability, which build 
the acronym DWV3. This classification method is mainly used to develop focused demand chains 
where processes are prioritized as a sequence of events with the end view of serving the ultimate 
consumer (Christopher & Towill, 2000). 
3.2.2. The three-dimensional global classification system 
The three-dimensional global classification system utilizes three product attributes, namely: product, 
demand, and lead-times. Each attribute is classified as one of two gradations (Christopher & Towill, 
2002): 
❖ Product (standard or special); 
❖ Demand (stable or volatile); and 
❖ Lead-time (short or long). 
The three-dimensional global classification system was developed with a focus on linking the supply 
chain strategy with the product lifecycle management, signifying that the most suitable supply chain 
strategy of a product differs depending on its stage in the product lifecycle (Christopher & Towill, 
2002). 
3.2.3. The Product Supply Characterization (PSC) model  
Payne and Peters (2004) asserted that the PSC’s focus is on addressing total supply chain costs and 
service performance to the customer. The PSC model utilizes seven (7) product attributes which are: 
❖ Volume,  
❖ Volatility,  
❖ Order line value,  
❖ The frequency of order lines,  
❖ Order line weight,  
❖ Substitutability of a product and  
❖ Number of customers buying each 
product 
The DWV3 and the PSC can potentially suit a public healthcare pharmaceutical supply chain, largely 
because the DWV3 has been employed in developing a focused demand supply chain, which in this 
case the end goal will be to serve the patient. Furthermore, the PSC focuses on service performance 
for the customer, which in the case of the healthcare pharmaceutical supply chain would be the 
healthcare delivery to the patients. However, the three-dimensional global classification system takes 
into consideration the order qualifiers and order winners in a supply chain and could, therefore, be 
beneficial to a public healthcare pharmaceutical supply chain in the reduction of costs and increase 
in performance.  
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It is evident that the three prominent categorization methods that have been presented here differ in 
terms of the product attributes on which categorization decisions are based. A consolidated set of 
product attributes that have been developed in literature is presented in the following section and 
consequently, salient supply chain-driving product attributes for public healthcare supply chains are 
determined. 
 Salient supply chain-driving product attributes 
Harris, Sullivan, Componation, and Farrington (2006) conducted an extensive systematic literature 
review of post-2000 product attributes employable in matching product categories with appropriate 
supply chain strategies, which were not focused on one particular company or industry. The study 
yielded a compilation of 15 generic product attributes. Consequently, Sullivan et al. (2007) premised 
on these product attributes and defined the respective measurable characteristics of these product 
attributes. The complete set of product attributes defined by Harris et al. (2006) together with the 
measurable characteristics by Sullivan et al. (2007) are presented in Table 3.1.   
Table 3.1: Product attributes and their measurable characteristics (reproduced from Mapowo, Bam, de Kock, and van 
Eeden (2019) © 2019 IEEE) 
Product 
attributes 
Examples of measurable characteristics DWV3 The three-dimensional 
global classification 
system 
PSC 
Cost Supply chain, inventory, and manufacturing       
Demand Variability, predictability, volatility, and volume       
Quality Defects and yield percentage       
Financial Profit margin per part       
Product Physical characteristics       
Lifecycle Phase and length of time in phase       
Design Manufacturability of the product       
Standardization Few customized features of the product       
Customer Responsiveness in service       
Uncertainty Customer demand and market environment       
Delivery On-time or on-schedule       
Flexibility Handling of change in demand, design, and delivery       
Inventory Product held in Kanban/JIT inventory       
Lead time Response time to deliver the product       
Production Capability and capacity to produce in a lean 
environment 
      
 
The table provides an indication of which of these product attributes are utilized in each of the three 
product categorization methods discussed in the previous section. The product attributes compilation 
by Harris et al. (2006) confirms the work done by Christopher and Towill (2000), (2002) and Payne 
and Peters (2004) in coming up with the three product categorization methods discussed in Section 
3.2. However, as an example, product attributes such as volume, volatility, and variability utilized in 
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the DWV3 method represent different dimensions of the expanded form of the ‘demand’ attribute 
identified by Harris et al. (2006). 
The product categorization methods discussed in this section were developed for use in the 
commercial sector. The product attributes established from literature are generic and research has not 
yet considered determining critical product attributes in the public healthcare pharmaceutical supply 
chain sector specifically. However, while there are certainly many commonalities between the 
dynamics of commercial sector supply chains and public healthcare supply chains, there are also 
distinct differences which would need to be taken into consideration when selecting appropriate 
product attributes for product categorization in a public healthcare supply chain. Several salient 
characteristics that distinguish public healthcare supply chains from commercial supply chains are 
briefly discussed in the following discussion. 
Lingervelder, Bam, and Bam (2016) systematically compared and highlighted differences between 
donor-funded supply chains with commercial supply chains. In their findings, characteristics of public 
healthcare pharmaceutical supply chains were discussed under the donor-funded supply chains 
grouping.  Six of the 12 characteristics which Lingervelder et al. (2016) describe as having 
distinctions between the two types of supply chains are relevant to supply planning within the public 
healthcare pharmaceutical supply chain, namely:  
i) The goals and objectives of a commercial supply chain typically focus on competitive 
advantage, revenue generation and profit maximization, whereas the public healthcare 
pharmaceutical supply chain typically aims at efficiently and cost-effectively ensuring 
sustainable availability of medication (Christopher et al., 2009; Harris et al., 2010; 
Kritchanchai & Meesamut, 2015; Yadav et al., 2014).  
ii) Supply chains comprise of an upstream segment with activities such as manufacturing, 
financing, warehousing, and forecasting, etc., and a downstream segment with activities 
such as stock storage and distribution to retailers and consumers. Commercial supply 
chains primarily manage the two segments coupled together while public healthcare 
supply chains ordinarily decouple the segments from one another (Nicholson, English, 
Guenther, & Claiborne, 2013).  
iii) In a public healthcare pharmaceutical supply chain, finances come from government 
funding and/or charitable donations from organizations and the recipients of the 
products and services often pay very little or nothing at mostly insignificant profit 
Stellenbosch University https://scholar.sun.ac.za
 Page | 41  
 
margins. However, in commercial supply chains, revenue generated from the sale of 
goods and services is largely the source of finance (Beamon & Balcik, 2008).  
iv) For public healthcare supply chains, especially at the national tier level, demand is 
largely characterized by unpredictability due to differences in the impact of the 
situation, demographic variations, and social and economic structures of the area. 
However, in commercial supply chains, there is considerable consistency in demand 
elasticity, demand patterns and forecasting abilities (Beamon & Balcik, 2008).  
v) The majority of public healthcare pharmaceutical supply chains have purchasing 
decisions that are made from competitive bidding processes, tenders, and short-term 
contracts or agreements, while commercial supply chains tend to pursue lasting 
relationships with partners to come up with long-term contracts and agreements 
(Schliephake, Stevens, & Clay, 2009).  
vi) Transport and logistics in public healthcare pharmaceutical supply chains have different 
orientations as opposed to commercial supply chains due to the complexity of 
conditions they must operate in. For example, commercial areas can opt not to target 
areas where there is poor transportation infrastructure but public healthcare 
pharmaceutical supply chains do not have that option as they have to address the 
population’s needs regardless of the operating conditions (Wassenhove, 2006).    
From the description of the six characteristics where public healthcare supply chains differ from 
commercial supply chains, it is evident that the product attributes deemed to be critical for product 
categorization in a commercial supply chain are not necessarily directly applicable to the public 
healthcare pharmaceutical supply chain without scrutiny and undergoing necessary adaptations or 
modifications. Thus, the triangulation approach is used to achieve strengthened construct validity and 
internal validity. The triangulation method is applied by firstly taking into account the understanding 
of the supply chain-driving product categorization methods as applied in various industries’ supply 
chains and subsequent product attributes as provided in the literature and already discussed in Section 
3.2 and this section. Secondly, subject matter experts (SMEs) are consulted to cross-check what 
literature provided, interpolating these provisions to public healthcare pharmaceutical supply chains. 
Finally, provisions from literature and inputs from SMEs are synthesized and a final list of proposed 
product attributes for use in public healthcare pharmaceutical supply chains are developed through 
the application of logical arguments and reasoning. Thus, as part of the triangulation method, the 
following section describes how inputs from SMEs were gathered as a second source of input for 
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determining the product attributes that are relevant in a public healthcare pharmaceutical supply 
chain. 
3.3.1. SME input incorporation methodology 
In order to determine appropriate supply chain-driving product attributes critical to the public 
healthcare pharmaceutical supply chain, a semi-structured interview was set up as shown in Appendix 
A. The compilation of product attributes by Harris et al. (2006) in Table 3.1 was used in the semi-
structured interview and the description of measurable characteristics of the product attributes by 
Sullivan et al. (2007) was provided in order to minimize ambiguity. A 5-point Likert-type scale was 
used to measure responses as this provided a greater degree of nuance than a simple ‘yes/no’ and 
gave granular feedback through a wide range of answer options. The Likert scale ranged from 
‘strongly unimportant’ to ‘strongly important’.  
Two open-ended questions were also included in the semi-structured interview, the first of these 
required that the respondents comment on the product attributes employed in the three generic product 
categorization methods established in this study. The responses indicated whether SMEs deemed the 
set of product attributes defined in any of the three established product categorization methods to be 
directly applicable to public healthcare pharmaceutical supply chains. The second open-ended 
question probed respondents to indicate whether apart from the 15 product attributes included in 
Table 3.1, there were any other product attributes which the respondent deemed critical. When 
interpreting these responses, care was taken to discern differences in wording but similarities in 
essence of the suggested product attributes compared to those already provided. Care was also taken 
in noting that research recommends that the number of product attributes to be used should strike a 
balance between too many and too few as it is neither desirable nor economically feasible to establish 
an extensive number of discrete supply chain pipelines as this would escalate operations management 
overheads (Christopher et al., 2009; Godsell et al., 2011; Harris et al., 2010). 
Since this study concerns SCM within the healthcare sector, individuals that are considered to be 
SMEs in either SCM or management of healthcare systems were selected as respondents and their 
backgrounds are detailed in Appendix B. Based on the different expertise of the SMEs and their 
various areas of specialty, the survey was designed to have a comprehensive base with views of the 
study from various critical expertise standpoints. These include the business analysis and 
improvement perspective, the VAN perspective, policy analysis perspective, maturity models 
analysis perspective, informed push model analysis perspective, strategic and operational supply 
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chain management perspective and the healthcare supply chain governance perspective. The input 
provided by these SMEs formed the second component of the triangulation method used in this study. 
3.3.2. SMEs feedback findings and analysis 
This section starts with a presentation of the results of the SME survey. Thereafter, a set of product 
attributes that have been selected based on the results of the SME survey are discussed in more detail. 
The discussion incorporates feedback received from the SMEs together with logical arguments. 
Specific emphasis is placed on arguments that are based on the characteristics that differentiate public 
healthcare pharmaceutical supply chains from commercial supply chains in general. In conclusion, a 
set of product attributes to be used for product categorization in public healthcare pharmaceutical 
supply chains is proposed. 
The first question of the survey required the SMEs to evaluate the importance of 15 product attributes 
for product categorization decision in public healthcare pharmaceutical supply chains. Additionally, 
respondents were requested to suggest additional product attributes that should also be taken into 
consideration. The feedback provided by the seven SMEs is summarized in Table 3.2 
If more than 50% (4+/7) of the respondents considered a product attribute to be either important or 
strongly important, then such a product attribute was deemed worthy of further consideration. Using 
this criterion, 12 of the 15 product attributes remained, namely: demand (7/7); lead time (7/7); 
delivery (6/7); quality (6/7); cost (6/7); life cycle (6/7); standardization (6/7); customer (6/7); 
uncertainty (6/7); flexibility (6/7); product (5/7); and financial (4/7).  
In response to an open-ended question, SMEs suggested four additional product attributes which they 
deem to be applicable, namely: shelf life; substitutability of the product; seasonality of the product; 
and a therapeutic group of the product.  
Each of the 12 product attributes that were indicated as being either strongly important or important 
by at least 50% of the respondents, as well as the four additional product attributes proposed by the 
respondents are considered in the discussion that follows. As per the triangulation method employed 
in this research, the discussion synthesizes inputs from literature, the inputs received from the SMEs 
as well as logical reasoning to ascertain the most critical product attributes for use in public healthcare 
pharmaceutical supply chains. 
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Table 3.2: SME’s responses to literature compilation of product attributes, and other suggested product attributes 
(reproduced from Mapowo et al. (2019) © 2019 IEEE) 
 Frequency of Occurrence 
S
o
u
r
c
e 
Product Attributes Examples of Measurable Characteristics 
S
tro
n
g
ly u
n
im
p
o
rta
n
t 
U
n
im
p
o
rta
n
t 
N
eu
tra
l 
Im
p
o
rta
n
t 
S
tro
n
g
ly im
p
o
rta
n
t 
P
r
o
v
isio
n
s fr
o
m
 lite
r
a
tu
r
e 
Cost Supply chain, inventory, and manufacturing   1 5 1 
Demand 
Variability, predictability, volatility, and 
volume 
   1 6 
Quality Defects and yield percentage   1 3 3 
Financial Profit margin per part 1  2 3 1 
Product Physical characteristics   2 3 2 
Life cycle Phase and length of time in phase   1 3 3 
Design Manufacturability of the product  2 2 3  
Standardization Few customized features of the product  1  5 1 
Customer Responsiveness in service   1 2 4 
Uncertainty Customer demand and market environment   1 1 5 
Delivery On-time or on-schedule   1 2 4 
Flexibility 
Handling of change in demand, design, and 
delivery 
  1 5 1 
Inventory Product held in Kanban/JIT inventory   4 2 1 
Lead time Response time to deliver product    2 5 
Production 
Capability and capacity to produce in a lean 
environment 
 1 3 2 1 
S
M
E
s 
a
d
d
itio
n
s/su
g
g
e
stio
n
s 
Shelf life Expiry dates and obsolescence     2 
Substitutability of a 
product 
Alternatives of the same drug 
   1  
Seasonality of a product Change in demand with relation to seasons    1  
Therapeutic group Product physical characteristics, product class     1  
 
3.3.2.1. Cost and financial product attributes 
According to Payne and Peters (2004), when matching product categories with the appropriate supply 
chain strategies, the categorization should be based on balancing required customer service levels 
with the total costs of supplying that service level. Such considerations are the same for both 
commercial supply chains and public healthcare supply chains. Costing approaches that are driven 
by activity-based methods in a public healthcare pharmaceutical supply chain, which is mainly 
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financed by the government and/or donors, enable supply chain managers to make better-informed 
decisions pertaining to the customer, product, and channel cost/profitability by providing the true cost 
of sending a particular product via a certain supply chain pipeline (Abdulsalam et al., 2015; van der 
Veeken & Rutten, 1998).  
At the operational level, the true cost in under-resourced public healthcare pharmaceutical supply 
chains is driven by factors such as the number of orders placed and order line weight which translates 
to lot sizes and replenishment frequency (Payne & Peters, 2004). Finances as a product attribute entail 
measurable characteristics, such as ‘profit margin per part’, ‘cost of procurement’, ‘holding cost’, 
‘cost of obsolescence’ and ‘cost of distribution’. These measurable characteristics aid in decisions 
such as: determining the threshold between products that are deemed affordable and those that are 
not; and choosing a certain supply chain strategy over another, thus directing the number of orders 
placed and the order line weight which impacts lot sizes and replenishment frequency. While these 
characteristics are extensively defined in the commercial supply chains (where the focus, as 
established before, is largely on competitive advantage, revenue generation, and profit maximization) 
they are most likely less commonly defined in public healthcare pharmaceutical supply chains (where 
the primary aim is the sustainable and cost-effective availability of medicines), even though they are 
equally relevant in this context (Abdulsalam et al., 2015; Birhanu, Lanka, & Neelakanteswara Rao, 
2014; Kim, Fowler, Shunk, & Pfund, 2012). 
As public healthcare pharmaceutical supply chains in developing countries in general, and in South 
Africa in particular, operate on restricted budgets and are mostly under-resourced, the ‘cost to the 
supply chain’ characteristic is considered a significant concern as this has a direct impact on the 
ability to fulfill the aim of ensuring sustainable and cost-effective availability of medicines. Thus, 
consistent with literature provisions and the recommendations from SMEs, ‘cost to the supply chain’ 
is deemed to be a critical product attribute to the public healthcare pharmaceutical supply chain 
product categorization. 
3.3.2.2. Demand, customer and uncertainty product attributes 
Lee (2002) asserts that products with a dependable source of supply and stable demand should not be 
managed in the same way as those with unreliable supply and unpredictable demand. Fisher (1997) 
added that the demand for functional products can be forecasted with ease, while it is complex to 
forecast demand for innovative products due to the unpredictability of demand. As established before, 
some public healthcare pharmaceutical supply chains are characterized by unpredictability in demand 
due to demographic variations, as well as the social and economic characteristics of the area being 
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served. Therefore, dynamics in demand need closer scrutiny in such supply chains. Some products 
also have stable demand in certain circumstances and unstable in other, for example, seasonal 
products and those that spike in demand during certain circumstances e.g. disease outbreaks. Hence, 
within the public healthcare pharmaceutical supply chain, products that have predictable, 
circumstantial or unpredictable demand cannot use the same supply chain strategy (Harris et al., 2010; 
Lee, 2002).  
Based on this reasoning, the ‘customer responsiveness in service’ and ‘uncertainty of demand’ 
attributes as well as the ‘seasonality of a product’ attribute proposed by the SMEs, will be merged 
and considered under demand. Demand is considered as a primary attribute in the three-dimensional 
global classification system with gradations: volatile or stable; however, the secondary attributes of 
demand—i.e. volume, volatility, and variability—have been used in the DWV3 classification system 
and these secondary attributes have been further expanded to formulate all seven of the PSC’s product 
attributes. This suggests that the consideration of demand as a product attribute is a priority to both 
commercial supply chains and public healthcare pharmaceutical supply chains. The use of the stated 
secondary and expanded attributes results in strategies which are highly sensitive to slight changes in 
the product portfolio and are needful of frequent review (Kritchanchai & Meesamut, 2015). Hence, 
such forms of the demand attribute are not the most appropriate for use on a national or global scale 
of the public healthcare pharmaceutical supply chain which is susceptible to extensive 
unpredictability (Aitken, Childerhouse, Christopher, & Towill, 2005; Godsell et al., 2011). The forms 
of the demand attribute should, however, be used as pointers in defining the threshold between 
demand that is considered volatile versus demand that is considered stable. Moreover, use of the 
secondary and expanded product attributes would result in an extensive number of differentiated 
pipelines which makes the supply chain unnecessarily complex as alluded to before. Based on the 
literature findings and SME input, demand should be considered as a critical product attribute in the 
public healthcare pharmaceutical supply chain since it embeds the secondary attributes and will make 
the supply chain strategies less sensitive to slight changes in the pharmaceutical product portfolio.    
3.3.2.3. Quality and life cycle product attributes 
From the perspective of production and operations management, quality is a product attribute with 
measurable characteristics such as defects and yield percentage that can be used for product 
categorization (Roscoe & Baker, 2014). In the context of a public healthcare pharmaceutical supply 
chain specifically, quality can be considered with measurable characteristics such as obsolescence 
and shelf life which pertain to inventory management (Musa, Gunasekaran, & Yusuf, 2014). This is 
potentially an important consideration as, unlike commercial supply chains which can choose to forgo 
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areas with unfavorable conditions, public healthcare pharmaceutical supply chains have a mandate to 
reach all populations regardless of the ease of accessibility, and hence inventory management has to 
be aligned to product life cycle to keep service levels high. Moreover, life cycle, which is derived 
from the shelf life (defined as  the recommended time that products can be stored while maintaining 
acceptable quality under specified conditions of distribution, storage, and display) and from lifetime 
(defined as the first date of use until the product expires/stops working), can be merged together with 
the consideration of quality (Christopher, 2011).   
Life cycle consideration is vital for products within the pharmaceutical product portfolio as this metric 
can vary significantly between products. Products with short life cycles require both a short end-to-
end pipeline and rapid time to market to facilitate continuous replenishment in relation to demand 
during the product life cycle (Aitken et al., 2005). This is applicable particularly to pharmaceutical 
products which need a cold chain. Products with short life cycles also potentially pose a greater risk 
of obsolescence. Examples of measurable characteristics for life cycle such as quality, lifetime, shelf 
life and obsolescence will thus be used to define the threshold between temporal and lasting life 
cycles. Based on these provisions from literature and how quality and life cycle were ranked by the 
SMEs, life cycle should be considered as a highly critical product attribute to a public healthcare 
pharmaceutical supply chain.  
3.3.2.4. Product and standardization product attributes 
The consideration of the physical characteristics of the product, which can be conceptualized as a 
binary gradation of either being standard or special according to Christopher and Towill (2002), 
appears to be vital in the selection of supply chain strategies. In terms of the level of standardization 
of products, Fisher's (1997) distinction between functional products (which satisfy basic needs with 
no significant change over time, and have longer life cycles with predictable demand and low profit 
margins) and innovative products (which are defined as having more volatile demand, shorter life 
cycles, and high profit margins) is relevant.  
The product’s physical characteristics and standardization considerations are potentially important 
considerations for both commercial supply chains and public healthcare pharmaceutical supply 
chains. SMEs highlighted the need to consider ‘therapeutic group’ and ‘substitutability of the product’ 
as product attributes, these can be merged into this discussion of the product’s physical characteristics 
and standardization of the product. In public healthcare pharmaceutical supply chains specifically, 
different products in the pharmaceutical product portfolio address different therapeutic needs and 
have different demand trends. Therefore, considering which products perform in what manner is 
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deemed critical in the selection of an appropriate supply chain strategy for a group of products which 
perform similarly. Furthermore, decisions on the positioning of inventory and capacity flexibility can 
be facilitated by information on the product’s physical characteristics and standardization of the 
product, in order to cost-effectively hedge against volatile demand (Harris et al., 2010).  
In terms of information to use when categorizing products according to physical and standardization 
attributes, end-to-end signals for the various products can be obtained and crucial flows of 
information can occur not only within the supply chain but also from the marketplace to the supply 
chain (Godsell et al., 2011).  
Thus, the therapeutic nature, substitutability of the product, criticality of the product, standardization 
of the product category and the physical characteristics of the product are deemed critical aspects. 
These product’s characteristics should be taken into consideration in making a distinction between 
‘standard’ and ‘special’ products and consequently identifying appropriate supply chain strategies in 
the public healthcare pharmaceutical supply chain. A more entailing distinction between ‘standard’ 
and ‘special’ pharmaceutical products based on the therapeutic nature, criticality of the product, and 
standardization of the product category will be given in Section 3.4. 
3.3.2.5. Delivery and lead time product attributes 
The consideration of delivery lead time has been an essential aspect in the development of focused 
demand chains where processes are prioritized as a sequence of events with the end goal of serving 
the ultimate consumer (Childerhouse, Aitken, & Towill, 2002). The time window for delivery is an 
appropriate consideration in ‘leagile’ strategies—where both lean and agile paradigms are involved—
with products that either require rapid replenishment soon after an order is placed or products 
expected to have a short life cycle in the market (Aitken et al., 2005). The lead time consideration is 
potentially important for both commercial supply chains and public healthcare pharmaceutical supply 
chains. A failure in service levels of time-to-market results in lost sales and opportunity costs, 
implying that lead time to resupply a market drives the organization’s capability to respond quickly 
to demand even when there is a bullwhip effect (Qi et al., 2009). Moreover, too long a lead time 
results in stock-outs and obsolescence, leading to market mediation costs and penalties as per 
stipulated regulations in contracts, tenders or constitution (Christopher, Peck, & Towill, 2006; 
Christopher & Ryals, 2014). Based on these considerations and the input from the SMEs on the 
delivery lead time, the attribute is deemed essential in enhancing the sustainable availability of 
medicines in public healthcare pharmaceutical supply chains. This is because pharmaceutical 
products are needed at different times, at different primary healthcare facilities in different volumes 
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and at different costs to the supply chain. The ability of delivery lead time to be lean when there is a 
need to deliver to stock, and the ability of delivery lead time to be agile when there is a need to deliver 
to demand, will potentially drive decision-making on whether to utilize on-time or on-schedule 
deliveries. This is likely particularly applicable for pharmaceutical categories such as epidemic 
medication where there is low and fairly constant demand in times where there are no outbreaks, and 
sudden surges in demand in times where there are outbreaks.  
Thus, it is recommended that measurable characteristics such as order cycle time, supply takt time, 
response time to deliver the product, on-time or on-schedule deliveries, and time service levels are 
used to define the threshold between short and long lead time. 
3.3.2.6. Flexibility product attribute 
Lastly, flexibility in measurable characteristics such as the handling of the change in demand, design, 
and delivery, is an aspect that can be designed inherently for a supply chain strategy. This can form 
part of the product categorization under the supply chain strategy implementation and management 
itself. Thus the ‘flexibility’ attribute should be considered not under the product attributes taxonomy 
but under the supply chain strategy taxonomy. This supply chain strategy taxonomy will be developed 
in Sections 3.6 of this chapter. 
3.3.3. Deduced product attributes taxonomy 
Based on the preceding discussion and the findings presented in this chapter, it is proposed that the 
critical product attributes for product categorization in the South African public healthcare 
pharmaceutical supply chain are product, demand, cost, life cycle and lead time to deliver, which 
form the acronym PDCL2. These product attributes, together with examples of measurable 
characteristics for each attribute, are summarized in Table 3.3. 
Table 3.3: Consolidated product attributes for product categorization in the public healthcare pharmaceutical supply 
chain (reproduced from Mapowo et al. (2019) © 2019 IEEE) 
Public Healthcare Pharmaceutical Supply 
Chain Product Attributes (with gradations) 
Examples of Measurable Characteristics 
Product (standard or special) 
Therapeutic nature, substitutability of the product, 
standardization of product category and physical characteristics. 
Demand (stable or volatile) Variability, volatility, volume, and uncertainty. 
Cost to the supply chain (affordable or expensive) 
Procurement cost, holding cost, obsolescence cost and 
distribution cost. 
Life cycle (temporal or lasting) Product lifetime, shelf life, obsolescence, and product quality. 
Lead time to deliver (short or long) 
Supply cycle time, supply takt time, response time to deliver 
product, on-time or on-schedule and time service levels. 
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In line with the preceding discussion, these consolidated product attributes can be viewed in binary 
gradations. These binary gradations are given in the first column of Table 3.3. 
It is proposed that since the intention is to use the product attributes at both the national and provincial 
operational levels under the informed push model of the VAN reference framework, each province 
should determine and define its own threshold between the binary gradations within the boundaries 
provided by the national tier, based on the measurable characteristics associated with each product 
attribute. This means that each province is responsible for quantifying, for example, what constitutes 
a long lead time or what constitutes a high cost, based on the province’s specific circumstances i.e. 
provincial healthcare budgets, the marketplace, ease of doing business, etc. As a recommendation to 
the various provinces, the basis for determining the thresholds between the binary gradations can be: 
Product attribute: The proposed basis for determining this threshold requires a high-level 
understanding of certain classification and nomenclature systems that are used in healthcare. 
Consequently, this is discussed in detail in Section 3.4. 
Demand attribute: The threshold between stable and volatile demand can be determined based on 
measurable characteristics such as volume, variability, volatility, and uncertainty, as established in 
Table 3.3. For the South African public healthcare pharmaceutical supply chain, variability, volatility, 
and uncertainty are recommended to be the most salient measurable characteristics for determining 
between stable and volatile demand. This is because the concepts of variability, volatility and 
uncertainty narrate to both demand and supply predictability and spikes in demand which 
significantly affect the upstream supply chain—bullwhip effect (Christopher et al. 2009). Hence, 
pharmaceutical products that have fairly constant or predictable demand in the short or medium-term 
demand and/or supply plans of a province can be considered ‘stable’ while those that spike 
unpredictably can be considered ‘volatile’. 
Cost to the supply chain attribute: The threshold between affordable and expensive cost can be 
determined based on measurable characteristics such as procurement cost, holding cost, obsolescence 
cost and distribution cost as established in Table 3.3. At the operational level, the true cost of the 
stated measurable characteristics is driven by factors such as the number of orders placed and order 
line weight which translates to lot sizes and replenishment frequency. Consequently, order line 
values, frequency of order lines and order line weights can then be used to determine between 
expensive and affordable cost based on the procurement cost, holding cost, obsolescence cost and 
distribution cost. This marks whether a product bundle’s supply pipeline has an affordable or 
expensive cost to the supply chain (Harrison, Lee, & Neale, 2018; Qi et al., 2009). 
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Life cycle attribute: The threshold between temporal and lasting life cycle can be determined from 
the view of measurable characteristics such as product lifetime, shelf life, obsolescence, and product 
quality as established in Table 3.3. For the South African public healthcare pharmaceutical supply 
chain, it is recommended that the most important measurable characteristics in determining the 
threshold between temporal and lasting life cycle are: (i) the shelf life which defines the recommended 
time that pharmaceutical products can be stored while maintaining acceptable quality under specified 
conditions of distribution, storage, and display; and (ii) the lifetime which defines the first date of use 
until the pharmaceutical product expires/stops working. Shelf life and lifetime enable supply chain 
managers to determine the risk of obsolescence of pharmaceutical products and should be considered 
in the context of the cost to the supply chain i.e. procurement cost, holding cost, obsolescence cost 
and distribution cost. Products that require a short end-to-end pipeline, rapid time to market and have 
short shelf life and lifetime can be considered to have a temporal life cycle, with the opposite being 
true for a lasting life cycle. 
Lead time to deliver attribute: The threshold between short and long lead time can be determined 
from the view of measurable characteristics such as supply cycle time, supply takt time, on-time or 
on-schedule and time service levels as established in Table 3.3. For the South African public 
healthcare pharmaceutical supply chain, it is recommended that important measurable characteristics 
in determining the threshold between short and long lead time to deliver pharmaceutical products are: 
(i) the supply takt time which defines the ratio between available time and customer demand; (ii) 
supply cycle time which defines the average time to complete a particular process in order to meet 
demand; and (iii) time service levels. Pharmaceutical products that cannot be sourced nor replenished 
rapidly based on the supply cycle time, supply takt time, and time service levels, can constitute the 
long lead time, while the opposite is true for a short lead time.   
In this section, the triangulation method which involved the use of literature, SME input and the 
application of logical arguments and reasoning based on an understanding of SCM in public 
healthcare, has been used to propose the most appropriate product attributes for product 
categorization in the public healthcare pharmaceutical supply chain. These product attributes are 
essential in matching pharmaceutical products in the product portfolio with appropriate supply chain 
strategies in order to enhance the cost-effective and sustainable availability of medicines. 
Establishment of the PDCL2 product attributes taxonomy, which defines the functional requirements 
of the product categorization framework design, provide answers to questions raised in the research 
agenda set by Mapowo, Bam, de Kock, and van Eeden (2018) for the incorporation of product 
categorization into the South African public healthcare pharmaceutical supply chain. It is deemed 
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feasible to incorporate the PDCL2 product attributes taxonomy into the VAN reference framework of 
the South African public healthcare pharmaceutical supply chain specifically, and the taxonomy is 
most likely also applicable in the public healthcare pharmaceutical supply chains of other countries. 
As briefly mentioned in the preceding discussion, the healthcare industry has established standardized 
classifications and nomenclature systems that are applicable to medication. The succeeding section 
provides an understanding of how pharmaceutical products can be bundled up together according to 
the established standardized classifications in the healthcare sector, thereby proposing a mechanism 
for determining the threshold between the ‘standard’ and ‘special’ gradations of the pharmaceutical 
‘product’ attribute. 
 Classification and nomenclature systems in healthcare 
The Global Standards 1 (GS1)5, in an executive summary in 2015, compiled and suggested that 
healthcare classification and nomenclature systems are typically developed for distinct purposes, such 
as Anatomical Therapeutic Chemical (ATC) classification by the World Health Organization (WHO), 
tariff code harmonization by the World Customs Organization and more strategic purposes such as 
purchasing and spend analytics or regulatory purposes such as Global Device Nomenclature (GMDN) 
(Global Standards 1, 2015).  
Table 3.4: Prominent horizontal and vertical classification and nomenclature standards (adapted from Global Standards 
1 (2015))  
System Definition/Description 
Maintenance 
Agency 
Declared Purpose 
eCl@ss 
Standardized Material and Service 
Classification and Dictionary - cross-industry 
product data standard for classification and 
description of products and services  
eCl@ss 
Association 
Procurement, controlling and 
distribution. Company-wide 
process data management as well 
as engineering. 
UNSPSC 
United Nations Standard Products and Services 
Code® (UNSPSC®) is an open, global, 
multisector standard for efficient, accurate 
classification of products and services 
Managed by GS1 
US for the UN 
Development 
Programme 
(UNDP) 
Used for: Cost-effective 
procurement optimization. Full 
exploitation of electronic 
commerce capabilities. Typically 
used by purchasing organizations 
for spend analysis 
AHFS 
American Hospital Formulary Service and 
Pharmacologic Therapeutic Classification - 
classification allows the grouping of drugs with 
similar pharmacologic, therapeutic, and/or 
chemical characteristics 
American Society 
of Health-System 
Pharmacists 
Clinical: The mission of AHFS 
Drug Information® (AHFS DI®) 
is to provide an evidence-based 
foundation for safe and effective 
drug therapy. 
 
 
5
 GS1 is an international standards organization that develops and maintains global standards for the sake of business 
communication. It has worldwide member bodies in more than 100 countries. 
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Appendix C provides a listing of the various classification and nomenclature systems that are used in 
healthcare (limited and with a direct impact to supply chain strategies) and the acknowledged purpose 
of each system. Table 3.4 provides an excerpt of the list in Appendix C, detailing the two most 
commonly used horizontal (i.e. cross-industry) systems, namely: eCl@ss; and United Nations 
Standard Products and Services Code (UNSPSC). The table also provides detail on one vertical (i.e. 
industry-specific) system, namely: American Hospital Formulary Service and Pharmacologic 
Therapeutic classification (AHFS) (Hepp, Leukel, & Schmitz, 2007).  
Research has suggested that bundling the pharmaceutical products according to the eCl@ss 
classification has the potential to aid with a number of functions in the supply chain, including: spend 
analysis; lot sizing in procurement; and better supply and distribution planning (Global Standards 1, 
2015). The UNSPSC standard facilitates the mining of consumption data. As such, if it is employed, 
it could not only aid spend analysis but could also support more cost-effective procurement. 
Furthermore, in the context of VAN, by facilitating the mining of consumption data, the UNSPC 
standard could impact visibility and analytics positively. Categorizing products according to the 
AHFS standard would aid in grouping medicines with shared pharmacological and therapeutic 
characteristics—such products would most probably have similar demand trends.  
An alternative mechanism for categorizing pharmaceutical products is to base this categorization on 
the medicine schedule, which defines different levels of regulatory control of pharmacologically 
active substances, either in the context of active pharmaceutical ingredients, naturally-occurring 
products or extracts thereof, or finished pharmaceutical products (Medicine Control Council, 2014). 
The Innovative Pharmaceutical Association South Africa (2016) distinguished pharmaceuticals to be 
either unscheduled medicine or over-the-counter (OTC) medicine or prescription medicine according 
to their schedules—where a medicine schedule is a number assigned to a pharmaceutical product 
according to its benefits and risks i.e. the lower the risk the lower the number assigned to it. 
Unscheduled medicines, for example, aspirin and vitamins have a schedule of 0 (S0) and these can 
be purchased in an open shop e.g. local supermarket, health shop or pharmacy. OTC medicines 
include treatments for headaches, colds and coughs and these have a schedule of 0, 1 and 2, and can 
be purchased without a prescription at a pharmacy. Prescription medicines have a schedule of 3 (S3) 
or higher and can only be obtained with a prescription from the doctor, dentist or permitted health 
professional (Innovative Pharmaceutical Association South Africa, 2016; Medicine Control Council, 
2014). These schedules are summarized in Table 3.5. 
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Table 3.5: Medicine schedules (adapted from Innovative Pharmaceutical Association South Africa (2016)) 
Medicine 
schedule 
Available at: 
0 General shops like supermarkets e.g. simple analgesics 
1 Over-the-counter (OTC) in a pharmacy e.g. antifungal skin creams 
2 OTC in a pharmacy with sale record to be kept e.g. a cough and cold medication 
3 Prescription only from the pharmacy dispensary—6 months repeat allowed e.g. diabetes medicine 
4 Prescription only from the pharmacy dispensary—6 months repeat allowed e.g. anti-infectives 
5 Prescription only from the pharmacy dispensary—repeats stipulated e.g. psycho-active medicines 
6 Prescription only, therapeutic narcotics e.g. narcotic painkillers 
7 Controlled substance e.g. cannabis and heroine 
8 Strictly controlled substances e.g. nabilone, amphetamine and dexamphetamine 
In this study, taking from the most salient medicine groupings from the various classification and 
nomenclature systems that are used in healthcare, medicine schedules will be used to grade the 
‘product’ attribute of the established PDCL2 product attributes taxonomy. In general, the scheduling 
status of a medicine/substance is decided based on the safety in use and the requirements for 
professional advice and/or supervision in the medicine use (Medicine Control Council, 2014). 
Moreover, consideration is given to the requirements for control over access, possession, and supply 
of these medicines as stipulated in international agreements/standards. The Medicine Control Council 
(2014) summarized the essential factors in determining the schedule of medication as follows:  
➢ evidence of substance toxicity and the safety in use;  
➢ the intended use of the substance/medicine;  
➢ the need for medical diagnosis, monitoring, and management by a healthcare professional;  
➢ the potential for abuse of the medicine; and 
➢ the need for access to the medicine/substance. 
In line with the approach proposed in Section 3.3, there is a need for a binary gradation of the 
‘product’ attribute of the PDCL2 product attributes taxonomy. It is proposed that the categories in the 
medicine schedule can be divided into two bundles for this purpose. More specifically, it is proposed 
that the S0, S1, S2, S3 and S4 medicine schedules can be bundled to form the “standard” category 
defined in the PDCL2 product attributes taxonomy and the S5, S6, S7, and S8 medicine schedules can 
be bundled to form the “special” category. This bundling of the medicine schedules takes dosage 
form, route of administration, strength, indication, dose, duration of treatment or a combination of 
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these factors into account, with the less restrictive regulatory control of pharmacologically active 
substances constituting the S0-S4 bundle/gradation. Moreover the S0-S4 medicine schedule bundle 
are mostly high-volume products, administered with a limit of 6 months’ repeat supply and have 
better ease of access/availability as they can be found in general shops and pharmacy dispensaries 
with less restrictive regulatory control (Innovative Pharmaceutical Association South Africa, 2016; 
Medicine Control Council, 2014). In contrast, the S5-S8 medicine schedule bundle/gradation are 
mostly low-volume products which may have a moderate to high potential for abuse or for producing 
dependence, which then necessitates close medical management and supervision and strict control 
over supply with some medicine only being available to medical practitioners who have obtained 
special permission from the Medicines Control Council for use and prescription (Medicine Control 
Council, 2014). Therefore, these two medicine schedule bundles/gradations (S0-S4 and S5-S8) can 
be supplied differently and would need different supply chain strategies based on the other gradations 
of the PDCL2 product attributes taxonomy. Therefore, the medicine schedules will be identified as 
part of the design restrictions (R) of the framework input to the framework development.  
In the development of the product categorization framework, it is important to note that the 
implementation of product categorization pursues or seeks to address different goals, this is discussed 
in the succeeding section.  
 Which goals should product categorization target?  
Ketchen and Hult (2007) suggested that there are various goals that one could seek to achieve through 
the implementation of product categorization in a supply chain and that the methodologies employed 
in implementing product categorization depend upon the goal that is being pursued. Three potential 
goals that are associated with product categorization in a supply chain are:   
➢ Cost-based. Costs (and profits) cannot be disregarded in the development of the product 
categorization concept, however, cost-based analyses only (i.e. estimating, allocating and 
assigning costs) leave much unanswered. Ozkul (2012) states that a particular shortcoming of 
cost-based analysis used in isolation is the inability to assign costs directly to vital business 
entities. Ketchen & Hult (2007) opine that the cost-based approach revolves around the 
connotation of resolving problems rather than seeking opportunities. 
➢ Value-based. This approach entails categorizing products by economic value, for instance, the 
total revenue generated. The approach, therefore, is not exclusively concerned with assigning 
costs, instead of segmenting product categories to determine profitability (Lee, 2002). Ozkul 
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(2012) opine that the approach does not constitute categorizing just for the sake of categorizing 
and recommend that the categories that are used should be sizeable enough to complement the 
supply chain strategy.  
➢ Needs-based. When the goal is needs-based, categorization is done on differentiated product 
drivers that clients have for a distinct supply chain service. Therefore products are categorized 
based on a common set of clients’ needs and internal resources, such as sales, and the 
categorization can provide insight on determining and validating clients’ needs (met or unmet) 
(Ketchen & Hult, 2007). The purpose is to match sector needs with the correct supply chain 
service with the aim of gaining competitive advantage (Fisher, 1997). 
The product categorization concept as applied in the South African public healthcare pharmaceutical 
supply chain in this study, can be viewed as having both a needs-based and a cost-based goal. This is 
primarily due to the supply planning focus, which is on the sustainable availability of medication 
(need) in a cost-effective manner (cost).  
A discussion of supply chain strategies is provided in the succeeding section to determine the most 
salient taxonomy for the product categorization framework development.  
 Generic supply chain strategies classifications 
Various generic supply chain strategies classifications have been suggested in the literature and 
according to Fisher (1997), two supply chain types exist (i.e. physically efficient and market 
responsive) as briefly introduced in Section 2.2 and 3.2. Supply chains in various industries suffer 
from an excess of some products and a shortage of others due to the supply chain’s inability to 
effectively predict demand (Harris et al., 2010). Fisher (1997) posited that the root cause of the 
problems such supply chains face is a mismatch between the product-type and the supply chain-type.  
The various generic supply chain strategies classifications will be discussed in the remainder of this 
chapter as part of identifying building blocks for decision making on product categorization 
framework design requirement specifications.   
3.6.1. Physically efficient and market responsive supply chain classification  
Physically efficient supply chains’ fundamental focus is cost reduction and the efficient use of 
resources (Fisher, 1997). Sullivan et al. (2007) emphasized that this type of supply chain pursues the 
creation of the lowest possible cost of operation through the removal of all non-value adding 
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activities, pursuing economies of scale and optimizing resource utilization. Fisher (1997) proposes 
that companies that offer functional products should employ an efficient supply chain. 
In contrast, the market responsive supply chain is fundamentally focused on meeting the customer 
delivery expectations irrespective of demand variability (Fisher, 1997). Fisher (1997) proposes that 
market responsive supply chains are most appropriate for innovative products. The possibility of a 
stock-out increases when product demand is uncertain and volatile (Harris et al., 2010). Lee (2002) 
also asserts that supply disruption risks are mitigated in market responsive supply chains by the 
strategic placement of inventories and thus such a supply chain can adapt to customer, market, and 
supply uncertainty. Table 3.6 details the generic attributes of physically efficient and market 
responsive supply chains. 
Table 3.6: Physically efficient and market responsive supply chains (adapted from Fisher (1997)) 
 Physically efficient Market responsive 
Primary purpose 
Supply predictable demand efficiently 
at the lowest possible cost 
Respond quickly to unpredictable demand to minimize 
stock-outs, forced markdowns, and obsolete inventory 
Inventory strategy 
Generate high turns and minimize 
inventory throughout the chain 
Deploy significant buffer stocks of parts or finished 
goods 
Lead-time focus 
Shorten lead time if it does not 
increase the cost 
Invest aggressively in ways to reduce lead time 
Product-design 
strategy 
Maximize performance and minimize 
cost 
Use modular design to postpone product 
differentiation for as long as possible 
As elaborated by Fisher (1997) when he classified supply chains as either physically efficient or 
market responsive, literature has further classified supply chain strategies based on: lean and agile 
(also inclusive of the leagile or hybrid supply chain). Another prominent classification that has been 
proposed in the literature and which is employed within the description of the VAN blueprint is the 
distinction between pull and push strategies (Birhanu et al., 2014). Other supply chain strategies do 
exist; however, they fundamentally derive and extend from the aforementioned supply chain 
classifications. 
3.6.2. Lean and agile supply chain classification 
Leanness and agility of supply chains have been employed for instance in cost reduction and coping 
with uncertainty, and these exhibited variations in production volume, the degree of product variety 
required and product variability (Birhanu et al., 2014). Classification based on leanness and agility 
(as well as leagility) has largely been attributed to Naylor, Naim, and Berry (1999), who defined 
agility and leanness as:  
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Agility—"using market knowledge and a virtual corporation to exploit profitable 
opportunities in a volatile marketplace.” 
Leanness—"developing a value stream to eliminate all waste, including time, and to ensure a 
level schedule” 
In essence, the lean strategy is at most the equivalent of Fisher’s physically efficient and, the agile 
strategy is at most the equivalent of Fisher’s market responsive. Research has argued that lean 
principles are more convenient for functional/commodity products where demand is predictable and 
agile principles are more convenient for innovative products where there is unpredictable demand 
(Birhanu et al., 2014). The applications of leanness and agility are shown in Figure 3.1. 
Demand 
for variety 
High 
Less 
convenient 
Agility 
Low Leanness 
Less 
convenient 
  
Low High 
  
Demand for variability  
Figure 3.1: Leanness and agility applications (adapted from Naylor et al. (1999)) 
Minnich (2007) termed a combination of lean and agile strategies a hybrid supply chain, arguing that 
there are instances where either a purely lean or agile approach might not be appropriate, in which 
case the two may be combined to form a hybrid supply chain. The hybrid supply chain concept is 
synonymous to the ‘Leagile’ supply chain strategy which combines lean and agile strategies at a 
decoupling point (where leanness will be used upstream and agility downstream of the decoupling 
point) so as to optimize supply chain management (Naim & Gosling, 2011). Leagile supply chain 
strategies can be used where demand is stable and predictable for some products and the converse 
can be true for other products within the same product portfolio, hence the merging of the strategies. 
Christopher, Peck, and Towill (2006) went on to propose four types of supply chain pipelines 
sensitive to supply uncertainties and lead times as shown in Figure 3.2. 
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Figure 3.2: How demand/supply characteristics determine the pipeline selection strategy (adapted from Christopher et 
al. (2006)) 
Christopher et al. (2006) argued that a ‘continuous replenishment’ pipeline would be an appropriate 
strategy in situations where lead-times are short, and demand is predictable. They suggested that this 
is how companies such as Procter & Gamble use the Vendor Managed Inventory—which is the use 
of point-of-sale data for rapid replenishment of individual stores—to manage their supply chain with 
Wal-Mart in the USA.  If demand is unpredictable and lead-times are long, the ‘postponement’ 
pipeline, which entails the use of strategic inventory to configure/assemble/distribute as per need, is 
viable (Christopher et al., 2006). When lead-times are long and demand is predictable, ‘lean’ 
strategies are employable and when lead-times are short and demand is unpredictable, ‘agile’ 
strategies are more viable (Christopher et al., 2006). 
The use of lean, agile and leagile strategies can potentially be applied to the South African public 
healthcare pharmaceutical supply chain as product demand in the pharmaceutical product portfolio 
varies in stability and predictability.  
3.6.3. Pull and push supply chain classification 
Another prominent classification of supply chain strategies that have been proposed in the literature 
is the distinction between pull and push strategies. Birhanu et al. (2014) posited that long-term 
forecasts are the basis for production decisions in push-based systems, while demand drives 
production decisions in pull-based systems. In pull strategies, execution of processes is initiated in 
response to customer orders, and in push strategies, these processes are initiated in expectation of 
customer orders (Olhager, 2003). Pull and push strategies can be combined to form a push-pull 
LEAN 
Plan and execute 
AGILE 
Postponement 
AGILE 
Quick response 
LEAN 
Continuous 
replenishment 
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strategy similar to the case of lean and agile strategies being combined to form leagile strategies. 
Olhager (2003) asserted that in the push-pull strategy, based on network equilibrium, the push 
element is utilized in the component procurement while the pull element is used for production. Kim, 
Fowler, Shunk, and Pfund (2012), however, suggested that in as much as the push-pull strategy has 
benefits for example in lowering inventory costs and flexibility in adapting to a volatile market, the 
strategy has potential supply chain risks. These risks relate to the capability to fulfill orders and 
robustness against external variability. Birhanu et al. (2014) added that different locations require 
different inventory levels to be responsive to lead time requirements to customer deliveries. Unstable 
order fulfillment performance can occur if the processing time and transportation time are too long in 
relation to customer delivery lead time requirements, resulting in penalties for service level failures, 
opportunity costs and loss of goodwill (Kim et al., 2012).  
A pull and push classification system describe the VAN concept where the shift is towards an 
informed push system as detailed in Sections 1.1 and 2.5. 
3.6.4. Salient supply chain strategies classifications 
Various supply chain strategies have been developed in research, which premised on the 
aforementioned strategies. The salient, most descriptive and holistic models being the ones developed 
by Perez (2013) in the form of six generic supply chain models, which he grouped into two clusters 
that align to the types of supply chains defined by Fisher—physically efficient and market responsive 
supply chains. These generic supply chain strategies align with the supply chain operations reference 
framework (SCOR)6 four distinct processes, namely source; make; deliver; and plan (Huan, Sheoran, 
& Wan, 2004). Three of Perez’s generic supply chains are oriented to achieve physical efficiency and 
the other three are oriented to achieve market responsiveness. 
 
 
 
 
 
 
6 The SCOR model integrates the well-known business process concepts such as: benchmarking, re-engineering, and process 
measurement, into a cross-functional framework with: standard descriptions of management processes; relationships among the 
standard processes; management practices that produce best performance; standard metrics to measure process performance; and 
standard alignment to software features and functionality (Huan et al., 2004). 
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The three physically efficient supply chain models defined by Perez (2013) are: 
❖ Continuous-flow supply chain: This supply chain employs a ‘make to stock’ decoupling point 
where production is scheduled to replenish predefined stock levels based on a specific reorder 
point for inventory in the production cycle. It pursues high service levels and low inventory levels. 
It is mainly proposed for businesses with short shelf-life products, for example, bread and dairy 
products.  
In the South African public healthcare pharmaceutical supply chain, such a strategy is potentially 
useful in the supply of selected chronic medication which can potentially be regularized since the 
demand is stable and predictable. Pharmaceuticals can be supplied using a ‘supply to stock’ 
decoupling point. The strategy can also be used for seasonal prescription medication and certain 
OTC medication by replenishing predefined stock levels within the season of high demand. The 
same approach is possibly applicable even during seasons of low demand but with a different 
predefined stock level. 
❖ Efficient supply chain: This supply chain has production scheduled based on sales expectations 
for the duration of the production cycle, using a ‘make to forecast’ model as a decoupling point. 
It has been proposed for businesses with commoditized products, for example, cement and steel. 
Such a supply chain strategy is potentially useful in the public healthcare pharmaceutical supply 
chain in supplying anticipated demand of prescription and OTC medication with a steady and 
predictable demand. Pharmaceuticals can use a ‘supply to forecast’ decoupling point. It can also 
be used in supplying forecasted vaccine medication according to the known demographics of a 
particular area/region.  
❖ Fast supply chain: This supply chain has production scheduled in a single batch per stock keeping 
unit (SKU), with the size being defined by the season’s sales expectations, and utilizing a ‘make 
to forecast’ decoupling point. The fast supply chain has been proposed for companies that engage 
in catalogue sales and trendy apparel, for example, fashionable clothing. 
Such a strategy is potentially useful in the public healthcare pharmaceutical supply chain in 
supplying seasonal pharmaceuticals of any category (chronic, prescription, OTC medicine, etc.) 
using a ‘supply to forecast’ decoupling point. It is possibly useful for pharmaceuticals that have 
a stable and predictable demand within the seasons.  
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The three market responsive supply chain models defined by Perez (2013) are: 
❖ Custom-configured supply chain: This supply chain is characterized by multiple configurations 
of the finished product on a unique platform, using a ‘configurable to order’ decoupling point. 
The custom-configured supply chain has been recommended for assembly of personalized 
products, for example, computers and vehicles. 
Such a supply chain can possibly be useful in supplying personalized medicine which can be 
prescription, epidemic or vaccine pharmaceuticals in a public healthcare pharmaceutical supply 
chain. A ‘configurable to need’ decoupling point could potentially be used to supply strictly 
controlled substances/medicine of higher (7 or 8) medicine schedules, e.g. nabilone, 
amphetamine, and dexamphetamine, as per need of the targeted patients.  
❖ Agile supply chain: This supply chain employs a ‘make to order’ or sometimes ‘make to stock’ 
decoupling point, where items are produced after a purchase order has been placed by the 
customer. It has been proposed for businesses that are characterized by unpredictable demand and 
is essential for companies that use unique specifications for each customer to manufacture 
products, for example, chemical specialties and packaging. 
This strategy can be used in a public healthcare pharmaceutical supply chain to supply 
pharmaceuticals according to unique needs of PHCFs that exist in unpredictable environments 
e.g. tourist resort areas where there is much movement of people in and out of the area. Such areas 
can potentially be prone to infections that may not normally be prevalent in an area, hence the 
need to be agile in reaction to such eventualities.  
❖ Flexible supply chain: This supply chain is characterized by adaptability, which entails the 
capability to reconfigure internal processes to meet a specific need (or solve a problem) of a 
customer using a ‘design to order’ decoupling point. It is mainly proposed for service companies 
that encounter unexpected situations and emergencies faced with long periods of low workload 
and high demand peaks, for example, the medical emergency response sector.  
This strategy can possibly be useful in a public healthcare pharmaceutical supply chain in 
supplying epidemic medication during times of outbreaks as the adaptable approach could be 
useful in responding to emergencies in the healthcare system.   
As discussed, the premise of this research is that aligning each pharmaceutical product with an 
appropriate supply chain strategy has the potential to optimize the performance of the public 
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healthcare supply chain and possibly enhance sustainable medication availability. Various levers are 
to be controlled in order to effectively implement the appropriate supply chain strategy and these are 
discussed in the succeeding section. 
 Levers to control in supply chain strategy implementation 
Perez (2013) posited that the interrelation of four main elements shapes an organization's supply chain 
strategy. These four elements, therefore, encompass the levers that can be adjusted in order to switch 
from one supply chain strategy to another. The four elements proposed by Perez (2013) are: 
• The industry framework—the marketplace; 
This entails the economic factors that influence competition in any industry and the interaction of 
suppliers, technological developments and customers (Cetinkaya, 2011; Perez, 2013). Perez 
(2013) posits that four main interrelated drivers exist within this framework:  
1. Demand variation, or demand profile, which influences asset utilization and drives 
production efficiency and product cost.  
2. Market mediation costs, which Fisher (1997) defined as costs emanating from mitigating 
imbalances of demand and supply, for example, price markdowns to counter excess supply. 
3. Product lifecycle, which influences the predictability of demand and market mediation costs, 
consequently impacting the speed of product development and continuous review of the 
product portfolios. 
4. Relevance of the cost of assets to total cost which relates to the asset utilization rate in 
correlation with business profits.  
• The organization's unique value proposal—its competitive positioning; 
This, according to Perez (2013), entails the organization’s competitive positioning by the use of 
‘order qualifiers’ and ‘order winners’. Order qualifiers define the minimum requirements in order 
to be considered as a relevant option by customers, whereas order winners define the best 
performance aspects of an organization that differentiate it from the rest thereby allowing it to 
win the customer. Determining the main ‘order winners’ as defined by the product attributes and 
service, allows the company’s unique value proposal to shape the key drivers’ synergy in driving 
the supply chain strategy to fulfill high service levels. 
• Internal processes—the supply chain processes;  
Perez (2013) further highlights that internal processes drive interlinks within the supply chain 
activities under source-make-and-deliver approaches, with the most important elements being 
asset utilization and the decoupling point location, among other factors. A decoupling point has 
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been defined to be a process within the value chain where a product assumes unique 
characteristics or specifications for a distinct customer. There exists a high interdependence 
between asset utilization and the decoupling point location, for example: 
1. When a business is oriented towards substantial relevance of cost of assets in relation to the 
total cost, and/or when the business’ unique value proposal is focused on low cost, then high 
asset utilization is a necessity. As a result, the decoupling point should be positioned at the 
end of the transformation process, or at the output point of the most cost relevant process. 
2. The production cycle drifts towards being long, so as to increase production efficiency when 
workload levelling is smoothed by forecasting. This is because, prior to a decoupling point, 
production processes are oriented towards a ‘push’ approach. In such an instance asset 
utilization is high. 
3. Processes are oriented towards a ‘pull’ approach after the decoupling point, therefore 
workload is variable and driven by demand. Asset utilization is at a moderate level and the 
production cycle becomes shorter to reduce order cycle time.  
4. Much inventory that is partially complete and ready to configure as per customer 
requirements, is located just before the decoupling point. 
5. In instances where the decoupling point is located farthest from the customer’s supply chain 
end, ease of customization of the product increases and buffering of demand should be 
supported by excess capacity. Furthermore, collaborative relationships with customers are 
mandated as they help reduce demand uncertainty.  
6. In instances where the decoupling point is located toward the customer’s end in the supply 
chain, product customization reduces. Consequently, the minimum order size is determined 
by the relevance of the transportation cost relative to the total cost. 
• Managerial focus—the link between the business strategy and supply chain processes. 
Perez (2013) further highlights that the managerial focus entails the decision-making process that 
governs the alignment between the competitive positioning and supply chain processes of an 
organization. The managerial focus determines the coherence between the business’ unique value 
proposal and the supply chain execution—which is a pass or fail area. Failures result from a 
managerial approach that emphasizes efficiency-oriented indicators irrespective of the 
organization’s competitive positioning. Such an approach can cause a business to focus on local 
efficiencies which may conflict with the business’ value proposal to customers, therefore creating 
a misalignment between the business strategy and the supply chain.  
Literature has suggested that regardless of these elements involving multiple factors, only some of 
these factors are essential drivers for supply chain strategy formulation and implementation. Though 
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the factors have largely been developed based on a generic conceptualization of the manufacturing 
industry, concepts that are applicable to the public healthcare pharmaceutical supply chain (supply 
planning) can be interpolated from those provided. As mentioned in the introduction to this section, 
these factors established by Perez (2013) are some of the levers to note and control when establishing 
supply chain strategy implementation, and are summarized in Table 3.7. The rightmost column in the 
table gives an indication of whether each lever is applicable to supply planning in the context of 
public healthcare. 
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Table 3.7: Levers to control in supply chain strategy implementation (adapted from Perez (2013)) 
  Oriented to efficiency Oriented to responsiveness Healthcare 
supply 
planning 
applicable? 
Continuous-flow Efficient Fast Custom-configured Agile Flexible 
B
u
si
n
es
s 
 
F
ra
m
ew
o
rk
 
 
Demand variation Low Medium to high Medium to high High High Unpredictable X 
Product lifecycle Long Long Short Short to medium Short to medium Undetermined X 
Market mediation 
cost 
Low Low Medium to high High High High 
X 
Relevance of 
assets in total cost 
Medium to high Medium to high Low to high Low to high before 
PDP 
Low to medium low 
 
C
o
m
p
et
it
iv
e 
p
o
si
ti
o
n
in
g
 Main difference in 
service 
High inventory 
turnover 
Perfect orders Short time from idea 
to market 
User-friendly, low 
effort order entry 
Agility relative to 
demand changes 
Understanding of 
customers’ needs 
X 
Main difference in 
product 
Best 
performance/cost 
ratio 
Best price Continuous portfolio 
renewal 
Configurable 
product 
Customizable 
product 
Adaptable process 
X 
M
an
ag
er
ia
l 
fo
cu
s 
End-to-end Collaborative 
relationships to build 
synergies 
Efficiency Continuous portfolio 
renewal 
Product 
configurability 
Agile response to 
changes in demand 
Resource flexibility 
X 
Servicing Information sharing 
for continuous 
improvement 
Perfect orders Short time from idea 
to market 
Order accuracy Short lead time Understanding of 
customers’ needs X 
Product Designed for fast 
manufacturability 
Low cost at standard 
performance 
Fast product 
development process 
Modular design for 
multiple 
configurations 
Designed for small 
batches 
Supported by 
complementary 
services 
X 
Transformation 
processes 
Regular schedule in 
optimal SKUs  
High rate of asset 
utilization 
High rate of asset 
utilization 
High rate of asset 
utilization before 
PDP/extra capacity 
after PDP 
Extra capacity in 
manufacturing and 
downstream 
Asset 
flexibility/capacity 
pooling 
 
Sourcing Collaborative 
relationships to build 
synergies 
Lowest-total-cost-
supplier 
(opportunistic) 
Pool of suppliers with 
short lead times and 
oriented to innovation 
Agile response to 
changes in demand 
Short lead time Agile response and 
process flexibility to 
adopt customers’ 
requirements 
X 
   
Demand buffering Inventory of finished 
product 
Inventory of 
finished product  
Inventory of finished 
product 
Inventory before 
PDP, extra capacity 
after 
Extra capacity Standby 
capacity/capacity 
pooling 
X 
Order penetration 
point 
Make to stock Make to forecast, 
sometimes make to 
order 
Make to forecast Configured to order/ 
assembly to order 
Make to order/make 
to stock 
Design to order 
X 
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  Oriented to efficiency Oriented to responsiveness Healthcare 
supply 
planning 
applicable? 
Continuous-flow Efficient Fast Custom-configured Agile Flexible 
S
u
p
p
ly
 c
h
ai
n
 p
ro
fi
le
 
 
Minimum order 
size 
Customers’ 
replenishment needs 
Minimum economic 
transportation batch 
Collection forecast End customers’ 
(replenishment) 
needs 
Minimum economic 
production/transpor
tation batch 
Minimum economic 
production batch  X 
Order cycle Replenishment 
according to a fixed 
cycle 
Fixed lead time or 
fixed cycle 
According to 
collection schedule 
As short as possible 
as per orders in PDP 
queue 
As short as possible 
as per customers’ 
orders in queue 
Flexible, as short as 
possible X 
Collaborative 
relationships 
Strategic 
relationships with key 
customers to build 
synergies 
Not relevant Cooperate to 
anticipate market 
trends/joint design 
Cooperation with 
key customers to 
anticipate aggregate 
demand at PDP 
Cooperation with 
key customers to 
anticipate capacity 
requirements 
Understanding of 
‘available to promise’ 
at any moment 
X 
Inventory strategy Small and frequent 
batches to increase 
inventory turns 
High level of 
inventory to 
optimize production 
efficiency 
A single batch per 
SKU based on 
collection forecast 
Inventory just 
before PDP 
Materials/compone
nts under a common 
platform 
Low inventory level 
and inventory pooling 
X 
Customization No No Usually no Yes, just in PDP and 
downstream 
processes 
Relevant in 
manufacturing and 
downstream 
processes 
Relevant in design 
and downstream 
processes 
 
Asset utilization 
rate 
High to very high Very high High to very high High before PDP, 
medium after PDP 
Medium to high Low to medium. 
Sometimes standby 
capacity 
X 
Production cycle As short as possible to 
reduce batch sizes 
Maximize on 
increasing batch 
sizes and efficiency 
As short as possible to 
reduce time from idea 
to market            
Long before PDP, 
short in PDP and 
downstream 
Variable as per 
customers’ orders 
accepted in queue 
As short as possible to 
reduce lead time  
Rate (takt) of 
workload 
Smoothed by 
customer demand 
Smoothed by rolling 
forecast 
Smoothed by 
collection forecast 
Smoothed by rolling 
forecast before 
PDP, peaks after 
PDP 
Peaks and valleys of 
high magnitude 
Capacity on standby 
for occasional use, 
high peaks when used 
X 
Sourcing 
buffering 
Inventory/one 
supplier for each key 
component 
Inventory/best-cost 
supplier on each 
occasion 
Pool of suppliers Inventory/pool of 
suppliers 
Inventory/pool of 
suppliers 
Pool of suppliers for 
critical resources X 
*PDP= Product decoupling point 
Stellenbosch University https://scholar.sun.ac.za
 Page | 68  
 
As indicated in Table 3.7, a total of four levers have been deemed to not be applicable to supply 
planning in the context of public healthcare. The ‘relevance of assets in total cost’ lever is deemed 
not to be relevant because it is only critical in industrial sectors which have a high correlation between 
business profits and asset-utilization rate (Perez, 2013). In the public healthcare supply chain context, 
the stated correlation is not strong and can possibly be useful in the actual manufacturing of the 
pharmaceuticals—which is outside the scope of this study. As stated in the preceding sections, the 
study is concerned with the supply planning’s product categorization, not inclusive of the 
pharmaceutical manufacturing on the supplier’s side as this will only be catered for in the tenders and 
contracts between the NDoH and the suppliers. The ‘transformation processes’ lever has been 
described by Perez (2013) in the context of transforming the raw materials into finished products 
together with the setting of the decoupling points in between the transformation process. This can 
possibly relate to the transformation processes within the pharmaceuticals manufacturing, which is 
outside the scope of this study and is deemed not to be relevant to supply planning within the VAN 
strategy. The ‘customization’ lever has been set by Perez (2013) to be applicable to the product design 
and manufacturing process, and this is also outside the scope of this study. Hence, the ‘customization’ 
lever is deemed not to be relevant to supply planning in the context of public healthcare. The same 
argument holds for the ‘production cycle’ lever as this denotes the time period of the production 
process in between the transformation process from raw materials to finished products—which is 
outside the scope of this study as previously stated. 
The definition and description of the aforementioned elements and levers for each supply chain 
strategy can be viewed as being generic. In the remainder of this chapter, each of the levers that have 
been deemed to be relevant to supply planning in the context of public healthcare will be discussed 
in the context of the VAN approach to supply chain management in general and service supply 
planning specifically. The aim is to provide how each of the levers could be operationalized in a South 
African public healthcare pharmaceutical supply chain that is managed according to the VAN 
principles in order to effect each of the six generic supply chain strategies that have been defined by 
Perez (2013). 
Each supply chain strategy has its own decoupling point as established in the literature, particularly 
Section 3.6.4. Similar to the elements and levers, these decoupling points have also been defined 
generically. Consequently, there is a need to translate these definitions so that they are contextualized 
to the informed push model of the VAN strategy; public healthcare pharmaceutical supply chains; 
and service supply planning. In Table 3.8, the definition and description of the decoupling point for 
each of the six supply chain strategies in contextualized to public healthcare pharmaceutical supply 
chain; VAN informed push model; and service supply planning. As is evidenced in the table, this 
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contextualization does not involve altering the decoupling point, instead, the description of the 
decoupling point is merely altered slightly to align it to the context of a public healthcare 
pharmaceutical supply chain that operates according to informed push principles. 
Table 3.8: Supply chain strategies and their decoupling points (adapted from Perez (2013)) 
Supply chain 
strategy 
Generic decoupling 
point, adapted from 
Perez (2013) 
Informed push model and public healthcare service supply 
planning-specific interpolated decoupling points 
Decoupling point Interpolated meaning 
Continuous-flow 
supply chain 
strategy 
Make to stock Supply to stock 
Supplying for stocking at facilities based on 
predefined stock levels. 
Efficient supply 
chain strategy 
Make to forecast/Make to 
order 
Supply to forecast/ 
Supply to need 
Supplying based on forecasted demand or 
based on the foreseen service needs of the 
facilities. 
Fast supply chain 
strategy 
Make to forecast Supply to forecast 
Supplying based on forecasted demand of 
facilities. 
Custom-configured 
supply chain 
strategy 
Configurable to order 
Configurable to 
need 
Configuring supply orders/formularies 
based on facility/patients’ needs e.g. the 
case of personalized medicine 
Agile supply chain 
strategy 
Make to order’/Make to 
stock 
Supply to need/ 
Supply to stock 
Supply based on the foreseen service needs 
of the facilities or based on facilities’ 
predefined stock levels. 
Flexible supply 
chain strategy 
Design to order 
Design supply to 
need 
Configuring the supply chain in response to 
facilities’ or patients’ service needs. 
 
It is recommended that these decoupling points be used for decision making on sourcing plans and 
replenishment plans per province, which is the intended output of the product categorization 
framework to be developed.  
The four main elements, as well as the levers contained in each element that have been deemed 
relevant to a public healthcare pharmaceutical supply chain, are discussed in the remainder of this 
chapter. 
3.7.1. Business framework—VAN enabled 
The roadmap of implementing the proposed supply chain strategies taxonomy and VAN will manage 
resource allocation across four main interdependent categories of intervention. Llewellyn (2016) 
mentioned that the rationale of the business framework in managing resource allocation will be to 
clarify and simplify how resources i.e. effort, time and money, are allocated across interventions. 
Priority setting becomes vital as the resources are devoted across the interventions in order to 
minimize opportunity cost pertaining to short term versus long term impacts in the supply chain. As 
indicated in Table 3.7, Perez’s business framework element contains three levers that are applicable 
to supply planning in the context of public healthcare, namely: demand variation; product lifecycle; 
and market mediation cost.  
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The VAN reference framework has established the four categories of intervention which supply chain 
strategy implementation from a business framework viewpoint can be driven, to be:  
3.7.1.1. VAN enabling elements 
In as much as the roadmap for VAN implementation will seek to identify enabling elements to be 
addressed over the long term, these must correlate with the supply chain strategies capabilities. 
Dynamics of demand variation, product lifecycle and market mediation cost as they vary along the 
spectrum of low to high should be understood in order to align with the appropriate supply chain 
strategy. The VAN enabling elements involve elements that will then likely focus on the long-term 
aspects of VAN implementation and product categorization incorporation, and these are detailed in 
Figure 3.3. In the figure, the details in black text have been established in the VAN framework and 
that in red have been established by the author to show how the VAN enabling elements can be 
consistent with the product categorization concept. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Enabling elements to be addressed over the long term (adapted from Llewellyn (2016))  
The VAN reference framework suggests that standard operating procedures (SOPs) will form the 
basis for staff competencies, policies and IT functionality and hence in practice, the AMD will drive 
the designing, monitoring, continuous improvement and operating analytical processes at the national 
Cross functional leadership 
Political will and 
policy enablers 
• Engagement of 
senior NDoH 
leadership 
• Engagement of 
policies 
• Drafted policies 
• Contracts and 
tenders with 
suppliers that 
enable selected 
supply chain 
strategies 
 
IT enablers 
• *MPC/Master 
data 
• *SVS/Rx 
integration i.e. 
-Rx Aggregation 
-Rx Replacement 
• Planning system 
of record i.e. 
-Use of excel Ad-
interim 
• Obtain data on 
consumption of 
pharmaceuticals, 
etc. to enable 
categorization 
according to the 
PDCL2 attributes 
SOPs in place for 
transactional and data 
gathering processes 
• Essential SOPs in 
place 
• SVS/Rx integration 
timeline 
• Informal Ad-
interim 
• Define thresholds 
for product 
attributes 
gradations of short 
vs long lead time, 
stable vs volatile 
demand, lasting vs 
temporal life cycle 
etc. 
Recruitment and 
training of people 
• VAN roles at 
AMD 
• VAN roles in 
PMPUs 
• Non-VAN 
roles in 
provinces 
*SVS= Stock Visibility Solution. MPC= Master Procurement Catalogue. 
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tier and other levels (Llewellyn, 2016). AMD has been suggested by the VAN reference framework 
to be responsible for the support of other levels to enable capacity building and determine the 
granularity level of analytics throughout the system which will define the IT functional requirements 
(Llewellyn, 2016). In such cases, it is suggested that the analysis of complex links within the public 
healthcare pharmaceutical supply chain is feasible and all six supply chain strategies can be activated 
for the different product categories based on end-to-end data visibility. Furthermore, according to the 
VAN framework, the AMD will lead the development of policies for data sharing and protocols for 
key transactional processes which then act as the source for supply chain planning data. 
High-quality data is crucial to enable the implementation of the VAN informed push model, but it is 
also a requirement to enable the categorization of products according to the PDCL2 product attributes 
taxonomy. Llewellyn (2017) suggests that this high-quality data includes: 
Timely and accurate stock on hand data: This facilitates supply planning. Timely data is essential for 
infrequent deliveries and accurate historical consumption data is critical for demand 
forecasting. 
Up to date ‘slowly changing’ data:  Maintaining formulary accuracy per facility is important for 
informed push of the appropriate pharmaceuticals based on the types of care offered by the 
facility. Up to date pricing data is important for reducing order amendments and forensic 
accounting on credit balances and accruals with suppliers. 
Consistent pharmaceuticals and location master data: Consistent pharmaceuticals nomenclature, 
priorities, and substitutes to reduce ambiguity between clinicians, budgeters, demand and 
supply planners. Consistent specifications of pharmaceutical products and packaging for 
distribution planning as well as accurate location data and replenishment pipeline (supply 
chain strategy) to enable supply, network and inventory policy optimization.   
3.7.1.2. VAN planning services  
Since the VAN reference framework seeks to migrate to an informed push model, it raises the need 
to carefully manage the variability of local organizations, roles, and processes using short as-is/ to-
be/ change cycles (Llewellyn, 2016). According to the VAN reference framework, the VAN services 
roll-out approach is enabled by locally relevant ‘pockets’ where a pocket is defined to be a collection 
of facilities that will roll out simultaneously, having common characteristics e.g. same budget 
ownership and same service levels (Llewellyn, 2016). Based on these similarities, it is suggested that 
such pockets of facilities should be serviced using the same supply chain strategies on distinct product 
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categories since they (the serviced facilities) share attributes such as market mediation costs, demand 
variation, and product lifecycles.  
The VAN framework endeavors to make historical and actual internal supply chain data reliably 
available to drive supply, demand and distribution plans. This reliable availability of data would 
facilitate the efforts to implement any of Perez’s six-supply chain strategies. Furthermore, the VAN 
framework intends to establish a cutover plan from facility ordering to informed push which takes 
into account the run-out of stock and any potential changes likely to cause data risks at any time 
(Llewellyn, 2016). In such a setting, it is suggested that it is feasible to then determine the appropriate 
placement of the decoupling point for each supply chain strategy for the various product categories. 
3.7.1.3. Optimization analyses 
The introduction of the VAN framework coupled with product categorization, will potentially enable 
and facilitate a basis for performance measurement and generate data to support the supply chain 
optimization. Consistent with the VAN reference framework suggestions, both the supply chain 
strategies taxonomy and the product categorization concept, in general, hold the potential to facilitate 
improved alignment between lead time to the facility and holding stock requirements. Furthermore, 
the VAN reference framework provides a platform for the supply chain strategies taxonomy as it 
seeks, in its implementation, to: 
• Investigate constraints to minimum order quantities on direct delivery supply and optimize 
cross docks/ warehouses. This will be consistent with the supply chain decoupling points 
positioning, for example, the continuous flow supply chain strategy which uses a ‘supply-to-
stock’ decoupling point and an efficient supply chain strategy which uses a ‘supply-to-
forecast’ decoupling point, just to name a few.   
• Improve forecasting accuracy and reduce order volatility by collaborating with suppliers to 
reduce supplier holding stock requirements as well as costs to the NDoH. Thus, suppliers’ 
deliveries can be consolidated and adherence to delivery dates that are consistent with the 
individual supply chain strategies can be encouraged. 
• Establish cross-docks or merges in transits, depending on the supply chain pipeline in 
question, to achieve delivery efficiencies and minimize large unallocated inventory volume. 
• Improve supplier cash flow by enhancing payment processes and segmenting the supply base 
to identify the most strategic suppliers and enhance collaboration by negotiating prices and 
improving service delivery expectations. 
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3.7.1.4. Continuous improvement 
The VAN reference framework proposes the feasibility of creating scalable and sustainable solutions 
through the use of overarching KPI dashboards/scorecards, prioritization of VAN services 
implementation, and evaluation of various options to optimize the overall system (Llewellyn, 2016). 
Supply chain strategies issues can be identified to seek continuous improvement by using, for 
example, a root-cause analysis approach coupled with a Plan, Do, Check and Act approach. 
3.7.2. Competitive positioning—VAN enabled 
The VAN reference framework has been developed and suggested to be an operating model that seeks 
to support the strategy for medicine availability. As such, the AMD strategy is driven by a complex, 
multi-stakeholder value chain which also underpins the achievement of the 90-90-90 targets7 and Test 
& Treat implementation. Incorporating the proposed supply chain strategies taxonomy as part of the 
implementation of the VAN reference framework, is expected to contribute to steering the 
pharmaceuticals value chain from an as-is state where inefficiencies and sub-optimal service delivery 
are observed, to a to-be state where the informed push principle is fully implemented and the system 
is able to support the National Health Insurance (NHI) initiative (Llewellyn, 2016). The VAN 
reference framework has suggested that the AMD’s role will be creating transversal contracts from 
which provinces can legitimately procure pharmaceuticals and ‘on contract’ procurement has been 
defined to be instances where: 
❖ Pharmaceuticals are bought from a supplier with whom a national transversal contract exists. 
❖ Pharmaceuticals are bought from a supplier where a buy-out situation exists—meaning the 
contracted supplier is out of stock and must involve a third party to fulfill orders. 
❖ Pharmaceuticals are bought on a nationally facilitated quotation basis—which may happen 
because a tender will have failed to create a contract for a required essential item due to 
supplier/market failures. 
❖ Pharmaceuticals are bought as per pressing need acknowledged and vetted according to the 
AMD guidelines.  
 
 
7 The 90-90-90 strategy entails that by 2020, 90% of vulnerable people should be screened for TB, 90% of people with TB should be 
diagnosed and treated, and the aim is to get 90% treatment success by the said time (Health Systems Trust, 2016). The 90-90-90 
strategy also aims to facilitate 90% of people living with HIV to know their HIV status, 90% of people diagnosed of HIV should 
receive sustained antiretroviral therapy and 90% of all patients receiving antiretroviral therapy should have viral suppression—i.e. 
reduction of viral load to an undetectable level—by 2020 (Health Systems Trust, 2016). 
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As indicated in Table 3.7, both levers of the competitive positioning element are deemed relevant to 
a public healthcare pharmaceutical supply chain. These levers are ‘main difference in service 
delivery’ and ‘main difference in pharmaceuticals’. It is evident that, under the ‘on contract’ 
conditions, the main difference in service of the supply chain strategies will be that: the continuous-
flow strategy will need high inventory turnover; the efficient strategy will need perfect orders; the 
fast strategy will need a short time from ordering to market; the custom-configured strategy will need 
user-friendly order entry; the agile strategy will need agility relative to demand changes; and the 
flexible strategy will need an understanding of customer’s exact needs (Olhager, 2003; Perez, 2013; 
Vonderembse, Uppal, Huang, & Dismukes, 2006). In the context of ‘on contract’ conditions, the main 
difference in pharmaceutical products as they are supplied will be: best performance/cost ratio in the 
case of the continuous-flow strategy; best price in the case of the efficient strategy; continuous 
product portfolio renewal in the case of the fast strategy; configurable product/orders in the case of 
the custom-configured strategy; customizable product/orders in the case of the agile strategy; and 
adaptable process in the case of the flexible strategy (Lamming, Johnsen, Zheng, & Harland, 2000; 
Perez, 2013; Rofin & Mahanty, 2017; Roscoe & Baker, 2014). The proposed operationalization of 
the two levers of the competitive positioning element in the context of the VAN blueprint and the 
South African public healthcare pharmaceutical supply chain, is summarized in Table 3.9. 
Table 3.9: Proposed operationalized levers of competitive positioning element (adapted from Perez 2013)) 
  Oriented to efficiency Oriented to responsiveness 
Continuous-
flow 
Efficient Fast Custom-
configured 
Agile Flexible 
C
o
m
p
etitiv
e 
p
o
sitio
n
in
g
 
Main difference 
in service 
delivery 
High 
pharmaceutical 
inventory 
turnover 
Perfect 
orders 
Short time 
from order 
to market 
User-
friendly as 
per need 
Agility 
relative to 
demand 
changes 
Based on 
patients’ 
exact 
needs 
Main difference 
in 
pharmaceuticals 
Best 
performance/ 
cost ratio 
Best 
price 
Continuous 
portfolio 
renewal 
Configurable 
product 
Customizable 
product 
Adaptable 
process 
 
3.7.3. Managerial focus—VAN enabled 
The VAN reference framework has been suggested by Llewellyn (2016) to be enabled by a single 
AMD led governance structure which must coordinate three types of activities across multiple 
organizations and IT systems, namely: 
➢ End to end visibility—where data is aggregated from multiple sources to bring end to end 
visibility across health commodities, programs and ultimately the entire supply chain. 
➢ Analysis and insight—which involve business and market intelligence, data visualization and 
predictive modeling to create operational plans for optimizing the system. 
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➢ Continuous improvement—where standardized problem resolution processes and conditional 
actions are employed to resolve challenges and implement ongoing improvements.  
Implementation of the VAN reference framework, in the context of the NHI, is meant to involve 
stakeholder engagement across multiple organizations with a clarification of connections between 
functions and their dependencies (Llewellyn, 2016). Llewellyn (2016) posited the core functions for 
short term review to include: 
▪ Health products and finances forecasting; 
▪ Demand planning of consumption at facilities; 
▪ Supply planning and inventory planning; 
▪ Distribution planning; 
▪ Budget planning and payment of suppliers; and 
▪ Linkage selection and update of the Master Procurement Catalogue and all other formularies.   
As indicated in Table 3.7, four levers of the managerial focus element are deemed relevant to a public 
healthcare pharmaceutical supply chain. The proposed operationalization of the two levers of the 
competitive positioning element in the context of the VAN blueprint and the South African public 
healthcare pharmaceutical supply chain, is summarized in Table 3.10.   
Table 3.10: Proposed operationalized levers of managerial focus element (adapted from Perez (2013)) 
  Oriented to efficiency Oriented to responsiveness 
Continuous-
flow 
Efficient Fast Custom-
configured 
Agile Flexible 
M
an
ag
erial fo
cu
s 
E
n
d
-to
-en
d
 
Collaborative 
relationships 
to build 
synergies 
Efficiency Continuous 
pharmaceutical 
product 
portfolio 
renewal 
Pharmaceutical 
product 
configurability 
Agile 
response to 
changes in 
demand 
Resource 
flexibility 
S
erv
icin
g
 
Information 
sharing for 
continuous 
improvement 
Perfect 
orders as per 
facilities’ 
needs 
Short lead time 
to deliver 
Accuracy in 
orders supplied 
Short lead 
time 
Understanding 
of patients’ 
needs 
P
ro
d
u
ct 
Operations 
designed for 
lean supply 
capability 
Low cost at 
standard 
supply 
performance 
Fast sourcing 
process 
Modular design 
in orders for 
multiple 
configurations 
Operations 
designed 
for supply 
in small 
batches 
Operations 
supported by 
complementary 
services 
S
o
u
rcin
g
 
Collaborative 
relationships 
to build 
synergies 
Lowest-
total-cost-
supplier 
(opportunisti
c) 
Pool of suppliers 
with short lead 
times and 
oriented to 
innovation 
Agile response 
to changes in 
demand 
Short lead 
time 
Agile response 
and process 
flexibility to 
adopt patients’ 
requirements 
 
Llewellyn (2016) suggests that the scope of the VAN strategy implementation with regards to 
pharmaceuticals includes: 
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• 14 pharmaceutical tenders on a rolling update schedule inclusive of vaccines; 
• All products included in the national Essential Medicines List (EML); and 
• Excludes medical-related item tenders. 
The aspects detailed in the turbine imagery in Figure 3.4 drive supply planning within the VAN 
blueprint to determine inventory targets. The VAN strategy suggests that the inventory targets should 
be based on the demand plan, pipeline specific variables and supplier input which then determine 
consensus in supply planning across pharmaceutical products and geographies (Llewellyn, 2016). 
However, based on the findings of this study, it is proposed that the planning variables should include 
the PDCL2 product attributes taxonomy coupled with the associated measurable characteristics of 
each attribute. Furthermore, it is proposed that the supply chain strategies taxonomy should be 
included as another driver for inventory targets (sourcing plan and replenishment plan) since these 
inventory targets facilitate supply chain strategy selection (order qualifiers vs order winners) and 
implementation.  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Supply planning overview with the PDCL2 product attributes taxonomy and supply chain strategies 
taxonomy incorporated (adapted from Llewellyn (2016)) 
Demand plan 
By product 
By geography 
Planning variables 
Demand forecast accuracy 
Replenishment frequency 
The PDCL2 product attributes 
taxonomy and their measurable 
characteristics. 
Supply chains strategies 
1.Continuous-flow strategy 
 2. Efficient strategy 
 3. Fast strategy 
 4. Custom-configured strategy 
 5. Agile strategy  
6. Flexible strategy 
Supplier collaboration 
Manufacturing constraints 
Production schedules 
Supplier stock holding 
Lead times 
Geography 
view by: 
Province/district 
Channel 
PHCFs 
 
Product view by: 
Product type 
Programmes 
Campaigns 
 
Sourcing plan 
(orders) & 
Replenishment 
plan (shipments) 
 
+ 
Depot 
Cycle 
stock + 
Safety 
stock –  
On-hand 
inventory
- Open 
orders 
Facility 
Cycle 
stock + 
Safety 
stock -  
On-hand 
inventory
- Open 
orders 
 
 
Inventory netting 
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3.7.4. Supply chain focus—VAN enabled 
Perez (2013) posited that the goals that are being pursued through the implementation of product 
categorization drive interactions between internal processes and activities, with an important 
interaction being the one between resource utilization and the decoupling point location.  
The implementation of the VAN strategy—transforming to an informed push—implies a significant 
change to the South African public healthcare pharmaceutical supply chain. Various enablers need to 
be in place to facilitate the rolling out of the VAN strategy coupled with the proposed supply chain 
strategies taxonomy. According to Llewellyn (2016), key priorities include: 
A fragmented IT landscape: An informed push model requires stock and consumption visibility, 
and therefore the implementation of the VAN strategy and the proposed supply chain 
strategies taxonomy will need to overcome a fragmented and incomplete IT landscape, as 
discussed in Section 2.4.2.1. 
Capacity building for staff: An informed push model needs workforce training and retention of 
specialized skills to accomplish analytical work. Therefore, the implementation of the VAN 
strategy coupled with the proposed supply chain strategies taxonomy will need to build on 
existing skills and continuously improve professionalism within the SCM. 
Governance: The VAN strategy coupled with the proposed supply chain strategies taxonomy will be 
implemented within a complex context of multiple stakeholders and interventions. Therefore, 
there is a need for strong governance to ensure synchronization with existing best practices 
and alignment with multiple efforts associated with the supply chain. 
It is within the discussed context that supply chain improvement efforts have been suggested within 
the VAN strategy, and for the sake of this study, these will be coupled with recommendations for the 
proposed supply chain strategies taxonomy implementation. The improvement actions detail how 
visibility and analytics within the VAN strategy can be synchronized with the AMD provisions, as 
summarized in Table 3.11. 
The current provincial role in planning involves: managing procurement and acquisition from 
suppliers on cross contracts; and managing stock—order processing, storage and distribution to 
PHCFs (Llewellyn, 2016). However, the new activities in the context of the VAN’s supply planning 
and the supply chain strategies taxonomy implementation, as described in Table 3.11, will be: creating 
plans based on local consumption trends, physical distribution constraints, and stock availability; and 
providing planning data for national health budget alignment and aggregation (Llewellyn, 2017).  
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Table 3.11: VAN supply planning activities and supply chain strategies taxonomy implementation for Provincial 
Medicine Procurement Units (adapted from Llewellyn (2017)) 
Visibility and analytics Actions Interactions with the AMD 
❖ Review alerts of facilities with 
long stock outs forecast based on 
the established pharmaceutical 
bundles/categories or inventory 
variances/deviations from plan. 
 
 
❖ Conduct a root cause analysis 
based on the PDCL2 product 
attributes taxonomy to determine 
the reason for inventory variances 
based on product 
bundles/categories: 
• Inventory policy: Is the 
safety stock correct? 
• Ordering process: Is there 
on-time approval and 
economic order quantities 
(EOQ)? 
• Is it an upstream inventory 
issue? 
• Is it a delivery issue (supplier 
or upstream depot)? 
• Is it payment issues? 
 
❖ Review shelf life and 
obsolescence wastage risks? 
❖ Configure supply chain 
strategies decoupling points 
accordingly. Determine if 
expediting with supplier or 
upstream supply can resolve 
stock out risks. 
 
❖ Determine if product 
bundle/category pipeline 
(supply chain strategy route) or 
safety stock settings need a 
review—assess the supply 
planning KPIs and consult the 
national tier to effect changes. 
 
 
 
 
 
 
 
 
 
 
 
❖ Review the supplier 
performance (service levels)—
identify issues to do with stock 
management and distribution 
standard operating procedures 
or adherence. 
❖ Escalate specific short-term asks 
to the national supply planner: 
• Supplier negotiation in 
stock/payment issues. 
 
 
 
❖ Review supply planning and 
supply strategies methodology 
recurrently: 
• Change the inventory 
channel (product category 
pipeline) or inventory 
policy. 
 
 
 
 
 
 
 
 
 
 
 
❖ Review the requirements for the 
standard operating procedure 
changes to prioritize 
transactional processes 
 
Returning to Perez's (2013) remark on the importance of the interactions between internal processes 
and activities, when the VAN strategy and the supply chain strategies taxonomy are considered, it is 
evident that there exists a high interdependence between resource utilization and decoupling point 
location. Consequently, as indicated in Table 3.7, many levers should be influenced to facilitate a 
supply chain strategy implementation, most of which are deemed relevant to a public healthcare 
pharmaceutical supply chain. The proposed operationalization of the two levers of the competitive 
positioning element in the context of the VAN blueprint and the South African public healthcare 
pharmaceutical supply chain, is summarized in Table 3.12.
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Table 3.12: Proposed operationalized levers of the supply chain profiles (adapted from Perez (2013)) 
  Oriented to efficiency Oriented to responsiveness 
Continuous-flow Efficient Fast Custom-configured Agile Flexible 
S
u
p
p
ly
 c
h
ai
n
 p
ro
fi
le
 
Demand buffering 
Predefined safety 
stock levels 
Predefined safety 
stock levels 
Predefined safety 
stock levels 
Inventory before PDP, 
extra capacity after 
Extra capacity 
Standby capacity or 
capacity pooling 
Order penetration 
point 
Supply to stock 
Supply to forecast, 
sometimes supply to 
need 
Supply to forecast Configured to need 
Supply to need or 
supply to stock 
Design supply to 
need 
Minimum order size 
Patients’ 
replenishment needs 
Minimum economic 
transportation batch 
Collection 
forecast 
End patients’ 
(replenishment) needs 
Minimum economic 
supply or 
transportation batch 
Minimum economic 
supply batch  
Replenishment 
supply cycle 
Replenishment 
according to a fixed 
cycle 
Fixed lead time or 
fixed cycle 
According to 
collection 
schedule 
As short as possible as 
per need in PDP queue 
As short as possible as 
per patients’ needs in 
queue 
Flexible, as short as 
possible 
Collaborative 
relationships 
Strategic 
relationships with key 
partners to build 
synergies 
Strategic 
relationships with 
key partners to build 
synergies 
Cooperate to 
anticipate market 
trends /joint 
design 
Cooperation with key 
partners to anticipate 
aggregate demand at 
PDP 
Cooperation with key 
partners to anticipate 
capacity requirements 
Understanding of 
‘available to need’ at 
any moment 
Inventory strategy 
Small and frequent 
batches to increase 
inventory turns 
High level of 
inventory to optimize 
supply efficiency 
A single batch per 
SKU based on 
collection 
forecast 
Inventory just before 
PDP 
Stock under a 
common platform 
Low inventory level 
and inventory 
pooling 
Customization No No Usually no 
Yes, just in PDP and 
downstream processes 
Relevant in supply 
operations and 
downstream processes 
Relevant in supply 
design and 
downstream 
processes 
Resource utilization 
rate 
High to very high Very high High to very high 
High before PDP, 
medium after PDP 
Medium to high 
Low to medium. At 
times standby 
capacity 
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  Oriented to efficiency Oriented to responsiveness 
Continuous-flow Efficient Fast Custom-configured Agile Flexible 
S
u
p
p
ly
 c
h
ai
n
 p
ro
fi
le
 
Supplier’s supply 
cycle 
As short as possible 
to reduce batch sizes 
Maximize on 
increasing batch sizes 
and efficiency 
As short as 
possible to reduce 
time from 
ordering to 
market            
Long before PDP, 
short in PDP and 
downstream 
Variable as per 
patients’ orders 
accepted in queue 
As short as possible 
to reduce lead time 
Rate (takt) of 
workload 
Smoothed by patients 
demand 
Smoothed by rolling 
forecast 
Smoothed by 
collection 
forecast 
Smoothed by rolling 
forecast before PDP, 
peaks after PDP 
Peaks and valleys of 
high magnitude 
Capacity on standby 
for occasional use, 
high peaks when used 
Sourcing buffering 
Inventory/one 
supplier for each key 
product bundle/ 
category 
Inventory/best-cost 
supplier on each 
occasion 
Pool of suppliers 
Inventory/pool of 
suppliers 
Inventory/pool of 
suppliers 
Pool of suppliers for 
critical resources 
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 Framework design requirements identified in Chapter 3 
Several framework design requirements have been defined in this chapter based on design 
requirements defined by van Aken et al. (2007), and are summarized in Table 3.13. The table details 
the selected design requirement as discussed in the chapter and the corresponding requirement ID.  
Table 3.13: Framework design requirements identified in Chapter 3 
Requirement Req. 
ID 
User requirements 
The framework must support supply planning decisions at different operational levels e.g. the national and 
provincial levels, by recommending an appropriate supply chain strategy for each pharmaceutical product. 
U1 
Each supply chain strategy, contextualized to the VAN strategy, should dictate an appropriate sourcing plan 
and replenishment plan based on its affiliated decoupling point. 
U2 
The framework must also provide a decision-making approach in special cases e.g. vaccine supply or 
delivery site restrictions and limited storage capacity. 
U3 
The framework’s output, which identifies as output of a supply plan, should be usable as input to a 
distribution plan. 
U4 
Functional requirements 
The framework must provide a clear mechanism for categorizing products according to their attributes. F1 
Products should be categorized according to the PDCL2 product attributes classification. F2 
Design restrictions 
The pharmaceuticals restricted to the demand plan product portfolio which describe the Essential Medicine 
List (EML) should be used as input to the supply plan product categorization framework. 
R1 
If products are bundled based on their inherent characteristics, the medicine schedules bundle S0-S4 and 
S5-S8 should be used. 
R2 
 
 Conclusion 
Objective 2 of the study was achieved in this chapter. Thus, a set of products attributes that are critical 
in matching product bundles/categories with appropriate supply chain strategies in the South African 
public healthcare supply chain were proposed. A brief overview of prominent standardized 
classifications and nomenclature systems used in the healthcare sector was provided and a basis for 
distinguishing between special and standard products was proposed based on one of these systems. 
A brief description of the goal of product categorization in the South African public healthcare supply 
chain was formulated. Furthermore, a critical supply chain strategies taxonomy for the product 
categorization framework development was determined and levers and controls for implementation 
of the identified supply chain strategies were discussed consistent with the VAN supply chain; VAN 
service supply planning; and the South African public healthcare pharmaceutical supply chain.  
The proposed product categorization framework is presented in the next chapter. 
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The VAN-Pharmaceutical Product 
Categorization Framework development 
 Introduction 
Various design requirements for the product categorization framework have been derived and defined 
in the preceding chapters using a mixed-methods approach. Having laid the foundation throughout 
the preceding chapters, this chapter seeks to address Objective 3 of this study: 
 
The succeeding section details the consolidated framework design requirements as established in this 
study. This is followed by a section presenting the schematic tree that depicts a description of the 
basis for categorization in determining which product attributes should be matched to which supply 
chain strategies and thus formulate different supply pipelines for different products. Consequently, a 
preliminary product categorization framework proposal (presented in Appendix D) will be developed 
and validated using SME interviews in Chapter 5. 
Although the framework validation is only presented in Chapter 5, the final version of the framework 
that incorporates the changes that were made in response to the validation feedback received is the 
version that is presented in this chapter. The preliminary framework document is included in the 
validation pre-read document in Appendix D. This approach is followed to avoid: duplicating the 
Research objective 3: To develop a framework, drawing from the findings of the first and 
second objectives, for the incorporation of product categorization into the South African 
public healthcare pharmaceutical supply chain, providing detail on: 
a) The basis for categorization—i.e. aligning and matching pharmaceutical product 
categories with appropriate supply chain strategies coupled with respective 
decoupling points and thus formulate different supply pipelines for different 
products; and 
b) The implication of categorization—i.e. what aspects of the South African public 
healthcare pharmaceutical supply chain would be implicated based on the product 
categorization framework. 
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framework in the main document; and interrupting the flow of the narrative of the thesis with a 
detailed presentation of the validation feedback before the framework itself is presented. 
Table 4.1: Consolidated design requirements from the preceding chapters 
Design requirement Req. 
ID 
Chapter 
identified 
2 3 
User requirements [U]: Outputs 
The framework must support supply planning decisions at different operational levels e.g. the 
national and provincial levels, by recommending an appropriate supply chain strategy for each 
pharmaceutical product. 
U1  X 
Each supply chain strategy, contextualized to the VAN strategy, should dictate an appropriate 
sourcing plan and replenishment plan based on its affiliated decoupling point. 
U2  X 
The framework must also provide a decision-making approach in special cases e.g. vaccine 
supply or delivery site restrictions and limited storage capacity. 
U3  X 
The framework’s output, which identifies as output of a supply plan, should be usable as input 
to a distribution plan. 
U4  X 
Functional requirements [F]: Parameters 
The framework must provide a clear mechanism for categorizing products according to their 
attributes. 
F1  X 
Products should be categorized according to the PDCL2 product attributes classification. F2  X 
Design restrictions [R]: Inputs 
The pharmaceuticals restricted to the demand plan product portfolio which describe the 
Essential Medicine List (EML) should be used as input to the supply plan product categorization 
framework. 
R1 X  
If products are bundled based on their inherent characteristics, the medicine schedules bundles 
S0-S4 and S5-S8 should be used. 
R2 X  
Boundary conditions [B]: Controls 
The framework’s output, in the form of recommendations for managing the public healthcare 
pharmaceutical supply chain, must align with the principles that underpin the Visibility and 
Analytics Network strategy, most importantly the concept of informed push. 
B1 X  
The framework’s output, in the form of recommendations for determining supply planning’s 
sourcing and replenishment plans, must contribute to determination of supplier collaboration 
constraints (contracts and tenders) within the funding limitations. 
B2 X  
The framework’s output, in the form of recommendations for managing the public healthcare 
pharmaceutical supply chain, must align with the principles that underpin the South African 
Constitution. 
B3 X 
 
Attention points [A]: Enablers 
The framework’s recommendation for managing supply chain strategies should ideally 
incorporate the direct delivery and depot system that are already operational in the South 
African public healthcare pharmaceutical supply chain 
A1 X 
 
 Consolidated design requirements  
Five different types of design requirements, for example, user requirements and design restrictions, 
are used in this research. As discussed in Section 1.5, these five types of design requirements are 
Stellenbosch University https://scholar.sun.ac.za
 Page | 84  
 
based on the work of van Aken et al. (2007). Throughout the preceding chapters, a detailed set of 
framework design requirements have been deduced, based on a mixed-methods approach, and this 
set of design requirements is consolidated in Table 4.1. The table details the design requirement 
description, requirement ID, and the chapter in which the design requirements were identified. 
As set out in Chapter 5, these design requirements were formally validated through semi-structured 
interviews with SMEs. The detailed results of the formal validation are presented in the following 
chapter, however, no changes to the design requirements were deemed necessary in response to the 
validation feedback received. Thus, the requirements presented here are also the final, validated set 
of framework design requirements. 
As described in Section 1.5, the synthesis of these requirements to develop the framework is based 
on the systems engineering input-output transformation process adapted from the US Department of 
Defence Systems Management College (2001). The application of this input-output product 
categorization process to the different types of requirements is depicted in Figure 4.1 with:  
❖ Design restrictions which are the input data—answered by the medicine schedules bundle: 
S0-S4 and medicine schedules bundles: S5-S8—as provided by the demand plan 
pharmaceuticals product portfolio; 
❖ Functional requirements which are the parameters—answered by the PDCL2 product 
attributes taxonomy—with which the synthesis of inputs is done to give outputs; 
❖ Boundary conditions which define and determine the controls of operation for the framework 
based on the levers of the VAN design and supplier collaboration constraints; 
❖ Attention points—which answer whether to use either the depot system or direct delivery 
system in the supply of pharmaceuticals—which are to be considered as enablers, in 
retrospect, as the framework is developed; and 
❖ Framework user requirements which define outputs—answered by the continuous-flow 
supply chain strategy; efficient supply chain strategy; fast chain supply strategy; custom-
configured supply chain strategy; agile supply chain strategy; and flexible supply chain 
strategy—from the framework which drive the determination of sourcing and replenishment 
plans to be used by the users—i.e. the VAN supply chain professionals. 
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Figure 4.1: Input-output product categorization process (adapted from The US Department of Defence Systems 
Management College, 2001)) 
The set of five product attributes defined in the PDCL2 product attributes taxonomy generates 32 
potential unique combinations of attributes which the framework must be able to accommodate. 
Arranging the attributes in a specific order generates a schematic tree that is a useful mechanism for 
visualizing one element of the logic that underpins the product categorization framework. This is 
detailed in the next section. 
Categorization 
process 
Attention points: 
Depot system or Direct 
delivery system 
Design restrictions: 
1. Medicine schedules 
bundle: S0-S4; 
2. Medicine schedules 
bundle: S4-S8 
 
Boundary conditions: 
Levers of the VAN design; 
supplier collaboration 
constraints; and the NDoH 
public healthcare 
pharmaceutical supply 
chain regulations, ethics 
and code of conduct 
 
Functional requirements: 
1. Product attribute; 
2. Demand attribute;  
3. Cost to the supply chain 
attribute;  
4. Lead time to deliver 
attribute; and  
5. Lifecycle attribute 
Framework user 
requirements: 
1. Continuous-flow 
supply chain strategy; 
2. Efficient supply 
chain strategy; 
3. Fast chain supply 
strategy; 
4. Custom-configured 
supply chain strategy; 
5. Agile supply chain 
strategy; and 
6. Flexible supply chain 
strategy 
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 The schematic tree that underpins the product 
categorization framework 
In Figure 4.2, the PDCL2 product attributes taxonomy is used to develop a schematic tree which 
illustrates the 32 unique combinations of the five product attributes. The schematic tree splits 
according to attributes in a deliberate hierarchical sequence, with the ‘product’ attribute being 
considered first. In the framework, a specific supply chain strategy, with an associated decoupling 
point, will be prescribed for each route, based on the discussed findings from this study.  
 
Figure 4.2: The schematic tree that underpins the product categorization framework  
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As indicated in the previous section, Perez’s six supply chain strategies, contextualized to the South 
African public healthcare pharmaceutical supply chain, will constitute the set of potential 
recommended strategies in the framework. High-level guidelines on the strategies and associated 
decoupling points that would be most suited to each of the PDCL2 attribute gradations are given in 
the remainder of this section. 
According to Fisher (1997), generic products can either be primarily functional or primarily 
innovative but for this study pharmaceutical products have been distinguished in Section 3.4 based 
on their medicine schedules with the pharmaceutical bundles being either of medicine schedules 
bundle: S0-S4 or medicine schedules bundle: S5-S8. Knowing this product distinction from the onset 
will give an indication on whether to consider supply chain strategies oriented towards efficiency or 
responsiveness as developed by Fisher (1997) and expanded by Perez (2013), discussed in Sections 
2.2; 3.2; 3.6; and 3.7. In this study, the ‘product’ attribute is graded as either medicine schedules 
bundle: S0-S4 or medicine schedules bundle: S5-S8, which correlates with the findings of Fisher 
(1997); Christopher and Towill (2002); and Perez (2013).  
The second product attribute in the schematic tree hierarchy is the ‘demand’ attribute and this has 
been graded in this study as either stable or volatile, concurring with the findings of Christopher and 
Towill (2002) as well as those of Payne and Peters (2004). Broadly: 
• In instances where demand is stable and predictable, medicines are better suited to supply 
chain strategies that have supply to forecast decoupling points; 
• In instances where demand is volatile and the stock has to be supplied based on predefined 
safety stock levels, supply chain strategies that are driven by efficiency are more suitable; and 
• In instances where demand is volatile and the stock has to be supplied to need or to stock, 
supply chain strategies that are oriented towards responsiveness are more suitable. 
The third product attribute in the schematic tree hierarchy is the ‘cost to the supply chain’ attribute 
which is graded, in this study, as either expensive or affordable. The choice of appropriate supply 
chain strategies selection should be based on balancing required patients’ service levels with the total 
costs of supplying that service level. Costing approaches that are driven by activity-based methods in 
the South African public healthcare pharmaceutical supply chain, which is mainly financed by the 
government and/or donors, enable VAN supply chain managers to make better-informed decisions. 
These decisions pertain to the patient, pharmaceutical product, and channel cost/profitability by 
providing the true cost of sending a particular pharmaceutical product via a certain supply chain 
pipeline (Harrison et al., 2018; van der Veeken & Rutten, 1998). In instances where the cost to the 
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supply chain is expensive, supply chain strategies oriented towards efficiency, where operations 
follow a lean thinking to eliminate wastes, may be useful as a mechanism for controlling costs. Under 
such circumstances, decoupling points such as supply to stock; supply to forecast; and supply to need 
can be of value. In instances where the cost to the supply chain is affordable, supply chain strategies 
that are oriented towards responsiveness could be valuable as these permit capacity pooling. In such 
instances, more stock can be held upstream (at the suppliers or a DoH depot), rather than at PHCFs, 
as it is affordable to supply the stock when needed. In instances where the cost to the supply chain is 
affordable and supply chain strategies oriented towards responsiveness are recommended, decoupling 
points, as defined in Table 3.8 and Table 3.12, that supply to need; or supply to stock; or that have 
supply orders/formularies that are configurable to need; or which can design supply to need, can be 
invaluable. 
The fourth product attribute in the schematic tree hierarchy is the ‘lead time to deliver’ attribute which 
is graded as either short or long. The time taken to deliver pharmaceutical products starting from the 
time when the order was requested, will help the VAN supply chain professionals to determine 
decoupling points positioning and prioritizing the sequence of events with the end goal of serving the 
ultimate consumer within supply planning. Selection of whether to use the depot system or direct 
delivery can be facilitated for. Supply chain strategies oriented towards efficiency can be used as they 
(VAN supply chain managers) employ a lean approach of minimizing waste and thus enable the 
supply of pharmaceuticals as soon as possible to mitigate long lead times. However, in some instances 
it may be critical to be leagile, utilizing the positives of being both lean and agile. In instances where 
the lead time is long, decoupling points such as supply to stock; supply to forecast; and supply to 
need can be of value, and these correlate with supply chain strategies oriented towards efficiency as 
given in Table 3.8 and Table 3.12. When lead time is short, it facilitates for flexibility in 
responsiveness as it is possible to react and deliver pharmaceuticals rapidly and, in such 
circumstances, supply chain strategies oriented towards responsiveness can be utilized if need be.  
The fifth product attribute in the schematic tree hierarchy is the ‘life cycle’ attribute graded as either 
lasting or temporal. Life cycle, which is derived from the shelf life and lifetime as detailed in Section 
3.3.2.3, facilitates for supply chain strategies oriented towards efficiency when it is long. Supply to 
stock, supply to forecast or supply to need decoupling points can be used as driven by the longevity 
of pharmaceutical product shelf life and lifetime. Pharmaceutical products with short life cycles 
require both a short end-to-end pipeline and rapid time to deliver as established in Section 3.3.2.3, 
therefore, supply chain strategies oriented towards responsiveness are a viable option. This is 
applicable particularly to pharmaceutical products which need a cold chain e.g. vaccines, as their 
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short life cycle poses a great risk of obsolescence. Use of decoupling points that supply to stock may 
not be advantageous due to the risk of obsolescence. In the case of the short life cycle, a supply to 
need or supply to forecast decoupling point may be advantageous especially if the lead time to deliver 
is short and the demand is stable and predictable. 
It is evident from the arguments presented in this section that a single product attribute cannot be used 
in isolation of the others when determining the appropriate supply chain strategy to use. Instead, the 
gradation of a product according to each of the five PDCL2 product attributes needs to be considered 
before recommending a supply chain strategy and associated decoupling point. 
From the 32 routes of the schematic tree, routes that yield the same recommended supply chain 
strategies can be grouped together and can form part of the inputs to a distribution plan. Though 
distribution planning is outside the scope of this study, it is recommended that the product 
categorization supply plan developed from this study, which facilitates for the determination of the 
sourcing plan and the replenishment plan by the VAN supply chain managers, be used to feed into 
the distribution plan. Bundling routes that share the same supply chain strategies, will avoid having 
more discrete supply chain pipelines than is necessary. It is neither desirable nor economically 
feasible to establish an extensive number of discrete supply chain pipelines for a distribution plan, as 
this would escalate operations management overheads, as discussed in Section 3.3 (Christopher et al., 
2009; Godsell et al., 2011; Harris et al., 2010). 
Having established the logic behind the schematic tree which underscores the product categorization 
framework termed the VAN-Pharmaceutical Product Categorization Framework8, with an indication 
of grading between long and short lead time; temporal and lasting lifecycle etc. already provided in 
Section 3.3.3, the product categorization framework main index is presented in Table 4.3 in Section 
4.4 and the product categorization process and framework is discussed based on the study’s findings. 
 The VAN-Pharmaceutical Product Categorization 
Framework  
Based on the input-output categorization process which the product categorization framework takes, 
an overarching process flow of the product categorization framework which can be used to describe 
 
 
8 The ‘VAN-Pharmaceutical Product Categorization Framework’ will be simply used synonymously with the ‘product categorization 
framework’. 
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the usage of the framework is given in Figure 4.3. The framework that is presented here incorporates 
the changes that were made in response to the feedback that was received from SMEs during the 
framework validation. As previously mentioned, in order not to interrupt the flow of the narrative, 
the detailed description of the validation process, as well as the feedback that was received, is 
presented in the succeeding chapter. The preliminary version of the framework (i.e. the version that 
was sent out for validation) is included in the validation pre-read document in Appendix D. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Overarching process flow of the VAN-Pharmaceutical Product Categorization Framework 
Input 
Product 
categorization 
Output 
Determine sourcing plans and replenishment plans 
for the product categories based on the 
recommended supply chain strategies’ profile and 
respective decoupling points. 
Use demand plan product portfolio which 
describe the Essential Medicine List (EML). 
Bundle the pharmaceutical products based on 
their medicine schedules: S0-S4 & S5-S8. 
Product attributes: 
Determine thresholds between gradations of the 
PDCL2 product attributes, using the attribute 
threshold index’s recommendations. 
Employ the decision tree logic on the medicine 
schedules bundles based the PDCL2 product 
attributes. 
Supply chain strategies: 
To each route of the PDCL decision tree, 
determine the appropriate supply chain strategy 
coupled with the corresponding decoupling 
point. 
Employ the decision-making philosophy in 
determining the appropriate supply chain 
strategies. 
Special cases index: 
Reconsider selected supply chain strategies 
based on the special cases index. 
Enabling environment: 
Levers of the VAN 
design especially the 
informed push model; 
supplier collaboration 
constraints; and the 
NDoH public healthcare 
pharmaceutical supply 
chain regulations, ethics 
and code of conduct 
1 
2 
3 
4 
5 
6 
Stellenbosch University https://scholar.sun.ac.za
 Page | 91  
 
As shown in Figure 4.3, the framework users must determine the threshold between the gradations 
for each of the PDCL2 product attributes. A detailed discussion of information that is relevant to 
determining the threshold for each gradation was presented in Section 3.3.3, and the most salient 
information from this discussion is presented in Table 4.2. This summary of only the most salient 
information into table format is intended to facilitate ease of use of the framework. 
Table 4.2: Consolidated product attributes with recommended thresholds for binary gradations (adapted from Mapowo 
et al. (2019) © 2019 IEEE)  
Public healthcare 
pharmaceutical supply 
chain product attributes 
(with gradations) 
Examples of 
measurable 
characteristics 
Recommended thresholds between the binary 
gradations for provinces in the South African public 
healthcare 
Product (standard or 
special) 
Therapeutic nature, 
substitutability of the 
product, standardization 
of product category and 
physical characteristics. 
Medicine schedules S0-S4 denoted as standard products and 
S5-S8 denoted as special products. 
Demand (stable or 
volatile) 
Variability, volatility, 
volume, and uncertainty. 
Pharmaceutical products with fairly constant or predictable 
demand in the short or medium-term demand and/or supply 
plan of a province can be considered ‘stable’ while those 
that spike unpredictably can be considered ‘volatile’. 
Cost to the supply chain 
(affordable or expensive) 
Procurement cost, 
holding cost, 
obsolescence cost and 
distribution cost. 
Order line values, frequency of order lines and order line 
weights can then be used to determine between expensive 
and affordable cost based on the procurement cost, holding 
cost, obsolescence cost and distribution cost. 
Life cycle (temporal or 
lasting) 
Product lifetime, shelf 
life, obsolescence, and 
product quality. 
Products that require a short end-to-end pipeline, rapid time 
to market and have short shelf life and lifetime can be 
considered to have a temporal life cycle, with the opposite 
being true for a lasting life cycle. 
Lead time to deliver (short 
or long) 
Supply cycle time, supply 
takt time, response time 
to deliver product, on-
time or on-schedule and 
time service levels. 
Pharmaceutical products that cannot be sourced nor 
replenished rapidly based on the supply cycle time, supply 
takt time and time service levels can constitute the long lead 
time, while the opposite is true for a short lead time. 
The main index of the product categorization framework is presented in Table 4.3. A leagile (lean + 
agile) approach is employed in proposing the most appropriate supply chain strategies so that the 
framework users (VAN supply chain managers) can capitalize on the benefits of being lean (efficient 
strategies) and those of being agile (responsive strategies). The high-level discussion of strategies that 
are best suited to each of the PDCL2 product attributes, described in Section 4.3, informed the 
selection of the most appropriate strategies for each of the 32 routes. The index offers 
recommendations rather than rigid prescriptions. Hence more than one appropriate supply chain 
strategy is recommended for each route. This approach reflects the complex reality of recommending 
an appropriate strategy based on the simultaneous consideration of the five PDCL2 product attributes. 
This approach also ensures that the use of the index does not make it infeasible to limit the number 
of discrete supply chain pipelines that need to be included in a distribution plan. As discussed in the 
previous section, this is desirable, both in terms of economic and operational feasibility. 
Stellenbosch University https://scholar.sun.ac.za
 Page | 92  
 
Table 4.3: VAN-Pharmaceutical Product Categorization Framework main index 
 
The PDCL2 product attributes taxonomy 
Supply chain strategies taxonomy 
Product Demand Cost Leadtime Lifecycle 
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Supply chain strategies Decoupling points 
1.  X  X  X  X  X  Fast or Agile strategy Supply to forecast or Supply to need/stock 
2.  X  X  X  X   X Efficient or Agile strategy Supply to forecast/need or Supply to need/stock  
3.  X  X  X   X X  Efficient or Fast or Agile strategy Supply to forecast/need or Supply to forecast or Supply to need/stock 
4.  X  X  X   X  X Efficient or Agile strategy Supply to forecast/need or Supply to need/stock 
5.  X  X   X X  X  Fast or Agile or Flexible strategy Supply to forecast or Supply to need/stock or Design-supply to need 
6.  X  X   X X   X Efficient or Agile or Flexible strategy Supply to forecast/need or Supply to need/stock or Design-supply to need 
7.  X  X   X  X X  Fast or Agile strategy Supply to forecast or Supply to need/stock 
8.  X  X   X  X  X Efficient or Agile strategy Supply to forecast/need or Supply to need/stock 
9.  X   X X  X  X  Efficient or Agile strategy Supply to forecast/need or Supply to need/stock 
10.  X   X X  X   X Continuous-flow or Efficient strategy Supply to stock or Supply to forecast/need 
11.  X   X X   X X  Efficient or Fast or Agile strategy Supply to forecast/need or Supply to forecast or Supply to need/stock 
12.  X   X X   X  X Continuous-flow or Efficient or Agile Supply to stock or Supply to forecast/need or Supply to need/stock 
13.  X   X  X X  X  Continuous-flow or Efficient or Fast Supply to stock or Supply to forecast/need or Supply to forecast  
14.  X   X  X X   X Continuous-flow or Efficient strategy Supply to stock or Supply to forecast/need 
15.  X   X  X  X X  Efficient or Fast or Agile strategy Supply to forecast/need or Supply to forecast or Supply to need/stock 
16.  X   X  X  X  X Continuous-flow or Efficient or Fast Supply to stock or Supply to forecast/need or Supply to forecast  
17.   X X  X  X  X  Fast or Custom-configured or Agile Supply to forecast or Configurable to need or Supply to need/stock 
18.   X X  X  X   X Fast or Agile or Flexible strategy Supply to forecast or Supply to need/stock or Design-supply to need 
19.   X X  X   X X  Fast or Custom-configured or Agile Supply to forecast or Configurable to need or Supply to need/stock 
20.   X X  X   X  X Efficient or Agile or Flexible strategy Supply to forecast/need or Supply to need/stock or Design-supply to need 
21.   X X   X X  X  Fast or Custom-configured or Flexible Supply to forecast or Configurable to need or Design-supply to need 
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The PDCL2 product attributes taxonomy 
Supply chain strategies taxonomy 
Product Demand Cost Leadtime Lifecycle 
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Supply chain strategies Decoupling points 
22.   X X   X X   X Fast or Custom-configured or Agile Supply to forecast or Configurable to need or Supply to need/stock 
23.   X X   X  X X  Fast or Custom-configured or Flexible Supply to forecast or Configurable to need or Design-supply to need 
24.   X X   X  X  X Fast or Custom-configured or Agile Supply to forecast or Configurable to need or Supply to need/stock 
25.   X  X X  X  X  Efficient or Fast or Agile strategy Supply to forecast/need or Supply to forecast or Supply to need/stock 
26.   X  X X  X   X Efficient or Fast or Custom-configured Supply to forecast/need or Supply to forecast or Configurable to need 
27.   X  X X   X X  Efficient or Fast or Flexible strategy Supply to forecast/need or Supply to forecast or Design-supply to need 
28.   X  X X   X  X Efficient or Fast or Custom-configured Supply to forecast/need or Supply to forecast or Configurable to need 
29.   X  X  X X  X  Continuous-flow or Efficient or Fast Supply to stock or Supply to forecast/need or Supply to forecast  
30.   X  X  X X   X Continuous-flow or Efficient Supply to stock or Supply to forecast/need  
31.   X  X  X  X X  Continuous-flow or Efficient or Fast Supply to stock or Supply to forecast/need or Supply to forecast  
32.   X  X  X  X  X Continuous-flow or Efficient Supply to stock or Supply to forecast/need 
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In the use of the product categorization framework, the users have to be cognizant of various special 
conditions which may necessitate an adjustment to the recommended strategy for the route. These 
special conditions and the associated adjusted supply chain strategy recommendations are indexed in 
Table 4.4. 
Table 4.4: VAN-Pharmaceutical Product Categorization Framework special cases index 
Condition Recommendation 
Are the pharmaceuticals seasonal? Opt for elements of supply chain strategies oriented towards efficiency 
when out of season and towards responsiveness when in season.  
Are the pharmaceutical products 
personalized medicine? 
Opt for the elements of the custom-configured supply chain strategy. 
Are the pharmaceutical products 
vaccines? 
Opt for a cold chain using a leagile (lean + agile) approach. Make use of 
elements of both strategies oriented towards efficiency and responsiveness.   
Are the pharmaceutical products 
epidemic medicine? 
Opt to orient towards the responsive strategies especially either agile and/or 
flexible supply chain strategies. 
Are the pharmaceutical products 
chronic medication? 
Opt for supply chain strategies oriented towards efficiency. 
Does the facility to which the products 
are being supplied have low storage 
capacity (though it is easily accessible)?  
Maintain the supply chain profile of the selected supply chain strategy as 
given in Table 3.12. Check applicability of direct delivery as compared to 
the depot system. 
Is the facility to which the products are 
being supplied easily accessible and its 
storage capacity is high? 
Maintain the supply chain profile of the selected supply chain strategy as 
given in Table 3.12. Check applicability of direct delivery as compared to 
the depot system. 
Is the facility to which the products are 
being supplied not easily accessible and 
its storage capacity is low? 
Buffer the supply chain profile of the selected supply chain strategy as given 
in Table 3.12 using the nearest facility with better capacity.  
Is the facility to which the products are 
being supplied not easily accessible, 
though the storage capacity is high? 
Opt for supply chain strategies with supply to stock/need/forecast 
decoupling points. Check applicability of the depot system as compared to 
direct delivery. 
* Facilities that are defined as a local ‘pocket’ (Section 3.7.1.2) within the VAN approach should manage each product 
category according to the same supply chain strategy. 
*In all other circumstances not specified, stick to the provisions of the product categorization framework. 
 
4.4.1. Patterns in the VAN-Pharmaceutical Product Categorization Framework  
Several patterns are evident in the recommended supply chain strategies, and associated decoupling 
points, for the 32 routes in Table 4.3. These are briefly discussed in the remainder of this section. 
4.4.1.1. Medicine schedules bundles: S0-S4  
The appropriate supply chain strategies selected in most routes for the S0-S4 medicine schedules 
bundles are oriented towards efficiency (lean). This is because in the South African public healthcare 
sector, S0-S4 medicines tend to be used for conditions with a great burden of disease and these are 
therefore mostly high-volume products.  
Other supply chain strategy options that were recommended for this group of medicines, were those 
that are oriented towards responsiveness (agile) meaning that in such instances a leagile (lean + agile) 
approach was preferred. Using supply chain strategies with a leagile approach can help in lowering 
the cost of supply to the supply chain; providing high relevance of resource utilization to the total 
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cost; and enhancing end-to-end efficiency thus enhancing availability and access to medicines and 
impacting supply chain efficiency positively.  
In all routes where the demand was stable, supply chain strategies with supply to forecast/need 
decoupling points were recommended. When demand was volatile, supply to stock/forecast 
decoupling points were recommended. A major motivation for considering supply chain strategies 
oriented towards efficiency (lean), was the opportunity to minimize wastes and consequently cost. 
Supply chain strategies with supply to need or supply to forecast decoupling points are mostly used 
in instances where lifecycle is temporal.  
4.4.1.2. Medicine schedules bundle: S5-S8  
The appropriate supply chain strategies selected in most instances/pipelines for the S5-S8 medicine 
bundles are oriented towards responsiveness (agile). In some instances, a mixture of supply chain 
strategies oriented towards both efficiency and responsiveness were recommended. This is because 
of the need to curb market mediation costs and be responsive in times of outbreaks, uncertainties in 
demand and uncertainties in customers’ needs by pooling capacity, since S5-S8 pharmaceuticals are 
mostly not high-volume products.  
The custom-configured and flexible strategies were frequently recommended in instances/pipelines 
where demand was volatile. This was due to the need to incorporate customization in the supply 
design and develop collaborative relationships with stakeholders affiliated to the South African public 
healthcare pharmaceutical supply chain based on ‘availability to need’ at any moment. Therefore, the 
supply to forecast; supply to need; and design supply to need decoupling points have been 
recommended. However, in instances where the demand is stable and the cost is expensive, the supply 
chain strategies selected are largely oriented towards both efficiency and responsiveness, pursuing a 
leagile approach. This helps in capitalizing on strengths from both approaches of efficiency and 
responsiveness to lower the cost of supply to the supply chain; provide high relevance of resource 
utilization to the total cost; and enhance end-to-end efficiency as established in the preceding 
discussion. 
Having described the patterns that are evident within the product categorization framework, an in-
depth view of the categorization framework itself is given in the following section, more specifically 
to show the decision-making approach/philosophy in selecting the appropriate supply chain strategy 
per supply route.  
Stellenbosch University https://scholar.sun.ac.za
 Page | 96  
 
 Demonstration of the decision-making philosophy 
From each medicine schedules bundle, two routes will be chosen as examples. The first route chosen 
as an example from each schedules bundle is a product with: volatile demand; expensive cost; short 
lead time; and temporal life cycle. The second route chosen as an example from each schedules bundle 
is a product with: stable demand; affordable cost; long lead time; and lasting life cycle. These are the 
first and the last routes for each medicine schedules bundle in Table 4.3. The decision-making 
approach/philosophy taken in recommending the supply chain strategies for each example route is 
provided in the paragraphs that follow. 
❖ Route 1:  
Medicine schedules bundle S0-S4 includes mostly high-volume products, with ease of access and a 
maximum repeat limit of six months, as previously established in Section 3.4. If such pharmaceuticals 
have a volatile demand, then there is a need to supply to stock or supply to need or at least supply to 
forecast to buffer the demand in times of uncertainties. Furthermore, since the cost to the supply chain 
in Route 1 is expensive, then there is a need to orient the supply chain towards efficiency (lean) to 
cut out costs and wastes. However, since the lead time is short and the life cycle is temporal, it calls 
for agility in responding to need with rapid replenishment to curb the risk of obsolescence due to the 
shortness of the lifecycle. Hence, the advantages of orienting the supply chain towards responsiveness 
(agility) are also needed and are facilitated by cooperation with key partners to anticipate capacity 
requirements. It is deemed necessary to make minimum order sizes based on the end patients’ 
replenishment needs in order to cut down on costs to the supply chain and short time from order to 
market/PHCFs. Therefore, Route 1 can benefit from being leagile (both lean and agile). 
Consequently, a fast or agile strategy with either supply to forecast or supply to need/stock decoupling 
points is recommended.   
❖ Route 16 
As a second example from the S0-S4 medicine schedules bundle, if such pharmaceuticals have a 
stable demand, then there is ease of forecasting and the products can be supplied to stock with 
replenishment according to a fixed cycle. This is made possible, as according to Route 16, the cost to 
the supply chain is affordable therefore the frequent delivery of small batches to increase inventory 
is feasible, with the minimum order size based on the patients’ replenishment needs. Orienting the 
supply chain towards efficiency (lean) will be preferred in order to maximize the efficiency that can 
be attained as, with the stable demand, there is less need for orienting towards responsiveness. Since 
the lead time is long and the life cycle is lasting in Route 16, it is feasible to use a supply to stock or 
supply to forecast/need decoupling point, as provided by the continuous-flow, efficient and fast 
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strategy, because the risk of obsolescence is low, and demand is predictable. To mitigate the long 
lead time, it is necessary to develop strategic collaborative relationships with key partners to build 
synergies and supply rapidly. Therefore, a continuous-flow or efficient or fast strategy with either a 
supply to stock, a supply to forecast/need, or a supply to forecast decoupling point, is recommended 
for Route 16. 
❖ Route 17 
Under the medicine schedules bundle S5-S8, which is mostly low-volume products, access is 
extensively regulated, and dosage repeats can exceed six months, as established in Section 3.4. If the 
pharmaceuticals have volatile demand and the cost to the supply chain is expensive, supply chain 
strategies oriented towards responsiveness to mitigate the unpredictability in demand can be 
appropriately employed. Moreover, if the lifecycle is temporal and the lead time is short, there is a 
need for rapid replenishment when necessary, keeping in mind the risk of obsolescence due to the 
shortness of the lifecycle of such products. It is deemed necessary to make the minimum order size 
based on the end patients’ replenishment needs in order to cut down on costs to the supply chain, 
hence some elements of orienting the supply chain towards efficiency are called for. Under such 
conditions, a leagile approach can be beneficial, capitalizing on both elements of efficiency (lean) 
and responsiveness (agile). If there is need to use personalized medicine, with the formulary 
customized based on the special needs of the patients or PHCFs, a configure to need decoupling point 
can be a useful mechanism to facilitate cooperation with key partners or PHCFs, by allowing 
aggregate demand to be anticipated at the product decoupling point. Therefore, a fast, a custom-
configured, or an agile strategy with a supply to forecast, a configure to need, or a supply to need/stock 
decoupling point is recommended for Route 17. 
❖ Route 32 
As a second example from the S5-S8 medicine schedules bundle, if the demand is stable, cost is 
affordable to the supply chain and lead time is long, then it is best to opt for supply chain strategies 
that are oriented towards efficiency, since there is ease of forecasting and efficient strategies can go 
some way towards mitigating the long lead time. The order cycle can be oriented towards a fixed 
cycle or a collection schedule and it is recommended to make the resource utilization rate high or 
very high since the condition within Route 32 is that the cost to the supply chain is affordable and 
such an approach is therefore permissible. Moreover, since the lifecycle is lasting, it is feasible to 
make use of a high level of inventory to optimize supply efficiency. It is more beneficial to orient 
such a supply pipeline towards efficiency than towards responsiveness. A supply to stock or a supply 
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to forecast/need decoupling point is useful in such circumstances, corresponding to a continuous-flow 
or efficient strategy respectively. 
As established in Table 4.4, in special cases, the provisions of the index will take precedence over 
what the above discussions provide, otherwise, if the special cases are not applicable then the 
preceding decision-making philosophy stands.  
In the following section, the relevance of the product categorization framework within the South 
African public healthcare pharmaceutical supply chain is discussed.  
 The VAN-Pharmaceutical Product Categorization 
Framework in the South African public healthcare 
pharmaceutical supply chain 
This section discusses how the product categorization framework could be integrated into the broader 
South African public healthcare pharmaceutical supply chain. The discussion is organized according 
to the five categories of design requirements. 
4.6.1. Design restrictions [R]: Inputs 
The two medicine schedules bundles (S0-S4 and S5-S8) found in the pharmaceutical product portfolio 
or Essential Medicine List (EML) or Master Procurement Catalogue (MPC) have been considered as 
inputs to the framework. As previously discussed, the S0-S4 medicine schedules bundle contains 
mostly high-volume products with better ease of access and a maximum repeat limit of six months 
while the S5-S8 medicine schedules bundle contains mostly low-volume products with access that is 
extensively regulated, and dosage repeats that can exceed six months. The entire pharmaceutical 
portfolio, including chronic medicine, prescription medicine, over-the-counter (OTC) medicine, 
epidemic medicine, and vaccine medicine is encompassed by these two categories. These products 
already exist in the South African public healthcare pharmaceutical supply chain and bundling them 
up according to the medicine schedules bundles, will aid in making these product bundles/categories 
less sensitive to slight changes in the pharmaceutical product portfolio. Such bundling ensures that 
categories do not have to be reconfigured each time there is a slight change in the pharmaceutical 
product portfolio. Hence, using the medicine schedules as the basis for bundling will potentially 
enhance the sustainability of the established categories regardless of the slight changes in the product 
portfolio that may occur over time.  
Stellenbosch University https://scholar.sun.ac.za
 Page | 99  
 
4.6.2. Functional requirements [F]: Parameters 
The establishment of the PDCL2 product attributes taxonomy detailed in Section 3.3, which answer 
the functional requirements of the product categorization framework design, provide answers to 
questions raised in the research agenda set by Mapowo et al. (2018) for the incorporation of product 
categorization into the South African public healthcare pharmaceutical supply chain. The PDCL2 
product attributes taxonomy, a component of the product categorization framework is deemed 
applicable in the VAN supply chain, VAN service supply planning, and the South African public 
healthcare pharmaceutical supply chain. Though the taxonomy was specifically developed for the 
contemporary South African context, it is most likely also more widely applicable in other public 
healthcare pharmaceutical supply chain country settings. As established in Section 3.3.3, it is 
proposed that since the intention is to use the PDCL2 product attributes taxonomy at national, 
provincial and facility tiers under the informed push model of the VAN strategy, each province should 
determine and define its own threshold between the binary gradations based on the measurable 
characteristics associated with each product attribute. These thresholds should be determined and 
defined within the boundaries provided by the national and provincial tiers as previously detailed in 
this study.  Examples of such boundaries include the National Treasury allocations; the Affordable 
Medicines Directorate (AMD); essential medicines selection; the standard treatment guidelines 
(STGs) and essential medicines lists (EMLs) at the provincial level; NDoH public healthcare 
pharmaceutical supply chain regulations, ethics and code of conduct; the health tenders and contracts; 
and finally, the licensed individuals and facilities involved in the pharmaceutical products delivery. 
This means that, in the use of the product categorization framework, each province is responsible for 
quantifying, for example, what constitutes a long lead time or what constitutes a high cost using 
recommendations such as those given in Section 3.3.3, based on the province’s specific circumstances 
i.e. provincial healthcare budgets, marketplace, ease of doing business, etc. 
4.6.3. User requirements [U]: Outputs 
The supply chain strategies taxonomy established in Sections 3.5, 3.6, and 3.7 together with the 
elements of each strategy which have been contextualized to the contemporary South African context, 
are useful as outputs of the product categorization framework. The product categorization framework 
with its set of supply chain strategies together with their decoupling points as defined in Table 3.8, 
will support supply planning decisions at different operational levels e.g. the national and provincial 
levels, by recommending an appropriate supply chain strategy for each pharmaceutical product. These 
supply chain strategies, contextualized to the VAN strategy, will be used to drive the sourcing/supply 
plan (i.e. supplier orders required) and a replenishment plan (i.e. stock transfers required) for each 
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pharmaceutical product, as previously mentioned in the study. These strategies have been established 
in the study as: continuous-flow supply chain strategy; efficient supply chain strategy; fast supply 
chain strategy; custom-configured supply chain strategy; agile supply chain strategy; and flexible 
supply chain strategy. 
The VAN supply chain managers, under the informed push model, will use (one of) the supply chain 
strategies and decoupling points recommended by the product categorization framework and make 
use of the decision-making approach in special cases e.g. vaccine supply or delivery site restrictions 
and limited storage capacity as given in Table 4.4. However, in as much as the established product 
categorization framework for supply planning seeks to satisfy a demand plan, the recommended 
supply chain strategies and decoupling points in the framework can be useful as inputs to a 
distribution plan and are thus recommended as a future study. 
4.6.4. Boundary conditions [B]: Controls 
The boundary conditions within the product categorization framework define and determine the 
controls of operation for the framework based on the levers of the VAN design, supplier collaboration 
constraints, and the NDoH public healthcare pharmaceutical supply chain regulations, ethics and code 
of conduct. These boundary conditions, as discussed in Section 2.4, provide an enabling environment 
for the public healthcare pharmaceutical supply chain’s operational functions, namely: product 
selection; quantification and procurement; inventory and distribution; and product use. The South 
African NDoH can make use of the product categorization framework in conjunction with the sector-
wide Procurement Division which was established in Section 2.4 to be responsible: for the essential 
medicines selection; the standard treatment guidelines (STGs) and essential medicines lists (EMLs) 
development for each health system level; the administration of health tenders and contracts; and 
finally, the licensing of the individuals and facilities involved in the pharmaceutical products delivery 
(Perumal-Pillay & Suleman, 2017). The product categorization framework will work within the South 
African public healthcare pharmaceutical supply chain governed by a legal framework consisting of 
policies, legislations, guidelines and SOPs, as previously discussed in this study, defined by The 
National Department of Health (1996) in the South African national drug policy to consist of: (i) 
medicine selection; (ii) traditional medicines; (iii) medicine pricing; (iv) procurement and 
distribution; (v) rational use of medicines; (vi) human resource management; (vii) research and 
development; (viii) technical cooperation; (ix) monitoring and evaluation; and (x) regulations and 
legislations.  
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4.6.5. Attention points [A]: Enablers 
As discussed in Sections 2.4 and 2.5, the South African pharmaceutical distribution network involves 
the central medicine stores, regional depots, hospital facilities and PHCFs (Berger et al., 2010; Zuma, 
2016). The supply chain strategies and decoupling points in the product categorization framework 
have been recommended cognizant of the two main methods of distribution, i.e. the depot system and 
direct delivery approach, which have been discussed in Sections 2.4 and 2.5. Use of third-party 
logistics (3PL) services between the regional/district depots and PHCFs by some provinces enable 
the distribution of pharmaceuticals under the depot system. Other provinces use contractors based on 
weight consignment so that deliveries cannot take place until the accumulation of stock reaches a 
certain threshold for dispatch (Berger et al., 2010). As previously mentioned in the study, a minority 
of the provinces employ a direct delivery system where medicines are directly distributed from the 
supplier/depots to the PHCFs, whereas with the rest of the provinces, stock flows through all the 
levels downstream (Zuma, 2016). As previously alluded to, the distribution of medicine downstream 
through all the levels, i.e. from provincial depot to district depot to hospital facilities to PHCFs, can 
affect the lead-times to deliver pharmaceuticals which consequently may shorten medicine lifecycle 
(shelf life and life time). Thus, in developing a distribution plan (which is outside the scope of this 
study), it is recommended to take cognizance of the supply chain strategy decoupling point in use 
(i.e. supply to forecast; supply to stock; supply to need; configurable to need; or design supply to 
need). 
 Conclusion 
The design requirements derived and defined in Section 1.5 in line with the approach recommended 
by van Aken et al. (2007), have been researched and synthesized in this study using a mixed-methods 
approach to develop a product categorization framework, thereby addressing Objective 3 of this 
study. At the start of the chapter, framework design requirements were consolidated followed by a 
presentation of the schematic tree that underpins the framework. The basis for product categorization 
was then established—i.e. determining which product attributes should be matched to which supply 
chain strategies and decoupling points—thus formulating different supply pipelines for different 
products. Patterns that are evident in the product categorization framework were discussed and a 
demonstration of the decision-making philosophy that underpinned the establishment of these routes 
was detailed. Furthermore, the implication of categorization was discussed – i.e. what aspects of the 
South African public healthcare pharmaceutical supply chain would be implicated based on the 
product categorization framework. 
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As discussed, the framework presented in this chapter already incorporates the updates that were 
made in response to the feedback received during the validation process. The validation process is 
detailed in the following chapter. 
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Validation of the VAN-Pharmaceutical 
Product Categorization Framework   
 Introduction 
The preliminary product categorization framework was developed based on five categories of 
framework design requirements, utilizing the systems engineering input-output transformation 
process illustrated in Figure 1.2 and in more detail in Figure 4.1. The framework made use of the 
product attributes (determined to be the PDCL2 product attributes taxonomy) critical in matching 
pharmaceutical product categories (initially based on their medicine schedules bundles: S0-S4; and 
S5-S8) with appropriate supply chain strategies (determined to be the supply chain strategies 
taxonomy adapted from Perez (2013)) in the South African public healthcare pharmaceutical supply 
chain particularly VAN strategy supply planning. The aim of this chapter is to verify and validate the 
product categorization framework consistent with Objective 4 of this study:  
 
In summary, the validation of this research was done in two parts: 
1. Framework validation through SME input analysis: Aiming to validate the design requirements 
employed in the framework development and the overarching construct of the product categorization 
framework. 
2. Framework validation through case study application: Aiming to test the operability and 
applicability of the principles of the product categorization framework. 
Research objective 4: To verify and validate the framework using subject matter experts 
(SMEs) validation interviews and a case study application. The sub-objectives associated 
with research objective 4 are: 
a) Validation interviews and iterative improvement of the framework—from preliminary 
to final product categorization framework—based on subject matter expert (SME) 
feedback; and 
b) To validate the final framework using a case study application and establish 
recommendations for future research. 
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A detailed discussion of the validation strategy employed in this research was presented in Section 
1.6. Both components of the validation contribute to ensuring a strengthened construct validity and 
internal validity of the product categorization framework. This is achieved by validating the integrity 
of the research output (the framework), specifically whether the design requirements that were used 
as the basis for the framework development are accurate, whether the framework is useful in 
addressing the investigated concept, and whether the recommendations that are provided by the 
framework are appropriate.  
 Validation through SME input analysis  
Mouton (2001) states that engagement with SMEs can be done using four different approaches, 
namely: (i) free attitude interviews; (ii) telephonic interviews; (iii) semi-structured interviews; and/or 
(iv) structured questionnaires. As established in Section 1.6, this study will employ interviews with 
SMEs—using semi-structured interviews and Likert scale rankings—in the form of an electronic 
questionnaire. Participants were prompted to answer a series of predetermined questions to allow for 
the analysis and interpretation of the collected evidence in a standard. According to Bryman and Bell 
(2014), the concept of e-research or online interviews can be used for both semi-structured interviews 
and self-completion questionnaires. Thus, semi-structured interviews and Likert scale rankings were 
employed in engaging the SMEs. 
A validation framework document which summarized the findings from this study served as a pre-
read material for the SMEs to familiarize with the study prior to the validation session. The pre-read 
document that was sent to the SMEs is included in Appendix D. 
The session required the SMEs to first familiarize themselves with the validation document pre-read 
document (detailed in Appendix D) to understand the overview of the study. Afterward, the 
participants were then required to complete a semi-structured interview sent out in the format of a 
Google form. In the semi-structured interview, participants were required to validate the framework 
design requirements and/or recommend improvements to the preliminary product categorization 
framework in the context of the VAN and the South African public healthcare pharmaceutical supply 
chain. After the completion of the validation session, the suggested improvements were incorporated 
into the preliminary product categorization framework to develop the final product categorization 
framework, presented in Chapter 4, which was then used in the case study workshop. The 
interviewees who participated in the SME input analysis were from diverse areas of expertise, as is 
detailed in the next section. 
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5.2.1. SME’s background—the interviewees 
According to Creswell (2014), qualitative participants are identified from purposeful sampling as 
opposed to random sampling, as these individuals are purposefully selected based on merit. The merit 
includes the participant’s expertise and knowledge applicable to the research topic which enables the 
participant to best assist the researcher concerning the research problem. 
In order to holistically examine the research problem and to gain insightful feedback from the process, 
six experts in public healthcare and/or supply chain management and/or the VAN strategy were 
identified as SMEs. A summary of the SME’s background is given in Table 5.1. 
Table 5.1: Interviewee background summary for SME input analysis 
Sector Participant 
(P) 
Background/Occupation Reason for inclusion 
Public healthcare 
(pharmaceuticals), 
VAN strategy and 
supply chain 
management 
P1 
An Industrial Engineer, Ph.D. candidate and 
a researcher in maturity models for demand-
driven supply chain management in the 
public healthcare sector. 
Knowledge in public healthcare 
supply chain maturity models is 
useful in determining and 
validating the framework on 
which product attributes are 
relevant in a public healthcare 
pharmaceutical supply chain. 
Supply chain 
management and 
public healthcare 
(pharmaceuticals) 
P2 
Experienced in extensive end-to-end supply 
chain and business excellence knowledge 
with hand-on experience through 30 years 
of international corporate exposure (Ricoh, 
Lego, Janssen Pharmaceuticals, Johnson 
and Johnson). Held international Global 
Executive positions across the pillars of 
Plan, Make, Source, Deliver 
including Director of Global Demand 
Management and Sales & Operations 
Planning Centre of Excellence.  
Has the Board of Director level experience 
and member of the SAPICS supply chain 
management professional body. 
Hands-on experience in leading 
process and technology 
improvement initiatives, as well 
as extensive and end-to-end 
supply chain and business 
excellence knowledge, is vital in 
validating the design 
requirements employed in the 
framework development and the 
overarching construct of the 
product categorization 
framework. 
Public healthcare 
(pharmaceuticals) 
and supply chain 
management 
P3 
A researcher with experience in ICT 
systems operation and projects particularly 
in the healthcare environment. Formerly 
served as an IT manager for the Health 
Commodity Tracking System (HCTS) 
supply chain management systems in 
Ethiopia. Extensive exposure to the 
pharmaceutical logistic information tracking 
system in supply chain management 
projects undertaken to improve the 
effectiveness and efficiency of 
pharmaceutical commodities management.   
Experience and knowledge in 
pharmaceutical commodities 
management are relevant to the 
concept of product categorization. 
Exposure to projects that focus on 
improving the effectiveness and 
efficiency of pharmaceutical 
products management for the 
public healthcare pharmaceutical 
supply chain is also relevant. 
Public healthcare; 
Supply chain 
management; and 
VAN strategy 
P4 
An industrial engineer, Ph.D. candidate and 
a researcher in policy analysis for the VAN 
reference framework implementation in the 
South African public healthcare supply 
chain. 
Knowledge about the VAN and 
policy analysis of the public 
healthcare supply chain is 
essential in validating the design 
requirements (particularly the 
‘boundary conditions’ which 
underpin the levers of the VAN 
design; supplier collaboration 
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Sector Participant 
(P) 
Background/Occupation Reason for inclusion 
constraints; and the NDoH public 
healthcare pharmaceutical supply 
chain regulations, ethics and code 
of conduct) employed in the 
framework development. 
Public healthcare 
(pharmaceuticals) 
and supply chain 
management 
P5 
A pharmacist with experience as a 
Dispensary Manager; Drug Distributor; 
Public health consultant and Chief of Party 
- USAID Global Health Supply Chain 
Program-Technical Assistance. Has worked 
with the Public and Private Sector 
pharmaceutical distribution for 25 years. 
Currently working in the South African 
NDoH. 
Knowledge about 
pharmaceuticals distribution is 
invaluable in the product 
categorization framework 
validation. This gives an in-depth 
input to the operational functions 
of the public healthcare supply 
chain, particularly medicine 
selection.  
Public healthcare 
(pharmaceuticals) 
and supply chain 
management 
P6 
A Professional Industrial Engineer with 
extensive experience (more than 20 years) 
in Supply Chain Management and Planning 
in South and Southern Africa (South Africa, 
Lesotho, Swaziland, Namibia, Botswana, 
Zambia, and Mozambique). Possesses skills 
in process modelling, business process re-
engineering, capital investment 
optimization, value engineering, project 
management, the theory of constraints, 
world class manufacturing and Six Sigma. 
Currently working as a supply chain 
consultant in the South African NDoH. 
Knowledge about the 
pharmaceutical supply chain 
management, particularly in the 
South African NDoH, process 
modelling, project management 
and understanding of the theory 
of constraints are highly relevant 
to the product categorization 
framework validation. 
5.2.2. Semi-structured interview questions 
The semi-structured interview questioned the interviewees on the design requirements, presented in 
Section 4.2, that were employed in the framework development and consequently the overarching 
construct of the product categorization framework itself. In most questions, the 5-point Likert scale 
was used to measure responses as this provided a greater degree of nuance than a simple ‘yes/no’.  
 
 
Usefulness Need 
Redundancy Recommendations 
 
 
 
Figure 5.1: Aspects considered in semi-structured interview questionnaire formulation (adapted from Creswell (2014); 
Mouton (2001)) 
To determine if similar tools 
already exist and the difference 
the proposed framework brings 
Determines the usefulness of the 
framework in the public healthcare 
pharmaceutical supply chain 
Determines aspects of the 
framework that need improvement 
Determines the need of such a 
framework in the public healthcare 
pharmaceutical supply chain 
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Furthermore, this gave granular feedback through a wide range of ranked answer options. The Likert 
scale ranged from ‘strongly agree’ to ‘strongly disagree’. If the interviewee ‘disagreed’ to a question, 
an open-ended question which requested the interviewee to provide an explanation for the answer 
was given as a follow-up question. The criteria incorporated in developing the validation questions 
and the key aspects of the semi-structured interview is given in Figure 5.1. 
A summary of the validation questions is given in Table 5.2, the full questionnaire is provided in 
Appendix E. 
Table 5.2: SME input analysis questions 
Aspect No. Question 
Functional 
requirements 
[F]: Parameters 
1 
Do you think the established PDCL2 product attributes taxonomy is a clear mechanism for 
categorizing pharmaceutical products according to their attributes? 
2 
Do you think the product attributes can be practically used to categorize pharmaceuticals 
effectively and efficiently?  
3 
Do you think the recommended approach for defining thresholds between the binary 
gradations for provinces in the South African public healthcare is reasonable? 
User 
requirements 
[U]: Outputs 
4 
 Do you think the supply chain strategies employed, based on Perez (2013), i.e.: continuous-
flow; efficient; fast; custom-configured; agile; and flexible supply chain strategies, are 
appropriate? 
5 
Do you think these supply chain strategies coupled with their respective decoupling points 
can be used effectively in a VAN-enabled public healthcare supply chain?  
6 
Do you think the interpolated meanings ascribed from the generic decoupling points are 
reasonable for an informed push model and public healthcare service supply planning?  
7 
Can the recommended supply chain strategies for each pharmaceutical product support 
supply planning decisions at different operational levels e.g. the national and provincial 
levels?  
Design 
restrictions [R]: 
Inputs 
8 
Do you think the bundling up of pharmaceutical products based on their schedules, the first 
bundle being S0-S4 and the second being S5-S8, is reasonable? 
9 
Do you think the use of these two medicine schedules bundles to describe the two gradations 
of the 'product' attribute in the PDCL2 product attributes taxonomy is reasonable?  
Boundary 
conditions [B]: 
Controls 
10 
Do you agree with the boundary conditions which define the product categorization 
framework design’s preferred solution space?  
Attention points 
[A]: Enablers 
 
11 
Do you agree with the acknowledging of the direct delivery and depot system attention 
points? 
The product 
categorization 
framework 
12 
Do you think the logic that governs the schematic tree which underpins the product 
categorization framework is appropriate?  
13 
Do you think 'the product categorization framework special cases index' is useful in aiding 
framework decision-making under stated special cases? 
14 
Do you think the decision-making philosophy employed in the product categorization 
framework is reasonable?  
15 
Do you think the incorporation of the product categorization framework in the context of the 
VAN strategy for the South African public healthcare pharmaceutical supply chain is 
beneficial? 
16 
To what extent do you agree that the product categorization framework can be used to 
categorize pharmaceuticals to enhance sustainable availability of medicines in a public 
healthcare pharmaceutical supply chain?  
17 
Are there any comments/additions/subtractions to the construct of the framework that you 
would like to make? 
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5.2.3. SME semi-structured interview feedback 
A summary of the responses is given in Figure 5.2. As discussed, interviewees were also afforded the 
opportunity to provide more detailed feedback via open questions. The responses received to the open 
questions are summarized in Table 5.3. As is evident from Figure 5.2, interviewees mostly selected 
‘agree’ or ‘strongly agree’ as feedback, broadly indicating positive feedback. Notable exceptions are 
Questions 7, 8 and 9 where one interviewee selected ‘disagree’ as feedback, furthermore, in the case 
of Question 9, a further three interviewees selected ‘neutral’ as feedback. These three questions are 
therefore selected for more in-depth discussion. 
 
Figure 5.2: SME feedback to the Likert scale semi-structured interview questionnaire 
In Question 7, interviewees were asked to indicate whether the recommended supply chain strategies 
for each pharmaceutical product could support supply planning decisions at different operational 
levels (e.g. the national and provincial levels). All participants either agreed or strongly agreed that it 
could, however, one participant disagreed specifically with the involvement of the national tier, 
stating that “Most of this will be for provincial level. National will only use this for strategic stock 
buffering and for national phase in and out type of discussions”. This feedback highlights the need 
to provide the framework for both national and provincial tiers, though much emphasis will be on the 
provincial tier as established throughout this study.  
In Question 8 interviewees were asked whether they thought the bundling up of pharmaceutical 
products based on their schedules, the first bundle being S0-S4 and the second being S5-S8, is 
reasonable. Though four participants either agreed or strongly agreed, one was neutral and one 
disagreed. The participant that disagreed stated that the S7-S8 medicines are not extensively used in 
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the South African public healthcare. This input is appreciated, however, since the intention of this 
study is to develop a framework that can not only accommodate pharmaceuticals that are commonly 
used in the public healthcare sector, but also those that are less commonly used, the S7-S8 medicine 
schedules were maintained in the framework for those few cases where these might be applicable. It 
is argued that this is in line with a holistic and sustainable approach to developing the framework. 
In Question 9 interviewees were asked whether they thought the use of these two medicine schedules 
bundles to describe the two gradations of the 'product' attribute in the PDCL2 product attributes 
taxonomy is reasonable. Two participants agreed, three indicated a neutral response and one 
disagreed, giving identical reasoning to that provided for Question 8. For similar reasons to those set 
out in the previous paragraph, the S7-S8 medicine schedules were maintained in the framework. 
The feedback received in response to Questions 7, 8, and 9 were discussed here as examples. The 
complete feedback that was received, as well as responses to this feedback, is provided in Table 5.3. 
Table 5.3: SME feedback to semi-structured interview questionnaire 
Aspect No. Feedback and updates necessary to the study 
Functional 
requirements 
[F]: 
Parameters 
1 
All the participants agreed (1 strongly agreed and 5 agreed) that the established PDCL2 product 
attributes taxonomy is a clear mechanism for categorizing pharmaceutical products according 
to their attributes. In agreement, participant P5 emphasized the need “to account for physical 
attributes of the product i.e. cold chain, weight and volume” which was an aspect addressed 
in Section 4.4 particularly the special cases index in Table 4.4 and the decision making 
philosophy in Section 4.5.  
2 
All the participants agreed (3 strongly agreed and 3 agreed) that the product attributes can be 
practically used to categorize pharmaceuticals effectively and efficiently. 
3 
Five participants (5 agreed) thought that the recommended approach for defining thresholds 
between the binary gradations for provinces in the South African public healthcare is 
reasonable. One participant’s response (P4) was neutral. However, since the bulk (5/6) of the 
participants agreed, the recommended approach for defining thresholds between the gradations 
is deemed reasonable for the provinces.  
User 
requirements 
[U]: Outputs 
4 
Five of the participants agreed (3 strongly agreed and 2 agreed) that the supply chain strategies 
employed, based on Perez (2013), i.e.: continuous-flow; efficient; fast; custom-configured; 
agile; and flexible supply chain strategies, are appropriate. One participant’s response was 
neutral. 
5 
All the participants agreed (4 strongly agreed and 2 agreed) that the employed supply chain 
strategies coupled with their respective decoupling points can be used effectively in a VAN-
enabled public healthcare supply chain.  
6 
Four participants (1 strongly agreed and 3 agreed) thought that the interpolated meanings 
ascribed from the generic decoupling points are reasonable for an informed push model and 
public healthcare service supply planning? Two participants’ responses were neutral. 
However, in agreement, P5 suggested that “the healthcare facilities need categorization too 
based on location, size and storage capacity. Although location will be accounted for in lead 
time”. This has been determined to be part of future research to develop a facility 
categorization criterion to work in conjunction with the product categorization framework. 
Moreover, this health facilities categorization can be invaluable under a distribution plan 
(which is outside this study’s scope) to which the output of this study is an input.  
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Aspect No. Feedback and updates necessary to the study 
7 
Five of the participants agreed (1 strongly agreed and 4 agreed) that the recommended supply 
chain strategies for each pharmaceutical product can support supply planning decisions at 
different operational levels e.g. the national and provincial levels. However, 1 disagreed with 
the involvement of the national tier, stating that “Most of this will be for provincial level. 
National will only use this for strategic stock buffering and for national phase in and out type 
of discussions”. This highlights the need to provide the framework for both national and 
provincial tiers, though much emphasis will be on the provincial tier as established throughout 
this study. 
Design 
restrictions 
[R]: Inputs 
8 
Four participants (1 strongly agreed and 3 agreed) thought that the bundling up of 
pharmaceutical products based on their schedules, the first bundle being S0-S4 and the second 
being S5-S8, is reasonable. One participant’s response (P4) was neutral. However, one 
participant (P5) disagreed stating that the S7-S8 medicines are not extensively used in the 
South African public healthcare. This input is appreciated, however, since the intention of this 
study is to develop a framework that can not only accommodate pharmaceuticals that are 
commonly used in the public healthcare sector, but also those that are less commonly used, the 
S7-S8 medicine schedules were maintained in the framework for those few cases where these 
might be applicable. It is argued that this is in line with a holistic and sustainable approach to 
developing the framework.  
9 
Two participants (2 agreed) thought that the use of these two medicine schedules bundles to 
describe the two gradations of the 'product' attribute in the PDCL2 product attributes taxonomy 
is reasonable. Three participants’ responses were neutral. One participant disagreed and the 
explanation (as well as the reason for maintaining the initial position) is as given for question 
8.  
Boundary 
conditions 
[B]: Controls 
10 
Five participants (1 strongly agreed and 4 agreed) agreed with the boundary conditions which 
define the product categorization framework design’s preferred solution space. One 
participant’s response was neutral.  
Attention 
points [A]: 
Enablers 
 
11 
All the participants agreed (5 strongly agreed and 1 agreed) with the acknowledging of the 
direct delivery and depot system attention points. In agreement, P1 stated that “Global 
discussion are to move towards direct delivery provided that capacity is increased at facility 
level else the depot system will effectively act as a buffer”. This reaffirmed the need to consider 
both the direct delivery and the depot system within the product categorization framework. 
The product 
categorization 
framework 
12 
All the participants agreed (2 strongly agreed and 4 agreed) with the logic that governs the 
schematic tree which underpins the product categorization framework to be appropriate. In 
agreement, P2 added that “The schematic tree may have to differ according to the situation of 
the market where for example cost might end up being the last decision if there is an epidemic.” 
This was incorporated into Sections 4.3 and 4.5. 
13 
Four participants (2 strongly agreed and 2 agreed) agreed that 'the product categorization 
framework special cases index' is useful in aiding framework decision-making under the stated 
special cases. Two other participants’ responses were neutral. In agreement, P2 emphasized 
that there is need for “availability of distribution resources at a time of urgency, especially cold 
chain - keeping quality and compliance in mind” when using the special cases index. P5 added 
that “No one size fits all and there will be special cases. Strategic supply must be considered 
based on the therapeutic use of the product i.e. for ARVs if a patient miss treatment they may 
become resistant and there need to use more expensive medicines to treat their condition”. 
This reaffirmed the importance of the Product Categorization special cases index. P6 added 
that it can “probably become more useful and familiar when one starts using and interacting 
with it more often”. 
14 
All the participants agreed (4 strongly agreed and 2 agreed) that the decision-making 
philosophy employed in the product categorization framework is reasonable. 
15 
Five participants (4 strongly agreed and 1 agreed) agreed that the incorporation of the product 
categorization framework in the context of the VAN strategy for the South African public 
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Aspect No. Feedback and updates necessary to the study 
healthcare pharmaceutical supply chain is beneficial. One other participant’s response was 
neutral. 
16 
All the participants agreed (3 strongly agreed and 3 agreed) when asked to what extent they 
agreed that the product categorization framework can be used to categorize pharmaceuticals 
to enhance sustainable availability of medicines in a public healthcare pharmaceutical supply 
chain. In agreement, P6 mentioned that “I think it could work and is worth a try. Might have 
to try and simplify it further to ensure consistent application”. 
17 
This was set as an open-ended question which required participants to provide any 
comments/additions/subtractions to the construct of the framework: 
P1: No additional comment. 
P2: “The patient should always be top of mind, therefore my comment with regards to the 
decision framework and cost. These are special cases and should be handled with speed. How 
will this be measured and what KPI's will be used to ensure that there is speed to market for 
the patients within the VAN framework?” This emphasizes the use of the informed push model 
as provided within the VAN strategy. It also emphasizes the main goal of this study which is 
sustainable availability and access to medicines for the patients cost-effectively. However, 
measurement of KPIs used to ensure that there is speed to market for the patients within the 
VAN strategy, though outside this study’s scope, can be acknowledged as future study.  
P3: “The logic behind the framework is strong and it is a good contribution to the supply chain 
of pharmaceutical products. I recommend, the classification of pharmaceutical products to be 
consulted with pharmacists who have deeper knowledge about the commodities. Furthermore, 
laboratory supplies are usually integrated with pharmaceutical supply chain especially in the 
HIV/AIDS programs due to dependencies between the two commodities and to minimize supply 
chain costs. Hence it can be a recommendation for future research studies” This highlights 
that in as much as this study focused on supply of ‘drugs’ and not ‘devices’ as established in 
Section 1.3, it is necessary to have future study on how the supply of drugs and devices can be 
merged to minimize costs. This can be done in consultation with pharmacists since they 
possess deeper knowledge of both drugs and devices and how they can be merged. 
P4: No additional comment. 
P5: “I have added some in the comments above. Please feel free to reach out to me if you 
require clarification on any of these comments.” Additions and questions were added within 
the questionnaire. 
P6: “Very good - well done”. 
5.2.4. SME input analysis conclusion 
Overall, the results of the semi-structured interviews with SMEs indicate that the participants were 
content with the proposed product categorization framework. There was consensus on the idea that 
the product categorization framework can be used to categorize pharmaceuticals to enhance 
sustainable availability of medicines in a public healthcare pharmaceutical supply chain. In particular, 
the incorporation of the product categorization framework in the context of the VAN strategy proved 
to be beneficial to the South African public healthcare pharmaceutical supply chain.  
The strong degree of positive feedback indicates that the design requirements employed in the 
framework development and the overarching construct of the product categorization framework are 
valid. 
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 Validation through case study application 
Mouton (2001) states that a case study provides a detailed examination of an already existing case 
with the aim of providing descriptive, explanatory and exploratory findings. Four types of case study 
design methods are posited by Yin (2013), namely: single-case; multiple-case; holistic; and embedded 
case designs based on a 2 x 2 matrix. The holistic single-case design approach is chosen for this study. 
This is because the case for this study is underpinned by a combination of ‘critical’ (the VAN strategy 
and the product categorization framework designs) and ‘unusual’ (applicability and operability of the 
VAN strategy and the product categorization framework) rationales.  
The case study was conducted in a workshop format held at the head office of the NDoH in Pretoria. 
Preparation for the workshop included selecting three pharmaceuticals and four healthcare facilities 
(demand sites) to use as cases and preparing a fact sheet with data on these pharmaceuticals and 
facilities. In line with the holistic single-case design employed in this study, the validation pre-read 
document (detailed in Appendix D) was sent to participants ahead of the workshop.  
The workshop session started with a brief overview presentation of how the product categorization 
framework functions in matching product categories, based on their critical product attributes, with 
appropriate supply chain strategies in the South African public healthcare supply chain, particularly 
in the context of VAN supply planning. Next, the product categorization framework was applied to 
the three pharmaceuticals that had been selected for the case study to test the operability and 
applicability of the principles of the framework. The workshop participants contributed towards 
analyzing and identifying the potential impact of the final product categorization framework in 
enhancing sustainable availability of medicines in the South African public healthcare pharmaceutical 
supply chains. The participants were then requested to score the framework against various 
dimensions. 
5.3.1. Case study participants’ background 
As in the validation through SME input analysis, qualitative participants in the holistic single-case 
design were identified via purposeful sampling, based on merit. The main focus for the case study 
application is to test the applicability and operability of the product categorization framework in the 
South African public healthcare pharmaceutical supply chain. Therefore, participants with extensive 
experience in SCM in the South African public healthcare sector were identified to best assist the 
researcher concerning the case study application. A summary of the case study participants’ 
background is given in Table 5.4, as is indicated, both fulfill senior roles in the NDoH. An 
acknowledged limitation is the small number of workshop participants. The main reason for having 
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such a small number of participants is that there are a limited number of individuals in the South 
African public healthcare sector that possess the level of expertise that was sought for the purpose of 
the case study validation. A third participant was scheduled to participate but had to withdraw at short 
notice due to unforeseen personal circumstances. 
Table 5.4: Case study participants’ background 
Sector Participant 
(P) 
Background/Occupation Reason for inclusion 
Public healthcare 
(pharmaceuticals) 
and supply chain 
management 
P1 
A pharmacist working with the South 
African NDoH. Possesses experience as a 
dispensary manager, public health 
consultant, and USAID Global Health 
Supply Chain Program technical assistant. 
Has worked within the pharmaceutical 
distribution of the public and private sector 
for 25 years.  
Knowledge in pharmaceutical 
dispensing and distribution is 
invaluable in giving an in-depth 
input to the product categorization 
framework, specifically related to 
medicine selection and operational 
functions in general. 
Public healthcare 
(pharmaceuticals) 
and supply chain 
management 
P2 
An Industrial Engineer with 20 years’ 
experience with SABMiller in planning, 
manufacturing, capital optimization, and 
supply chain. Possesses experience in 
public healthcare pharmaceutical supply 
chain optimization for the South African 
NDoH focusing on demand and supply 
planning.  
Knowledge in public healthcare 
pharmaceutical SCM, particularly 
in the South African NDoH, is vital 
for the product categorization 
framework case study application. 
5.3.2. Case study application and evaluation feedback 
The case study followed the overarching process flow of the product categorization framework as 
given in Figure 4.3. The fact sheets, containing information on each of the PDCL2 product attributes 
for the three pharmaceuticals (detailed in Appendix F) were used as input to enable participants to 
determine the thresholds for gradations in terms of each of the PDCL2 attributes (e.g. stable vs volatile 
demand, expensive vs affordable cost). The information provided in Section 3.3.3 of this main 
document was summarised in tabular format (Table 2.1 of the pre-read document) to provide 
guidelines to the workshop participants on determining the threshold for each of the product 
attributes. Next, attributes of the four healthcare facilities (i.e. the demand sites, detailed in Appendix 
F) were used as inputs to determine whether any of the adjustments recommended in the special cases 
index (Table 4.4) had to be applied to the recommended strategy and decoupling point for each of the 
three pharmaceuticals. 
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5.3.2.1. Gradation of pharmaceuticals according to product attributes 
Three medicines were selected for the purpose of the case study, namely: i) Dolutegravir 50mg x 30 
tablets; ii) Vaccine: Influenza (inactivated) injection (0.5ml prefilled syringe antigenicity); and iii) 
Alprostadil, 0.5mg/ml, 1ml injection. One of these medicines is a chronic (ARV) medicine, the 
second is a vaccine (seasonal) medicine, and the third is a specialized psychotic medicine; thus, the 
three pharmaceuticals have distinct behaviour in the public healthcare pharmaceutical supply chain 
and are therefore deemed an appropriate choice to demonstrate the operability of the framework. The 
data set used in in the case study application had limitations emanating from the unavailability of raw 
data in the South African public healthcare, though unavailability of data is not uncommon in medical 
data. Thus, a fact sheet was developed to inform the data for the use of the PDCL2 product attributes 
taxonomy within the case study application for data such as cost to the supply chain data; lifecycle 
data; lead time data, etc.  Such data was not readily available and could not be used at the time of the 
case study application hence, hypothetical description/data of the product attributes was established 
(informed by the public healthcare Master Procurement Catalogue (MPC)). A summary of the 
descriptions of the stated pharmaceutical drugs, which gives an overview of how the participants 
managed to distinguish between the PDCL2 product attributes gradations, is given below and is fully 
described in Appendix F.  
❖ ‘Product’ attribute 
Information from the MPC was used to determine whether each of the three pharmaceuticals were 
part of the EML, and to which therapeutic category and form of administration (injection, tablets, 
solution, granules, etc.) each pharmaceutical belonged. It was then determined which medicine 
schedule each pharmaceutical fall under. Thus, each of the three pharmaceuticals was classified as 
belonging to either the S0-S4 or the S5-S8 medicine schedules, thereby completing the gradation in 
terms of the ‘product’ attribute.  
❖ ‘Demand’ attribute 
A decision was taken to use demand data from a 6-month period and, for each pharmaceutical, the 
monthly demand volume (units) was established together with the associated percentage monthly 
change in volume. From such data, the volatility which entails the variation in product demand over 
a period could be determined using either the standard deviation or the variance, these two statistics 
were calculated using Microsoft Excel. Participants used their discretion to determine what 
constitutes stable demand in contrast to volatile demand based on the magnitude of the standard 
deviation or variance for each of the three pharmaceuticals. Participants emphasized the need to 
consider high volume in contrast to low volume products as well as the physical attributes of the 
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products e.g. drip liquid which comes in high volumes and is bulky. Participants also highlighted that 
a 6-month period is a short timeframe when considering seasonal products and, in such cases, longer 
periods e.g. 24 months are preferable.  
❖ ‘Cost to the supply chain’ attribute 
The MPC was used to determine the following information for each of the three pharmaceuticals: the 
price/unit; the minimum order quantity (MOQ); the holding cost/unit at a facility; the obsolescence 
cost/unit; and the distribution cost/unit. The cost/MOQ in the fact sheet was compared to the expected 
performance benchmarked to the best practices of ISO 13485:20169 as an example. Participants used 
this data to grade each of the three pharmaceuticals as having either an affordable or an expensive 
cost to the supply chain. However, participants highlighted that it could be more appropriate for the 
various provinces to use the absolute cost/product contrary to benchmarking it against a standard or 
cost/MOQ. 
❖ ‘Lead time to deliver’ attribute 
Information on the lead times to deliver for each product, based on tenders, contracts and distribution 
plans, was extracted from the MPC. In the case study application, the lead time of each of the three 
pharmaceutical products was benchmarked against the median lead time of the rest of the products in 
the MPC. The median lead time of all of the products in the MPC is 14 days, whilst the lead times of 
the three pharmaceutical products under consideration are 21, 10, and 7 days, therefore the three 
products that were selected for the case study represent a range of lead times. Based on this data, 
participants graded each of the three products as having either a short or long lead time. 
❖ ‘Lifecycle’ attribute 
For each of the three pharmaceuticals, data on both the lifetime (thus the time from the manufacture 
date to the expiry of the product) as well as whether the product needs to be stored at a specific 
temperature were included in the factsheet. Two of the pharmaceuticals do not require temperature-
controlled storage and have lifetimes of 12 and 24 months respectively, while the third has a shelf 
life of 12 months at 2 - 8°C. Based on this data, participants distinguished between lasting and 
 
 
9
 ISO 13485:2016 defines the quality management standards that an organization must adhere to for it to demonstrate its ability to 
supply medical devices and related services that consistently meet customer requirements and other applicable regulatory requirements. 
Organizations can be involved in different lifecycle stages e.g. design and development, production, storage and distribution, or 
installation of a medical device and provision of associated activities, e.g. technical support. 
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temporal lifecycles. Participants emphasized that the majority of pharmaceuticals that are handled by 
the NDoH have a 24-month lifetime which can be classified as a lasting lifecycle. 
The gradation of each of the three pharmaceuticals for each attribute is detailed in Table 5.5. There 
was no disagreement between the two workshop participants in terms of these gradations. 
Table 5.5: PDCL2 product attributes gradations for the case medicines 
Medicine 
Product Demand Cost to supply chain Lead time Lifecycle 
S0-S4 S5-S8 Volatile Stable Expensive  Affordable Short Long Temporal Lasting 
Dolutegravir 50mg x 30 
tablets 
x   x  x  x  x 
Vaccine: Influenza 
(inactivated) injection 
(0.5ml prefilled syringe 
antigenicity) 
x  x   x x  x  
Alprostadil, 0.5mg/ml, 1ml 
injection 
 x  x x  x  x  
 
5.3.2.2. Supply chain strategy routes identified from the case study 
Based on the PDCL2 product attributes gradations summarized in Table 5.5, the routes as well as the 
recommended supply chain strategies and decoupling points were identified using the main index of 
the product categorization framework (Table 3.1 of Appendix D). These are: 
➢ Dolutegravir 50mg x 30 tablets: Route 16. Continuous-flow, efficient, or fast strategies with 
decoupling points: supply to stock; supply to forecast/need; or supply to forecast, respectively. 
➢ Vaccine: Influenza (inactivated) injection (0.5ml prefilled syringe antigenicity): Route 5. Fast, 
agile, or flexible strategy with decoupling points: supply to forecast; supply to need/stock; or 
design-supply to need, respectively. 
➢ Alprostadil, 0.5mg/ml, 1ml injection: Route 25. Efficient, fast, or agile strategy with 
decoupling points: supply to forecast/need; supply to forecast; or supply to need/stock, 
respectively.  
5.3.2.3. Application of the special cases index 
Following the overarching process flow of the product categorization framework as given in Figure 
4.3, the presence of any of the conditions detailed in the special cases index (Table 4.4), was 
considered next. As mentioned previously, a succinct description of the conditions at four facilities 
to which the medicines are to be supplied was formulated as part of the preparation for the case study 
workshop. The conditions at the four facilities are: 
❖ Facility A: A district hospital with low storage capacity (though it is easily accessible). 
❖ Facility B: A district hospital with high capacity and easily accessible. 
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❖ Facility C: A remote clinic not easily accessible, though the storage capacity is high. 
❖ Facility D: A remote clinic not easily accessible and the storage capacity is low. 
It was evident at this that point the product categorization framework special cases index (detailed in 
Table 4.4) was vital in deciding on one supply chain strategy out of the two or three strategies 
recommended for each of the three pharmaceutical products.  
5.3.2.4. Summarized results for each case 
Based on the product categorization framework special cases index and the supply chain strategy 
profiles, participants stated that Dolutegravir tablets can use a continuous-flow strategy with a supply 
to stock decoupling point when being supplied to Facility A. This is largely due to the need to mitigate 
the low storage capacity by use of facility replenishment according to a fixed cycle and a supplier’s 
supply cycle that is as short as possible to reduce batch sizes among other attributes of the continuous 
flow strategy profile. An efficient supply chain strategy was deemed useful when supplying 
Dolutegravir tablets to Facility B. This is to ensure a high level of inventory through predefined safety 
stock levels for demand buffering while optimizing supply efficiency via a very high resource 
utilization rate, among other attributes of the efficient supply chain profile. A fast supply chain 
strategy was deemed useful in supplying Dolutegravir tablets to Facilities C and D due to the need to 
have a replenishment supply cycle based on a collection schedule, a resource utilization rate which 
can be high to very high, and a supplier’s supply cycle that is as short as possible to reduce time from 
ordering to market (facilities). However, in the case of Facility D, neighboring facilities can also be 
used to buffer inventory.   
The flexible strategy was deemed useful in instances where the supply of the influenza vaccine 
injection, which is a seasonal drug, is in season. The flexible strategy is associated with a flexible and 
as short as possible replenishment supply cycle and resource utilization rate that is low to medium 
with standby capacity when supplying to facilities. Out of season, the fast strategy with supply to 
forecast decoupling point was deemed useful for reasons previously mentioned for this strategy.  
The efficient strategy with a supply to forecast/need decoupling point was deemed useful in supplying 
the Alprostadil injection to Facilities B and C for similar reasons as those previously mentioned for 
this strategy. The fast strategy with a supply to forecast decoupling point was deemed useful in 
supplying the Alprostadil injection to Facility A for reasons previously stated for this strategy. When 
supplying this pharmaceutical to Facility D, an agile strategy with a supply to need/stock decoupling 
point could be used in order to: keep resource utilization on medium to high levels; maintain an 
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inventory/pool of suppliers for sourcing buffering; and keep the replenishment supply cycle as short 
as possible as per patients’ needs. 
The discussion above facilitates for the determination of sourcing plans and replenishment plans for 
the product categories based on the recommended supply chain strategies’ profile and associated 
decoupling points which will be done by VAN professionals in each of the nine South African 
provinces. This will be done cognizant of the levers of the VAN design, especially: the informed push 
model; supplier collaboration constraints; and the NDoH public healthcare pharmaceutical supply 
chain regulations, ethics and code of conduct. 
5.3.2.5. Framework scoring at the conclusion of the workshop 
At the conclusion of the case study workshop, the two participants were requested to score the 
framework against two key dimensions, namely:  
1. Do you think the use of the product categorization framework and its tools is robust and 
sustainable for the South African public healthcare pharmaceutical supply chain in the context 
of the VAN supply planning? 
2. Do you think the use of the product categorization framework and its tools is beneficial in 
enhancing sustainable availability of medicines in the South African public healthcare 
pharmaceutical supply chain in the context of the VAN supply planning? 
 
Figure 5.3: Participant feedback to the framework score questions 
As is illustrated in Figure 5.3, in both instances participants agreed that the use of the product 
categorization framework and its tools is robust and sustainable and that the use of the framework 
would be beneficial in enhancing sustainable availability of medicines in the South African public 
healthcare pharmaceutical supply chain in the context of the VAN supply planning.  
0 1 2 3
Question 2
Question 1
Strongly agree Agree Neutral Disagree Strongly disagree
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5.3.3. Case study application conclusion 
The final product categorization framework was applied and thereby validated by the use of a case 
study application which sought to confirm the operability and applicability of the product 
categorization framework in the South African public healthcare context. The case study workshop, 
conducted with participants from the NDoH SCM, illustrated that the framework can provide a clear 
mechanism for categorizing pharmaceutical products according to their attributes. Throughout the 
discussions, the workshop participants endorsed that the supply chain strategies coupled with their 
respective decoupling points can be used effectively in a VAN-enabled public healthcare supply 
chain. In terms of the framework scoring data gathered at the end of the case study workshop, it is 
recognized that it is not ideal to have only two data points for these metrics, and the limited number 
of workshop participants has already been discussed in Section 5.3.1. It is, however, argued that the 
data presented in Figure 5.3, should be viewed as supplementary to the conclusions that can be drawn 
on the operability and applicability of the framework from considering the case study as a whole.  
In conclusion, based on the details of the case study as a whole, it can be concluded that the product 
categorization framework is operable, applicable and beneficial to the South African public healthcare 
pharmaceutical supply chain. This conclusion is supported by the supplementary data gathered from 
the two workshop participants. 
 Conclusion 
In the first part of this chapter, the preliminary product categorization framework was validated using 
SME input analysis through semi-structured interviews. Feedback from the SMEs was incorporated 
to develop the final product categorization framework. As previously mentioned, in order to avoid 
both duplicating the framework in the main document and interrupting the flow of the narrative of 
the thesis, the preliminary product categorization framework which was validated using SME input 
analysis is presented in Appendix D, while the version of the framework that is presented in Chapter 
4 incorporates all changes that were made in response to the validation feedback.  
In the second part of the chapter, a case study is presented. The final version of the framework, 
presented in Chapter 4, was used during the case study workshop. Based on the results of the case 
study, the framework has been found to be operable and applicable in the contemporary South African 
public healthcare pharmaceutical supply chain. It is also concluded that the framework has the 
potential to make a contribution towards enhancing sustainable availability of medicines.  
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Conclusions and recommendations 
This chapter presents a summary of the research findings of each chapter. A discussion of the 
limitations and contributions of the study will also be presented followed by recommendations for 
future research based on the foundations laid in this study.   
 Research summary 
The background, research aim and objectives, scope of the study, research design and methodology, 
and the validation strategy were presented in Chapter 1. Background of the research was provided by 
setting out the need to curb stockouts within the South African public healthcare pharmaceutical 
supply chain. It was proposed that a mixed-method research can be used to answer the question: how 
best to match pharmaceutical products and their attributes with supply chain strategies in the South 
African public healthcare pharmaceutical supply chain to enhance sustainable availability of 
medicines based on the VAN strategy? Five categories of requirements, posited by van Aken et al. 
(2007), were proposed for use in this research to ensure a balanced approach in the design and 
development of a framework, namely: user requirements; functional requirements; design 
restrictions; boundary conditions; and attention points. A basic systems engineering approach 
underscored by a basic input-output transformation process was formulated for use in the research. 
The rationale for the research was developed in Chapter 2, providing arguments for the likely benefit 
of incorporating the concept of product categorization into the South African public healthcare 
pharmaceutical supply chain. Objective 1 was therefore addressed in this chapter. A systematic 
literature review was employed to identify relevant literature on the concept of product 
categorization—its applications in industries, impacts, and concepts used in the application thereof. 
The chapter further investigated the product categorization methods that have been used in relation 
to SCM in various industries, including the healthcare industry. The chapter aimed at deriving 
information from the literature that could be used to draw conclusions on the likely feasibility and 
applicability of product categorization in the South African public healthcare pharmaceutical supply 
chain. Findings from this chapter were published in a peer-reviewed conference article presented at 
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the 29th annual conference of the Southern African Institute for Industrial Engineering10. Two 
categories of framework design requirements, namely boundary points and attention points, were 
identified and defined in this chapter. 
Objective 2 was addressed in Chapter 3, developing the set of product attributes to be used as the 
basis for categorization in the framework and identifying an appropriate supply chain strategies 
taxonomy to utilize in the framework development. A triangulation method was used to determine 
the product attributes that are critical in matching pharmaceutical products with appropriate supply 
chain strategies in the South African public healthcare supply chain. The identified set of attributes 
are product, demand, cost to the supply chain, lead time to deliver and life cycle, which forms the 
acronym PDCL2. Findings from this section of the chapter were published in a peer-reviewed 
conference article presented at the 25th ICE/IEEE International Technology Management 
Conference11. The chapter also sought to understand how pharmaceutical products can be bundled 
together for the purpose of the framework, using established standardized classifications and 
nomenclature in the healthcare sector. A threshold that is based on the medicine schedule bundles 
was selected. Six supply chain strategies that have been formulated by Perez (2013) were proposed 
as appropriate for use in the framework development. Three of these strategies are oriented to achieve 
efficiency (i.e. continuous-flow, efficient, and fast strategies) and the other three are oriented to 
achieve responsiveness (i.e. custom-configured, agile, and flexible strategies). Operational levers for 
implementation of the identified supply chain strategies were discussed consistent with: the VAN 
supply chain; VAN service supply planning; and the South African public healthcare pharmaceutical 
supply chain. The last three categories of the framework design requirements were identified in this 
chapter, namely: user requirements; functional requirements; and design restrictions. 
In line with Objective 3 of the study, the framework design was presented in Chapter 4. The chapter 
started with a presentation of the consolidated design requirements, identified in Chapters 2 and 3. A 
schematic tree that depicts the underlying structure of the framework was presented next. The final 
version of the framework, incorporating changes made in response to the feedback received during 
 
 
10 The article citation is: Mapowo, N., Bam, L., de Kock, I., & van Eeden, J. (2018). “Incorporating Product Categorization to 
improve the performance of SA’s public healthcare supply chain: A research agenda.” In SAIIE29 Proceedings, 24th – 26th of 
October 2018, Spier, Stellenbosch, South Africa (pp. 391–404). 
11 The full article citation is as follows: Mapowo, N., Bam, L., de Kock, I., & van Eeden, J. (2019). “Enabling product categorisation 
in a public healthcare pharmaceutical supply chain by underscoring the product attributes taxonomy”. Accepted for publication in: 
Proceedings of the 25th ICE/IEEE International Technology Management Conference, 17th – 19th of June 2019, Sophia Antipolis, 
Nice, France. © 2019 IEEE.  
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validation was also presented. The detailed logic underpinning a set of framework recommendations 
was documented to serve as an illustration. Finally, the way in which the framework could be 
integrated into the broader South African public healthcare pharmaceutical supply chain was briefly 
discussed. 
The validation of the framework was presented in Chapter 5. In line with the validation strategy 
described in Chapter 1, two phases of validation were conducted. During the first phase of validation, 
the design requirements and the framework was validated using SME interviews. The feedback 
indicated that: the design requirements were accurate, and the overarching construct of the VAN-
Pharmaceutical Product Categorization Framework is valid and expected to be beneficial to the South 
African public healthcare pharmaceutical supply chain under the VAN informed push model. 
Therefore, not many changes were made in the final product categorization framework. During the 
second phase of validation, a case study was implemented via a workshop hosted at the NDoH SCM 
section. The aim of the case study was to test the operability and applicability of the product 
categorization framework. Three pharmaceutical products, as well as four hypothetical healthcare 
facilities (demand sites), were selected for use during the case study. The case study affirmed that the 
product categorization framework is operable, applicable and likely to be beneficial to the South 
African public healthcare pharmaceutical supply chain. 
 Contributions to literature and practice 
This research contributes to both the academic literature and the public healthcare pharmaceutical 
SCM. It adds to the body of literature by providing an example of how a mixed-methods approach 
can be applied to developing a framework to address a real-world operational problem. Literature had 
not provided critical product attributes specifically for the public healthcare pharmaceutical SCM and 
this study provides this in the form of the PDCL2 product attributes taxonomy. Finally, the framework 
itself constitutes a contribution to literature. 
In terms of contributions to practice, this study proposes a mechanism for enhancing sustainable 
availability of medicines within the South African public healthcare pharmaceutical supply chain by 
employing supply chain strategies that are aligned to the attributes of products. The VAN strategy 
informed push model within the South African public healthcare pharmaceutical supply chain 
currently does not incorporate the product categorization concept, the framework that has been 
developed in this research, therefore, makes a valuable contribution to the VAN toolkit. The VAN-
Pharmaceutical Product Categorization Framework main index offers recommendations rather than 
rigid prescriptions, hence more than one appropriate supply chain strategy is recommended for each 
route. This enables the framework users to limit the number of discrete supply chain pipelines that 
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need to be included in a distribution plan as this is desirable both in terms of economic and operational 
feasibility. 
 Limitations to the study 
This study was set within an SCM system of Product Service Supply Chains (PSSCs) where delivery 
of healthcare by practitioners in the South African public healthcare supply chain is deemed to be the 
service while the medication/pharmaceuticals are the products. The research output is mainly 
intended for VAN professionals who will analyze and optimize complex links at the provincial level 
in the public healthcare pharmaceutical supply chain informed push model. These professionals make 
inventory planning and management recommendations to primary healthcare facilities (PHCFs), 
though they will be informed by the provisions at the national level. Furthermore, this study focused 
on the VAN strategy supply planning which makes use of the demand plan as input and the supply 
plan’s output becomes an input to a demand plan. Thus, the demand plan and the distribution plan 
were not in the scope of this study.  
A number of limitations that relate to the case study were highlighted in the preceding chapter, 
namely: the small number of workshop participants; and the limited publicly available data for use in 
the case study. 
 Recommendations and future work 
During the process of conducting this research, recommendations and opportunities for future study 
were identified. These are detailed in the following sections. 
6.4.1. Recommendations 
In the use of the PDCL2 product attributes taxonomy, it is proposed that each province should 
determine and define its own threshold between the attributes’ binary gradations within the 
boundaries provided by the national tier, based on the measurable characteristics associated with each 
product attribute. This means that each province should be responsible for quantifying, for example, 
what constitutes a long lead time or what constitutes a volatile demand, based on the province’s 
specific circumstances (i.e. provincial healthcare budgets, the marketplace, ease of doing business, 
etc.). 
It is recommended that, from the 32 routes of the schematic tree in the VAN-Pharmaceutical Product 
Categorization Framework, routes that yield the same recommended supply chain strategies can be 
grouped together and can form part of the inputs to a distribution plan. Therefore, it is recommended 
that the product categorization supply plan developed from this study, which facilitates the 
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determination of the sourcing plan and the replenishment plan by the VAN supply chain managers, 
be used to feed into the distribution plan. The recommendation to bundle routes that share the same 
supply chain strategies will help to avoid having more discrete supply chain pipelines than is 
necessary. It is neither desirable nor economically feasible to establish an extensive number of 
discrete supply chain pipelines for a distribution plan, as this would escalate operations management 
overheads, as discussed in the study.  
6.4.2. Future work 
Based on the findings from the SME input analysis and the case study application, there is a need for 
further research on how best to categorize healthcare facilities based on location, size, storage 
capacity, etc. under a distribution plan. These ‘pockets’—where a pocket is defined as a collection of 
facilities that will roll out simultaneously, having common characteristics (e.g. same budget 
ownership, and same service levels)—should be serviced using the same supply chain strategies for 
each of the routes, since they (the serviced facilities) share attributes such as market mediation costs, 
demand variation, and product lifecycles. In as much as distribution planning was outside the scope 
of this study, a facility categorization criterion could work in conjunction with the VAN-
Pharmaceutical Product Categorization Framework—but this suggestion needs to be tested and 
validated.  
Furthermore, during the validation workshops, it was identified that there is a need for research on 
the measurement of KPIs that will be used to monitor the speed to market for pharmaceuticals within 
the VAN framework—although this was outside the scope of this study. This will contribute to 
ensuring that the patient is always the priority.  
In the study, it was identified that laboratory supplies (‘devices’ as defined in Section 1.3) are usually 
integrated within the pharmaceutical supply chain, especially in HIV/AIDS programs, due to 
dependencies between the two commodities and to minimize supply chain costs. Therefore, in as 
much as this study focused on the supply of ‘drugs’ and not ‘devices’ as established in Section 1.3, 
future research on how the supply of drugs and devices can be merged to minimize costs is 
recommended.  
Lastly, though the framework was designed specifically for the contemporary South African context, 
it is likely that it may be more widely applicable, especially to other countries that are utilizing the 
VAN concept. Thus, future research on the transferability of the VAN-Pharmaceutical Product 
Categorization Framework to other countries would be valuable. Research could also be conducted 
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on understanding which dynamics of the VAN-Pharmaceutical Product Categorization Framework 
should be adapted in order to make the framework suitable for countries where the VAN strategy is 
not implemented, and where approaches such as an uninformed push or uninformed pull are used to 
manage the supply chain.   
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Appendix A: Products attributes semi-
structured interview 
A google form was used to present the semi-structured interview and participants were informed that 
the aim of this study is to determine a shortlist of the most important product attributes to be used in 
matching product categories with appropriate supply chain strategies—product categorization—in 
order to enhance sustainable availability of medicines in a public healthcare pharmaceutical supply 
chain. The scope of the study is limited to product categorization for supply planning at national and 
provincial tiers of the department of health. The supply planning aims to drive decision making in 
sourcing and replenishment of pharmaceuticals to enhance sustainable availability of medicines to 
end users at public healthcare facilities. The author had in mind the product attributes given in Table 
1 and the product categorization methods attached. You can (if necessary) make use of the attached 
information to respond to the following questions. Three open-ended questions are provided at the 
end. Eight minutes is all it can take! 
Table 1: Product attributes and their measurable characteristics (reproduced from Mapowo, Bam, de Kock, and van 
Eeden (2019) © 2019 IEEE) 
Product 
attributes 
Examples of measurable characteristics DWV3 The three-dimensional 
global classification 
system 
PSC 
Cost Supply chain, inventory, and manufacturing       
Demand Variability, predictability, volatility, and volume       
Quality Defects and yield percentage       
Financial Profit margin per part       
Product Physical characteristics       
Lifecycle Phase and length of time in phase       
Design Manufacturability of the product       
Standardization Few customized features of the product       
Customer Responsiveness in service       
Uncertainty Customer demand and market environment       
Delivery On-time or on-schedule       
Flexibility Handling of change in demand, design, and delivery       
Inventory Product held in Kanban/JIT inventory       
Lead time Response time to deliver product       
Production Capability and capacity to produce in a lean 
environment 
      
 
These 15 product attributes in Table 1 can be seen to be the basis for determination on the three well 
documented methods that can address SCM product categorization selection, namely: the DWV³ by 
Christopher and Towill (2000), the three-dimensional global classification system by Christopher and 
Towill (2002) and the Product Supply Characterization (PSC) model by Payne and Peters (2004). 
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1.1 The DWV3 classification 
The DWV³ classification system utilizes five product attributes, namely the Duration of the product 
lifecycle, the time Window for delivery, the Volume, the Variety and the Variability, which build the 
acronym DWV3. This classification method is mainly used to develop focused demand chains where 
processes are prioritized as a sequence of events with the end view of serving the ultimate consumer 
(Christopher & Towill, 2000). 
1.2 The three-dimensional global classification system 
The three-dimensional global classification system utilizes three product attributes, namely: product, 
demand, and lead-times. Each attribute is classified as one of two gradations (Christopher & Towill, 
2002): 
❖ Product (standard or special); 
❖ Demand (stable or volatile); and 
❖ Lead-time (short or long). 
The three-dimensional global classification system was developed with a focus on linking the supply 
chain strategy with the product lifecycle management, signifying that the most suitable supply chain 
strategy of a product differs depending on its stage in the product lifecycle (Christopher & Towill, 
2002). 
1.3 The Product Supply Characterization (PSC) model  
Payne and Peters (2004) asserted that the PSC’s focus is on addressing total supply chain costs and 
service performance to the customer. The PSC model utilizes seven (7) product attributes which are: 
❖ Volume,  
❖ Volatility,  
❖ Order line value,  
❖ The frequency of order lines,  
❖ Order line weight,  
❖ Substitutability of a product and  
❖ Number of customers buying each 
product 
Based on the information provided above (including the highly respected knowledge you possess), 
please answer the following short questions: 
1. Which product attributes in Table 1 would you say are important in determining product categories 
and matching them with distinct supply chain strategies in a public healthcare pharmaceutical supply 
chain—for supply planning? Mark with an (x) for each appropriate answer. 
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 Strongly 
unimportant 
Unimportant Neutral Important Strongly 
important 
Cost (Supply chain/inventory/manufacturing) O O O O O 
Demand (Variability, predictability, volatility, 
and volume) 
O O O O O 
Quality (Defects and yield percentage) O O O O O 
Financial (Profit margin per part) O O O O O 
Product (Physical characteristics) O O O O O 
Lifecycle (Phase and length of time in phase) O O O O O 
Design (Manufacturability of the product) O O O O O 
Standardization (Few customized features of 
the product) 
O O O O O 
Customer (Responsiveness in service) O O O O O 
Uncertainty (Customer demand and market 
environment) 
O O O O O 
Delivery (On-time or on-schedule) O O O O O 
Flexibility (Handling of change in demand, 
design, and delivery) 
O O O O O 
Inventory (Product held in Kanban/JIT 
inventory) 
O O O O O 
Lead time (Response time to deliver product) O O O O O 
Production (Capability and capacity to 
produce in a lean environment) 
O O O O O 
 
2 What is your comment on the product attributes employed in the 3 generic product categorization 
methods provided in the attached information above, with regards to determination of product 
attributes usable in product categorization in public healthcare pharmaceutical supply planning? 
 
3. Apart from the 15 product attributes that were asked about, compiled by Sullivan (2007) as 
highlighted in the attached information, are there any other product attributes you think are critical 
for supply planning and product categorization in a public healthcare pharmaceutical supply chain 
(taking heed of semantics)? Please state and motivate 
 
4. Upon completion of the study, I wish to send you a feedback on the outcome of the study. Please 
provide your frequently used email address if you are willing to get the feedback. 
 
 
 
Thank you very much for your time. 
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Appendix B: Background of SMEs used in 
developing the product attributes taxonomy 
Individuals that are considered to be SMEs in either SCM or management of healthcare systems were 
selected as respondents to the semi-structured interview presented in Appendix A and their 
backgrounds are thus detailed here in Appendix B. The SMEs belonged to different expertise within 
various areas of specialty. These include the business analysis and improvement perspective, the VAN 
perspective, policy analysis perspective, maturity models analysis perspective, informed push model 
analysis perspective, strategic and operational supply chain management perspective and the 
healthcare supply chain governance perspective. The input provided by these SMEs formed the second 
component of the triangulation method used in the determination of the most critical product attributes 
to public healthcare pharmaceutical supply chains. Table 1 presents the sector; 
background/occupation; and the reason for inclusion for each of the SMEs. 
Table 1: SMEs used in developing the product attributes taxonomy 
S
e
c
to
r 
P
r
o
fe
ss
io
n
a
l 
(P
) Background/occupation Reason for inclusion 
H
ea
lt
h
ca
re
 a
n
d
/o
r 
su
p
p
ly
 c
h
ai
n
 m
an
ag
em
en
t P
1
 
A researcher with experience as an external consultant, 
Technical Advisor: leadership and governance—
advising district health management in South Africa 
on leadership and governance issues and a board 
member at Uhambo Foundation. Currently working as 
a Senior Analyst at Broadreach Healthcare. 
Extensive experience in healthcare 
governance issues and internal project 
management enables good and unique 
opinions about critical product attributes 
essential for a public healthcare 
pharmaceutical supply chain, especially in 
South Africa. 
P
2
 
A researcher and experienced professional in the field 
of Logistics and Supply Chain Management 
particularly strategic and operational supply chain 
management in support of development and 
humanitarian programmes. Served as the director and 
principal consultant of a supply chain consultancy firm 
and worked for UNICEF in Copenhagen as a supply 
chain specialist focusing on capacity development and 
programme integration. 
Knowledge and expertise in Logistics and 
Supply Chain Management is vital in 
determining product attributes that sit well 
with strategic and operational 
pharmaceutical supply chain management. 
P
3
 
An Industrial Engineer and a researcher in maturity 
models for demand-driven supply chain management 
in the public healthcare sector.  
Knowledge in public healthcare supply chain 
maturity models is useful in determining and 
possibly developing a framework or model 
for which product attributes hits the ‘mark’ 
in public healthcare pharmaceutical supply 
chain. 
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S
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r 
P
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n
a
l 
(P
) Background/occupation Reason for inclusion 
P
4
 
A researcher with experience in ICT systems operation 
and project environment particularly healthcare 
environment. Once served as an IT manager for Health 
Commodity Tracking System (HCTS) in supply chain 
management systems in Ethiopia. Use of 
pharmaceutical logistic information tracking system 
was extensive in the pharmaceutical supply chain 
management projects he undertook for effective and 
efficient pharmaceutical commodities management.   
Experience and knowledge in 
pharmaceutical commodities management is 
useful in my study of pharmaceutical product 
categorization. More specifically, useful in 
prioritizing product attributes essential for 
the public healthcare pharmaceutical supply 
chain. 
P
5
 
A researcher with extensive experience in business 
engineering services and research. Particular expertise 
is in business modeling, analysis, and improvement. 
Worked on projects that pertain to business analysis, 
enterprise design, innovation management, systems 
implementation, process mapping, and value chain 
analysis. 
Understanding of the business (commercial) 
sector will provide an input that will still help 
the public healthcare pharmaceutical supply 
chain to stay competitive in spite of 
differences in focal points between the 
commercial and healthcare sectors. 
P
6
 
An industrial engineer and a researcher in policy 
analysis for the VAN reference framework 
implementation in the South African public healthcare 
supply chain 
 
 
An input from an angle of someone 
researching about the VAN and also policy 
analysis of the public healthcare supply 
chain is essential in determining critical 
product attributes from a policy standpoint. 
P
7
 
A researcher with experience as a Director of Intra-
Health International “Informed push model” project in 
Senegal. Worked with the health products cold chain 
in Mali and served health organizations on global, 
continental, regional and inter-country assignments. 
Notably, he has served as Head of Immunization 
System Strengthening Unit in the World Health 
Organization-Africa regional office on innovative 
solutions to existing and emerging challenges in health 
supply systems. 
Experience in understanding the informed 
push model—which is the aim of the VAN 
reference framework in the South African 
public healthcare pharmaceutical supply 
chain, is quite an asset to this study. 
Furthermore, his knowledge in African 
innovative solutions to existing and 
emerging challenges on health supply 
systems is important in the determination of 
critical product categorization attributes in 
the South African public healthcare 
pharmaceutical supply chain.  
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Appendix C: Classification and 
nomenclature in healthcare  
The Global Standards 1 (GS1) is an international standards organization that develops and maintains 
global standards for the sake of business communication. It has worldwide member bodies in more 
than 100 countries. In an executive summary in 2015, healthcare classification and nomenclature 
systems that are typically developed for distinct purposes were compiled and suggested. A listing of 
the various classification and nomenclature systems that are used in healthcare (limited and with a 
direct impact to supply chain strategies) and the acknowledged purpose of each system is presented 
here in Table 1. 
Table 1: Classification and nomenclature systems used in healthcare with a direct impact on supply chain strategies 
(adapted from Global Standards 1 (2015)) 
System Definition/Description Maintenance Agency Declared Purpose 
AHFS 
American Hospital Formulary Service and 
Pharmacologic Therapeutic Classification 
- classification allows the grouping of 
drugs with similar pharmacologic, 
therapeutic, and/or chemical characteristics 
American Society of 
Health System 
Pharmacists 
Clinical: The mission of AHFS 
Drug Information® (AHFS DI®) 
is to provide an evidence-based 
foundation for safe and effective 
drug therapy. 
CND 
Classificazione Nazionale dei Dispositivi 
medici (CND) - Italian classification 
system for medical devices 
Italian Health Ministry 
Assessments of adverse events, 
transparent procurement 
processes by the national health 
system. 
CPV 
Common Procurement Vocabulary (CPV) 
establishes a single classification system 
for public procurement aimed at 
standardizing the references used by 
contracting authorities and entities to 
describe the subject of procurement 
contracts  
The Office for Official 
Publications of the 
European 
Communities 
(OPOCE) 
The CPV establishes a single 
classification system for public 
procurement aimed at 
standardizing the references used 
by contracting authorities and 
entities to describe the subject of 
procurement contracts. 
eCl@ss 
Standardized Material and Service 
Classification and Dictionary - cross 
industry product data standard for 
classification and description of products 
and services  
eCl@ss Association 
Procurement, controlling and 
distribution. Company-wide 
process data management as well 
as engineering. 
GMDN 
Global Medical Device Nomenclature -To 
give a common generic descriptor for 
medical devices having similar features, 
characteristics and intended use for 
exchange of data between regulatory 
bodies. 
GMDN Agency 
The GMDN is used for: 
Data exchange between 
manufacturers, regulators and 
healthcare authorities. Exchange 
of post-market vigilance 
information. Supporting 
inventory control in hospitals. 
Purchasing and supply chain 
management 
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System Definition/Description Maintenance Agency Declared Purpose 
GPC 
Global Product Classification - A system 
that gives a common language for 
grouping products in the same way 
GS1 
GPC gives buyers and sellers a 
common language to group 
products the same way globally to 
ensure effective data 
synchronization in the Global 
Data Synchronization Network 
(GDSN). 
NAPCS 
North American Product Classification 
System Identify, define, and classify the 
final products and services produced and 
transacted by reporting units within each 
industry 
US Census Bureau, 
jointly with like 
agencies of Canada 
and Mexico 
The long-term objective of 
NAPCS is to develop a market 
oriented, or demand-based, 
hierarchical classification system 
for products (goods and services) 
NHS 
eClass 
The National Health System (NHS)-eClass 
is a bespoke classification system for 
products and services, managed by the 
English NHS. The purpose of NHSeClass 
is to facilitate the accurate analysis of 
expenditure. 
NHS-eClass was for 
the English NHS but is 
now administered by 
NHS Shared Business 
Services. 
NHS-eClass was designed to 
support the accurate and 
standardized classification and 
cataloguing of products and 
services,  
UNSPSC 
United Nations Standard Products and 
Services Code® (UNSPSC®) is an open, 
global, multisector standard for efficient, 
accurate classification of products and 
services 
Manged by GS1 US 
for the UN 
Development 
Programme 
(UNDP) 
Used for: Cost-effective 
procurement 
optimization. Full exploitation of 
electronic 
commerce capabilities. Typically 
used by purchasing organizations 
for spend analysis 
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Appendix D: Framework validation 
document  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PRODUCT CATEGORIZATION 
FRAMEWORK VALIDATION 
Private and confidential document 
PRE-READ DOCUMENT 
Authored by: Newton Mapowo 
Louzanne Bam 
Imke H. de Kock 
Joubert van Eeden 
Edward Llewellyn 
 
 
 
Development of a product categorization 
taxonomy framework for the South 
African public healthcare pharmaceutical 
supply chain to enhance sustainable 
availability of medicines—VAN enabled 
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FOREWORD  
This document serves as pre-read material necessary for validation. The document provides an understanding 
of the product categorization taxonomy framework developed for the South African public healthcare 
pharmaceutical supply chain in the context of supply planning for the Visibility and Analytics Network (VAN). 
An overview of the background of the study, the methodology and a summary of the study’s literature is 
provided.  Consequently, the product categorization framework together with the decision-making philosophy 
is given.  
In the interest of maximizing on the limited time available, each participant should ideally read through this 
document prior to filling in the assessment questionnaire. Participants should focus more on pages 3-4; and 12-
18. 
 
 
 
 
 
 
Newton Mapowo        Date 
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1.0 Introduction 
This section aims to provide an overview of the research inquiry by summarizing the background, research 
question, research aim, and the research design and methodology in developing the product categorization 
framework.  
1.1 Background 
The South African National Department of Health (NDoH) is in the process of rolling out the Visibility and 
Analytics Network (VAN) reference framework, with the aim of ensuring sustained availability of and access 
to medicines (Llewellyn, 2017). One of the objectives of the VAN strategy is to transform South Africa’s public 
healthcare pharmaceutical supply chain from an ‘uninformed pull’ system to an ‘informed push’ system. The 
distinction between these respective systems being that specialized supply chain management professionals will 
be utilized in each province. These professionals will analyze and optimize complex links in the public 
healthcare pharmaceutical supply chain and make inventory planning and management recommendations to 
primary healthcare facilities (PHCF), rather than the PHCFs doing so on their own. An informed push model 
will relieve the PHCF’s staff of sophisticated and time-consuming supply chain planning work and enable them 
to focus more on healthcare delivery (Llewellyn, 2017). 
At present, the VAN strategy does not incorporate the concept of product categorization—which entails the 
organization of products into categories according to shared attributes; more specifically, when supply chains 
are considered, attributes that are related or could influence the best supply chain management strategy for said 
products. Fisher (1997) proposed that the reason why supply chains do not perform as expected despite increased 
investments in effort and resources is an improper alignment of product attributes and supply chain strategies. 
Simchi-Levi, Clayton and Raven (2013) reasoned that “one size does not fit all” in the formulation of a supply 
chain strategy, highlighting the fact that different supply chain management strategies are most likely needed 
for products that differ in terms of attributes such as variability, volume, lead-time, lifecycle etc.  
In order to propose an approach for applying the principle of product categorization in the South African public 
healthcare pharmaceutical supply chain, the following research question and aim are pursued. The main question 
that guided this study was: How best to match pharmaceutical products and their attributes with supply chain 
strategies in the South African public healthcare pharmaceutical supply chain to enhance sustainable availability 
of medicines? 
1.2 Research aim 
The aim of this research inquiry is to contribute towards improving the sustainable availability of medicines in 
the South African public healthcare pharmaceutical supply chain by proposing a suitable framework for the 
application of the concept of product categorization. 
1.3 Methodology of the research 
For the study, a mixed method research approach was employed where secondary quantified data sources on 
the South African public healthcare pharmaceutical supply chain were utilized to determine and define the 
research problem. Framework design requirement categories were identified as defined and given in the table. 
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Table 1.1:  Framework design requirement categories (adapted from van Aken, Berends, and van der Bij (2006)) 
Framework 
design 
requirement 
category 
Generic definition of requirement category 
User requirements 
[U] 
These are the critical and distinct requirements, as deemed by the framework user, which are used to define the 
constraints in framework development. 
Functional 
requirements [F]; 
These are the fundamental enablers which facilitates the functionality, performance or result of the framework’s 
design and use. 
Design restrictions 
[R]; 
These are the scope, exclusions, limits, and elements of the framework design’s preferred solution space. 
Boundary 
conditions [B]; 
These are the categorical requirements or rules that cannot be altered and must be met e.g. ethics, code of 
conduct and legislation. 
Attention points 
[A]. 
These are the desirable and relevant requirements of the framework design though they are not binding nor 
restrictive. 
 
The synthesis of these requirements to develop the framework followed a basic input-output categorization 
process, as in Figure 1.1: 
 
Figure 1.1: Input-output transformation process (adapted from The US Department of Defense Systems Management College (2001)) 
To determine these framework design requirements, the rationale which explored the concept of product 
categorization and the South African public healthcare pharmaceutical supply chain was given. Next, solutions 
were developed which were the product attributes taxonomy and the supply chain strategies taxonomy. 
Consequently, the product categorization framework was developed based on the findings.   
1.4 The aim of this workshop 
The workshop’s first objective is to review and validate framework design requirements used to develop the 
preliminary product categorization framework and the framework’s construct itself. This is accomplished by 
getting feedback from subject matter experts (SMEs) on the framework. Consequently, based on the feedback 
received from the SMEs, necessary iterations and/or improvements will be made to develop a final product 
categorization framework. The second objective (after the validation session and updating the preliminary 
framework based on the SME feedback) is to conduct a case study on the final product categorization framework 
which will also require an SME engagement workshop. The case study will account for operability and 
applicability of the final product categorization framework. 
The succeeding section details the literature that supported the development of the preliminary product 
categorization framework. The reader can skip some of the pertinent parts of the literature overview if familiar 
with the content, but readers can find the preliminary product categorization framework in Section 3 (page 12). 
 
 
Categorization process 
Attention points 
Design 
restrictions 
Boundary conditions Functional requirements 
Framework user 
requirements 
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2.0 Literature overview 
In this section, the supportive literature for the development of the product categorization framework is briefly 
discussed. Firstly, a brief discussion of the VAN strategy in the South African public healthcare supply chain 
will be given. Secondly, the formulation of the product attributes taxonomy will be discussed. Thirdly, the 
classification and nomenclature in healthcare will be summarized. Fourthly, the synthesis of the supply chain 
strategies taxonomy will be established giving detail on the levers to control in supply chain strategy 
implementation.   
2.1 The VAN strategy in the South African public healthcare pharmaceutical supply chain 
The demand plan feeds into the supply plan and the supply plan feeds into the distribution plan within the South 
African public healthcare pharmaceutical supply chain (Llewellyn, 2017). The scope of this study focuses on 
the supply planning, which under the VAN strategy seeks for coordination of inventory and orders to optimize 
the delivery of products to meet the patients’ needs—i.e. to provide sufficient products at the right place and at 
the right time in order to fulfil the demand plan.  
The outputs from a supply plan are sourcing orders and replenishment orders with supply planning variables 
such as lead time, safety stock, stock on hand, minimum order quantities and delivery channel costs (Llewellyn, 
2017). The product categorization framework’s recommended supply chain strategies aligned with 
pharmaceutical products and their product attributes, are thus proposed from this study to drive the sourcing 
orders and replenishment orders. This will be enabled by the VAN stage 3 operationalization which utilizes 
trained and informed supply chain planners. The planners use technology to make order recommendations based 
on the visible sock levels and consumption data at facilities (Llewellyn, 2017). 
2.2 Solution development: Product attributes and supply chain strategies taxonomy 
This section discussed, synthesized and determined the product attributes that are critical in matching product 
categories with appropriate supply chain strategies in the South African public healthcare supply chain 
particularly the VAN supply planning. The section also gives an understanding of how pharmaceutical products 
can be bundled up together according to the established standardized classifications and nomenclature in the 
healthcare sector. Furthermore, supply chain strategies were identified that were critical for the product 
categorization framework development and levers and controls for supply chain strategies implementation was 
given consistent with the VAN supply chain; VAN service supply planning; and the South African public 
healthcare pharmaceutical supply chain. 
2.2.1 Salient supply chain-driving product attributes 
After conducting an extensive systematic literature review, it was identified that the product attributes 
established from literature are generic and research has not yet considered determining critical product attributes 
in the public healthcare pharmaceutical supply chain sector specifically. While there are certainly many 
commonalities between the dynamics of commercial sector supply chains and public healthcare supply chains, 
there are also distinct differences which were taken into consideration when selecting appropriate product 
attributes for product categorization in a public healthcare supply chain.  
Due to the differences in characteristics between the commercial and the public healthcare supply chains, the 
triangulation approach was used to synthesize and identify critical product attributes to public healthcare thereby 
enabling a strengthened construct validity and internal validity. The triangulation method firstly took into 
account the understanding of the supply chain-driving product categorization methods as applied in various 
industries’ supply chains and subsequent product attributes as provided in the literature. Secondly, subject 
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matter experts (SMEs) were consulted to cross-check what literature provided, interpolating these provisions to 
public healthcare pharmaceutical supply chains. Finally, provisions from literature and inputs from SMEs were 
synthesized and a final list of proposed product attributes for use in public healthcare pharmaceutical supply 
chains were developed through the application of logical arguments and reasoning.  
Based on the findings from the triangulation method employed, it is proposed that the critical product attributes 
for product categorization in the South African public healthcare pharmaceutical supply chain are product, 
demand, cost to the supply chain, life cycle and lead time to deliver, which form the acronym PDCL
2
. These 
product attributes, together with examples of measurable characteristics for each attribute, are summarized in 
Table 2.1. 
Table 2.1: Consolidated product attributes for product categorization in the public healthcare pharmaceutical supply chain (adapted 
from Mapowo, Bam, de Kock, and van Eeden (2019) © 2019 IEEE) 
Public healthcare 
pharmaceutical supply 
chain product attributes 
(with gradations) 
Examples of measurable 
characteristics 
Recommended thresholds between the binary 
gradations for provinces in the South African public 
healthcare 
Product (standard or 
special) 
Therapeutic nature, substitutability of 
the product, standardization of product 
category and physical characteristics. 
A more entailing threshold between the standard and special 
gradations is given in detail in Section 2.2.2. 
Demand (stable or volatile) 
Variability, volatility, volume, and 
uncertainty. 
Pharmaceutical products with fairly constant or predictable 
demand in the short or medium-term demand and/or supply 
plan of a province can be considered ‘stable’ while those 
that spike unpredictably can be considered ‘volatile’. 
Cost to the supply chain 
(affordable or expensive) 
Procurement cost, holding cost, 
obsolescence cost and distribution 
cost. 
Order line values, frequency of order lines and order line 
weights can then be used to determine between expensive 
and affordable cost based on the procurement cost, holding 
cost, obsolescence cost and distribution cost. 
Life cycle (temporal or 
lasting) 
Product lifetime, shelf life, 
obsolescence, and product quality. 
Products that require a short end-to-end pipeline, rapid time 
to market and have short shelf life and lifetime can be 
considered to have a temporal life cycle, with the opposite 
being true for a lasting life cycle. 
Lead time to deliver (short 
or long) 
Supply cycle time, supply takt time, 
response time to deliver product, on-
time or on-schedule and time service 
levels. 
Pharmaceutical products that cannot be sourced nor 
replenished rapidly based on the supply cycle time, supply 
takt time and time service levels can constitute the long lead 
time, while the opposite is true for a short lead time. 
It is proposed that since the intention is to use the product attributes at national and provincial tiers’ operational 
levels under the informed push model of the VAN reference framework, each province should determine and 
define its own threshold between the binary gradations basing on the measurable characteristics given in Table 
2.1 as per the boundaries provided by the national tier. This means that each province is responsible for 
quantifying, for example, what constitutes a long lead time or what constitutes a high cost, based on the 
province’s specific circumstances i.e. provincial healthcare budgets, marketplace, ease of doing business etc. 
As a recommendation to the various provinces, the basis for determining the thresholds between the binary 
gradations is recommended in the third column of Table 2.1. 
2.2.2 Classification and nomenclature systems in healthcare 
The most salient distinction of pharmaceutical products is based on their medicine schedules which allows for 
different levels of regulatory control of pharmacological substances—where a medicine schedule is a number 
assigned to a pharmaceutical product according to its benefits and risks i.e. the lower the risk the lower the 
number assigned to it. These schedules are summarized in Table 2.2. 
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Table 2.2: Medicine schedules (adapted from Innovative Pharmaceutical Association South Africa (2016)) 
Medicine schedule Available at: 
0 General shops like supermarkets e.g. simple analgesics 
1 Over-the-counter (OTC) in a pharmacy e.g. antifungal skin creams 
2 OTC in a pharmacy with sale record to be kept e.g. a cough and cold medication 
3 Prescription only from the pharmacy dispensary—6 months repeat allowed e.g. diabetes medicine 
4 Prescription only from the pharmacy dispensary—6 months repeat allowed e.g. anti-infectives 
5 Prescription only from the pharmacy dispensary—repeats stipulated e.g. psycho-active medicines 
6 Prescription only, therapeutic narcotics e.g. narcotic painkillers 
7 Controlled substance e.g. cannabis and heroine 
8 Strictly controlled substances e.g. nabilone, amphetamine and dexamphetamine 
In this study, taking from the most salient medicine groupings from the various classification and nomenclature 
systems that are used in healthcare, medicine schedules will be used to grade the ‘product’ attribute of the 
established PDCL2 product attributes taxonomy. Moreover, for the VAN supply chain; VAN service supply 
planning; and the South African public healthcare pharmaceutical supply chain’s product categorization 
framework, two binary ‘product’ attribute gradations of these medicine schedules bundles can be established 
for the developed PDCL2 product attributes taxonomy. The first being the S0, S1, S2, S3 and S4 medicine 
schedule bundle and the second being the S5, S6, S7, and S8 medicine schedule bundle. The S0-S4 medicine 
schedules bundle are mostly high-volume products, administered with a limit of 6 months’ repeat supply and 
have better ease of access/availability as they can be found in general shops and pharmacy dispensaries with 
less restrictive regulatory control (Innovative Pharmaceutical Association South Africa, 2016; Medicine Control 
Council, 2014).  
However, the S5-S8 medicine schedule bundle/gradation are mostly low volume products which may have a 
moderate to high potential for abuse or for producing dependence, which then necessitates close medical 
management and supervision and strict control over supply with some medicine only available to medical 
practitioners who have obtained special permission from the Medicines Control Council for use and prescription 
(Medicine Control Council, 2014). Therefore, these two medicine schedule bundles/gradations (S0-S4 and S5-
S8) can be supplied differently and would need different supply chain strategies based on the other gradations 
of the PDCL2 product attributes taxonomy. Thus, the medicine schedules were identified as part of design 
restrictions (R) and will contribute to the framework development as the input to the framework since the 
product categorization framework can only categorize what already exist within the pharmaceutical product 
portfolio. 
2.3 Supply chain strategies taxonomy  
Having discussed various supply chain strategies, the most salient strategies for product categorization in the 
context of the VAN supply chain; VAN service supply planning; the South African public healthcare 
pharmaceutical supply chain; and the NDoH were identified as defined by Perez (2013):  
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Continuous-flow supply chain strategy: This supply chain employs a ‘make to stock’ decoupling point where 
production is scheduled to replenish predefined stock levels based on a specific reorder point for inventory in 
the production cycle. It pursues high service levels and low inventory levels. 
Efficient supply chain strategy: This supply chain has production scheduled based on sales expectations for the 
duration of the production cycle, using a ‘make to forecast’ model as a decoupling point. 
Fast supply chain strategy: This supply chain has production scheduled in a single batch per stock keeping unit 
(SKU), with the size being defined by the season’s sales expectations, and utilizing a ‘make to forecast’ 
decoupling point. 
Custom-configured supply chain strategy: This supply chain is characterized by multiple configurations of the 
finished product on a unique platform, using a ‘configurable to order’ decoupling point. 
Agile supply chain strategy: This supply chain employs a ‘make to order’ or sometimes ‘make to stock’ 
decoupling point, where items are produced after a purchase order has been placed by the customer. 
Flexible supply chain strategy: This supply chain is characterized by adaptability, which entails the capability 
to reconfigure internal processes to meet a specific need (or solve a problem) of a customer using a ‘design to 
order’ decoupling point. 
This set of supply chain strategies underscore the user requirements (U) of the product categorization framework 
development and will be used to link and match appropriately with each distinct pharmaceutical products 
bundle/category based on the established PDCL2 product attributes taxonomy. Each supply chain strategy has 
its own decoupling point defined generically in literature, but however, these definitions were translated to the 
informed push model of the VAN strategy; public healthcare pharmaceutical supply chain; and service supply 
planning in the study. Table 2.3 describes the decoupling points when contextualized and applied to public 
healthcare pharmaceutical supply chain; VAN informed push model; and service supply planning: 
Table 2.3: Supply chain strategies and their decoupling points (adapted from Perez (2013)) 
Supply chain 
strategy 
Generic decoupling point, 
adapted from Perez (2013) 
Informed push model and public healthcare service supply planning-
specific interpolated decoupling points 
Decoupling point Interpolated meaning 
Continuous-flow 
supply chain strategy 
Make to stock Supply to stock 
Supplying for stocking at facilities based on 
predefined stock levels. 
Efficient supply chain 
strategy 
Make to forecast/Make to 
order 
Supply to forecast/ 
Supply to need 
Supplying based on forecasted demand or based 
on the foreseen service needs of the facilities. 
Fast supply chain 
strategy 
Make to forecast Supply to forecast 
Supplying based on forecasted demand of 
facilities. 
Custom-configured 
supply chain strategy 
Configurable to order Configurable to need 
Configuring supply orders/formularies based on 
facility/patients’ needs e.g. case of personalized 
medicine 
Agile supply chain 
strategy 
Make to order’/Make to stock 
Supply to need/ 
Supply to stock 
Supply based on the foreseen service needs of the 
facilities or based on facilities’ predefined stock 
levels. 
Flexible supply chain 
strategy 
Design to order 
Design supply to 
need 
Configuring the supply chain in response to 
facilities’ or patients’ service needs. 
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It is recommended that the established decoupling points be used for decision making in sourcing plans and replenishment plans per province, which is the intended 
output of the product categorization framework to be developed. The study detailed how this supply chain strategies taxonomy within the product categorization 
framework to be developed, will be embedded within the four main elements that shape supply chain strategy implementation i.e. business framework; competitive 
positioning; managerial focus; and supply chain focus as defined by the Perez (2013) framework.  These four main elements, detailed in Table 2.4, were considered for 
the proposed supply chain strategies taxonomy within the VAN strategy implementation, South African public healthcare pharmaceutical supply chain and the NDoH 
according to Perez (2013).  
 
 
 
Table 2.4: Supply chain strategies taxonomy contextualized to supply planning—VAN enabled (adapted from Perez (2013)) 
  Oriented to efficiency Oriented to responsiveness 
Continuous-flow Efficient Fast Custom-configured Agile Flexible 
B
u
sin
ess 
fram
ew
o
r
k
 
Demand variation Low Medium to high Medium to high High High Unpredictable 
Product lifecycle Long Long Short Short to medium Short to medium Undetermined 
Market mediation 
cost 
Low Low Medium to high High High High 
C
o
m
p
etitiv
e 
p
o
sitio
n
in
g
 
Main difference in 
service delivery 
High pharmaceutical 
inventory turnover 
Perfect orders Short time from order to 
market 
User-friendly as per need Agility relative to demand 
changes 
Based on patients’ exact 
needs 
Main difference in 
pharmaceuticals 
Best performance/ cost 
ratio 
Affordability Continuous portfolio 
renewal 
Configurable product Customizable product Adaptable process 
M
an
ag
erial fo
cu
s 
End-to-end Collaborative relationships 
to build synergies 
Efficiency Continuous pharmaceutical 
product portfolio renewal 
Pharmaceutical product 
configurability 
Agile response to changes 
in demand 
Resource flexibility 
Servicing Information sharing for 
continuous improvement 
Perfect orders as per 
facilities’ needs 
Short lead time to deliver Accuracy in orders supplied Short lead time Understanding of patients’ 
needs 
Product Operations designed for 
lean supply capability 
Low cost at standard 
supply performance 
Fast sourcing process Modular design in orders for 
multiple configurations 
Operations designed for 
supply in small batches 
Operations supported by 
complementary services 
Sourcing Collaborative relationships 
to build synergies 
Lowest-total-cost-
supplier (opportunistic) 
Pool of suppliers with short 
lead times and oriented to 
innovation 
Agile response to changes in 
demand 
Short lead time Agile response and process 
flexibility to adopt patients’ 
requirements 
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  Oriented to efficiency Oriented to responsiveness 
Continuous-flow Efficient Fast Custom-configured Agile Flexible 
S
u
p
p
ly
 ch
ain
 p
ro
file 
Demand buffering Predefined safety stock 
levels 
Predefined safety stock 
levels 
Predefined safety stock 
levels 
Inventory before PDP, extra 
capacity after 
Extra capacity Standby capacity or capacity 
pooling 
Order penetration 
point 
Supply to stock Supply to forecast, 
sometimes supply to need 
Supply to forecast Configured to need Supply to need or supply to 
stock 
Design supply to need 
Minimum order 
size 
Patients’ replenishment 
needs 
Minimum economic 
transportation batch 
Collection forecast End patients’ (replenish- 
ment) needs 
Minimum economic supply 
or transportation batch 
Minimum economic supply 
batch  
Replenishment 
supply cycle 
Replenishment according 
to a fixed cycle 
Fixed lead time or fixed 
cycle 
According to collection 
schedule 
As short as possible as per 
need in PDP queue 
As short as possible as per 
patients’ needs in queue 
Flexible, as short as possible 
Collaborative 
relationships 
Strategic relationships 
with key partners to build 
synergies 
Strategic relationships 
with key partners to build 
synergies 
Cooperate to anticipate 
market trends /joint design 
Cooperation with key 
partners to anticipate 
aggregate demand at PDP 
Cooperation with key 
partners to anticipate 
capacity requirements 
Understanding of ‘available 
to need’ at any moment 
Inventory strategy Small and frequent batches 
to increase inventory turns 
High level of inventory to 
optimize supply 
efficiency 
A single batch per SKU 
based on collection forecast 
Inventory just before PDP Stock under a common 
platform 
Low inventory level and 
inventory pooling 
Customization No No Usually no Yes, just in PDP and 
downstream processes 
Relevant in supply 
operations and downstream 
processes 
Relevant in supply design 
and downstream processes 
Resource 
utilization rate 
High to very high Very high High to very high High before PDP, medium 
after PDP 
Medium to high Low to medium. At times 
standby capacity 
Supplier’s supply 
cycle 
As short as possible to 
reduce batch sizes 
Maximize on increasing 
batch sizes and efficiency 
As short as possible to 
reduce time from ordering 
to market            
Long before PDP, short in 
PDP and downstream 
Variable as per patients’ 
orders accepted in queue 
As short as possible to reduce 
lead time 
Rate (takt) of 
workload 
Smoothed by patients 
demand 
Smoothed by rolling 
forecast 
Smoothed by collection 
forecast 
Smoothed by rolling forecast 
before PDP, peaks after PDP 
Peaks and valleys of high 
magnitude 
Capacity on standby for 
occasional use, high peaks 
when used 
Sourcing buffering Inventory/one supplier for 
each key product bundle/ 
category 
Inventory/best-cost 
supplier on each occasion 
Pool of suppliers Inventory/pool of suppliers Inventory/pool of suppliers Pool of suppliers for critical 
resources 
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The literature review and synthesis helped to identify the framework design requirements, consolidated in Table 
2.5, i.e. User requirements [U]; functional requirements [F]; design restrictions [R]; Boundary conditions [B]; 
and Attention points [A] as defined by van Aken et al. (2006). The preliminary product categorization 
framework proposition for matching product bundles/categories with appropriate supply chain strategies will 
be given in Section 3.0. 
Table 2.5: Consolidated design requirements from the literature study and synthesis 
Design requirement Req. ID 
User requirements [U]: Outputs 
The framework must support supply planning decisions at different operational levels e.g. the national and provincial 
levels, by recommending an appropriate supply chain strategy for each pharmaceutical product. 
U1 
Each supply chain strategy, contextualized to the VAN strategy, should dictate an appropriate sourcing plan and 
replenishment plan based on its affiliated decoupling point. 
U2 
The framework must also provide a decision-making approach in special cases e.g. vaccine supply or delivery site 
restrictions and limited storage capacity. 
U3 
The framework’s output, which identifies as output of a supply plan, should be usable as input to a distribution plan. U4 
Functional requirements [F]: Parameters 
The framework must provide a clear mechanism for categorizing products according to their attributes. F1 
Products should be categorized according to the PDCL2 product attributes classification. F2 
Design restrictions [R]: Inputs 
The pharmaceuticals restricted to the demand plan product portfolio which describe the Essential Medicine List (EML) 
should be used as input to the supply plan product categorization framework. 
R1 
If products are bundled based on their inherent characteristics, the medicine schedules bundles S0-S4 and S5-S8 should 
be used. 
R2 
Boundary conditions [B]: Controls 
The framework’s output, in the form of recommendations for managing the public healthcare pharmaceutical supply 
chain, must align with the principles that underpin the Visibility and Analytics Network strategy, most importantly the 
concept of informed push. 
B1 
The framework’s output, in the form of recommendations for determining supply planning’s sourcing and replenishment 
plans, must contribute to determination of supplier collaboration constraints (contracts and tenders) within the funding 
limitations. 
B2 
The framework’s output, in the form of recommendations for managing the public healthcare pharmaceutical supply 
chain, must align with the principles that underpin the South African Constitution. 
B3 
Attention points [A]: Enablers 
The framework’s recommendation for managing supply chain strategies should ideally incorporate the direct delivery 
and depot system that are already operational in the South African public healthcare pharmaceutical supply chain 
A1 
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3.0 Product categorization framework development 
The synthesis of the design requirements to develop the framework was based on the systems engineering input-
output transformation process adapted from the US Department of Defence Systems Management College 
(2001) initially given in Figure 1.1. A framework derived from such a process will potentially enable the users—
VAN supply chain managers—to determine appropriate product-driven supply chain sourcing and 
replenishment strategies for the pharmaceutical products so as to enhance the sustainable supply of medicines 
and improve the supply chain performance. The proposed preliminary product categorization framework, based 
on the framework design requirements established in the study, will be underpinned by a schematic tree. The 
logic that governs the schematic tree, which underpins the product categorization framework, is detailed in the 
next section. 
3.1 The schematic tree that underpins the product categorization framework 
The PDCL2 product attributes taxonomy underscores the schematic tree and allows for analysis of a combination 
of pre-existing conditions on a product bundle/category before a supply chain strategy and decoupling point can 
be recommended. The PDCL2 product attributes taxonomy is set out in a schematic tree hierarchical sequence 
of the product attributes to consider, with ‘product’ being the first; ‘demand’ the second; ‘cost to the supply 
chain’ the third; ‘lead time’ the fourth; and ‘lifecycle’ the fifth as given in Figure 3.1. 
Based on various combinations of different gradations of the PDCL2 product attributes taxonomy, 
pharmaceuticals bundled first according to their schedules will yield 32 routes from the schematic tree. To each 
route, supply chain strategies coupled with their decoupling points were recommended based on the discussed 
findings from the study. The six supply chain strategies from the supply chain strategies taxonomy identified in 
the study were used as outcome decisions of the schematic tree. 
The product categorization framework, presented in Table 3.1, took a leagile (lean + agile) approach in selecting 
most of the appropriate supply chain strategies so that the framework users (VAN supply chain managers) can 
capitalize on benefits of being lean and those of being agile. These appropriate supply chain strategies were 
established based on a recommending approach rather than a prescriptive approach. This means that appropriate 
supply chain strategies are recommended to each route as two or three appropriate options from which supply 
chain professionals in different provinces can decide from. The supply chain strategies were selected 
counterbalancing orientation towards efficiency (lean) and responsiveness (agile).  
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Figure 3.1: The schematic tree that underpins the product categorization framework  
3.2 The preliminary product categorization framework proposal and analysis 
Based on the input-output categorization process which the product categorization framework takes, an 
overarching process/flow followed by the preliminary product categorization framework which can be used to 
describe the usage of the framework is given in Figure 3.2. 
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Figure 3.2: Overarching process flow of the product categorization framework 
The schematic tree philosophy, described in the preceding section, was used to examine preexisting requisites 
and conditions (using the medicine schedules bundles from the product portfolio and the PDCL2 product 
attributes taxonomy) and recommend appropriate supply chain strategies to be employed. The product 
categorization framework is presented in Table 3.1.                      
Input 
Product 
categorization 
Output 
Determine sourcing plans and replenishment plans 
for the product categories based on the 
recommended supply chain strategies’ profile and 
respective decoupling points. 
Use demand plan product portfolio which 
describe the Essential Medicine List (EML). 
Bundle the pharmaceutical products based on 
their medicine schedules: S0-S4 & S5-S8. 
Product attributes: 
Determine thresholds between gradations of the 
PDCL2 product attributes. 
Employ the decision tree logic on the medicine 
schedules bundles based the PDCL2 product 
attributes. 
Supply chain strategies: 
To each route of the PDCL2 decision tree, 
determine the appropriate supply chain strategy 
coupled with the corresponding decoupling 
point. 
Employ the decision-making philosophy in 
determining the appropriate supply chain 
strategies. 
Special cases index: 
Reconsider selected supply chain strategies 
based on the special cases index. Enabling environment: 
Levers of the VAN 
design especially the 
informed push model; 
supplier collaboration 
constraints; and the 
NDoH public healthcare 
pharmaceutical supply 
chain regulations, ethics 
and code of conduct 
1 
2 
3 
4 
5 
6 
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Table 3.1: The product categorization framework 
 
The PDCL2 product attributes taxonomy 
Supply chain strategies taxonomy 
Product Demand 
Cost to 
SC Leadtime Lifecycle 
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Supply chain strategies Decoupling points 
1.  X  X  X  X  X  Fast or Agile strategy Supply to forecast or Supply to need/stock 
2.  X  X  X  X   X Efficient or Agile strategy Supply to forecast/need or Supply to need/stock  
3.  X  X  X   X X  Efficient or Fast or Agile strategy Supply to forecast/need or Supply to forecast or Supply to need/stock 
4.  X  X  X   X  X Efficient or Agile strategy Supply to forecast/need or Supply to need/stock 
5.  X  X   X X  X  Fast or Agile or Flexible strategy Supply to forecast or Supply to need/stock or Design-supply to need 
6.  X  X   X X   X Efficient or Agile or Flexible strategy Supply to forecast/need or Supply to need/stock or Design-supply to need 
7.  X  X   X  X X  Fast or Agile strategy Supply to forecast or Supply to need/stock 
8.  X  X   X  X  X Efficient or Agile strategy Supply to forecast/need or Supply to need/stock 
9.  X   X X  X  X  Efficient or Agile strategy Supply to forecast/need or Supply to need/stock 
10.  X   X X  X   X Continuous-flow or Efficient strategy Supply to stock or Supply to forecast/need 
11.  X   X X   X X  Efficient or Fast or Agile strategy Supply to forecast/need or Supply to forecast or Supply to need/stock 
12.  X   X X   X  X Continuous-flow or Efficient or Agile Supply to stock or Supply to forecast/need or Supply to need/stock 
13.  X   X  X X  X  Continuous-flow or Efficient or Fast Supply to stock or Supply to forecast/need or Supply to forecast  
14.  X   X  X X   X Continuous-flow or Efficient strategy Supply to stock or Supply to forecast/need 
15.  X   X  X  X X  Efficient or Fast or Agile strategy Supply to forecast/need or Supply to forecast or Supply to need/stock 
16.  X   X  X  X  X Continuous-flow or Efficient or Fast Supply to stock or Supply to forecast/need or Supply to forecast  
17.   X X  X  X  X  Fast or Custom-configured or Agile Supply to forecast or Configurable to need or Supply to need/stock 
18.   X X  X  X   X Fast or Agile or Flexible strategy Supply to forecast or Supply to need/stock or Design-supply to need 
19.   X X  X   X X  Fast or Custom-configured or Agile Supply to forecast or Configurable to need or Supply to need/stock 
20.   X X  X   X  X Efficient or Agile or Flexible strategy Supply to forecast/need or Supply to need/stock or Design-supply to need 
21.   X X   X X  X  Fast or Custom-configured or Flexible Supply to forecast or Configurable to need or Design-supply to need 
22.   X X   X X   X Fast or Custom-configured or Agile Supply to forecast or Configurable to need or Supply to need/stock 
23.   X X   X  X X  Fast or Custom-configured or Flexible Supply to forecast or Configurable to need or Design-supply to need 
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The PDCL2 product attributes taxonomy 
Supply chain strategies taxonomy 
Product Demand 
Cost to 
SC Leadtime Lifecycle 
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Supply chain strategies Decoupling points 
24.   X X   X  X  X Fast or Custom-configured or Agile Supply to forecast or Configurable to need or Supply to need/stock 
25.   X  X X  X  X  Efficient or Fast or Agile strategy Supply to forecast/need or Supply to forecast or Supply to need/stock 
26.   X  X X  X   X Efficient or Fast or Custom-configured Supply to forecast/need or Supply to forecast or Configurable to need 
27.   X  X X   X X  Efficient or Fast or Flexible strategy Supply to forecast/need or Supply to forecast or Design-supply to need 
28.   X  X X   X  X Efficient or Fast or Custom-configured Supply to forecast/need or Supply to forecast or Configurable to need 
29.   X  X  X X  X  Continuous-flow or Efficient or Fast Supply to stock or Supply to forecast/need or Supply to forecast  
30.   X  X  X X   X Continuous-flow or Efficient Supply to stock or Supply to forecast/need  
31.   X  X  X  X X  Continuous-flow or Efficient or Fast Supply to stock or Supply to forecast/need or Supply to forecast  
32.   X  X  X  X  X Continuous-flow or Efficient Supply to stock or Supply to forecast/need 
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In the use of the product categorization framework, the users have to be cognizant of various special conditions 
which may affect both medicine schedules bundles (S0-S4; and S5-S8) and may necessitate a slightly different 
view of the framework. These recommendations will aid in realigning supply chain strategy selection together 
with their decoupling points. These conditions and recommendations are indexed in Table 3.2. 
Table 3.2: Product categorization framework special cases index 
Condition Recommendation 
Are the pharmaceuticals seasonal? Opt for elements of supply chain strategies oriented towards efficiency when out of 
season and towards responsiveness when in season.  
Are the pharmaceutical products 
personalized medicine? 
Opt for the elements of the custom-configured supply chain strategy. 
Are the pharmaceutical products vaccines? Opt for a cold chain using a leagile (lean + agile) approach. Make use of elements 
of both strategies oriented towards efficiency and responsiveness.   
Are the pharmaceutical products epidemic 
medicine? 
Opt to orient towards the responsive strategies especially either agile and/or flexible 
supply chain strategies. 
Are the pharmaceutical products chronic 
medication? 
Opt for supply chain strategies oriented towards efficiency. 
Does the facility to which the products are 
being delivered have low storage capacity 
(though it is easily accessible)?  
Maintain the supply chain profile of the selected supply chain strategy. Check 
applicability of direct delivery as compared to the depot system. 
Is the facility to which the products are being 
delivered easily accessible and its storage 
capacity is high? 
Maintain the supply chain profile of the selected supply chain strategy. Check 
applicability of direct delivery as compared to the depot system. 
Is facility to which the products are being 
delivered not easily accessible and its 
storage capacity is low? 
Buffer the supply chain profile of the selected supply chain strategy using the nearest 
facility with better capacity.  
Is facility to which the products are being 
delivered not easily accessible, though the 
storage capacity is high? 
Opt for supply chain strategies with supply to stock/need/forecast decoupling points. 
Check applicability of the depot system as compared to direct delivery. 
*In all other circumstances not specified, stick to the provisions of the product categorization framework. 
A demonstration of the decision-making philosophy in the product categorization framework is given in the 
succeeding discussion. 
3.2.1 Demonstration of the decision-making philosophy 
It would be tedious to provide the decision approach for each of the 32 routes of the product categorization 
framework, therefore, for the sake of demonstrating the decision-making approach to the reader, building on 
the schematic tree, two representative routes will be chosen. The intention is to demonstrate the synthesis 
involved in the decision-making approach/philosophy hence Route 1 and Route 32 will be discussed.  
❖ Route 1:  
If the medicine schedules bundle: S0-S4, which is mostly high-volume products; with better ease of access; 
and a maximum repeat limit of six months as previously established, has pharmaceuticals that have a volatile 
demand then there is need to supply to stock or supply to need or at least supply to forecast to buffer the 
demand in times of uncertainties. Furthermore, since the cost to the supply chain in Route 1 is expensive then 
there is need to orient the supply chain towards efficiency (lean) to cut out costs and wastes. However, since 
the lead time is short and the life cycle is temporal, it calls for agility in responding to need with rapid 
replenishment to curb the risk of obsolescence due to the shortness of the lifecycle. Hence, the advantages of 
orienting the supply towards responsiveness (agility) are also needed facilitated by cooperation with key 
partners to anticipate capacity requirements. It is deemed necessary to make minimum order sizes based on 
the end patients’ replenishment needs in order to cut down on cots to the supply chain and short time from 
order to market/PHCFs. Therefore, such an instance/pipeline with the conditions given in Route 1 can benefit 
from being leagile (both lean and agile). Thus, medicine schedules bundle: S0-S4, under these conditions, is 
recommended to use a fast or agile strategy with supply to forecast or supply to need/stock decoupling points 
respectively. 
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❖ Route 32 
Under the medicine schedules bundle: S5-S8, which is mostly low-volume products; extensively regulated 
access; and dosage repeats that can exceed six months as previously established, if the demand is stable, cost 
is affordable to the supply chain and lead time is long, then there is need to opt for supply chain strategies 
oriented towards efficiency since there is ease of prediction/forecasting and mitigate the long time from order 
to the facilities. The order cycle can be oriented towards a fixed cycle or a collection schedule and it is 
recommended to make the resource utilization rate high or very high since the condition within Route 32 is 
that the cost to the supply chain is affordable and therefore is permissible. Moreover, since the lifecycle is 
lasting, then it is feasible to make use of high level of inventory to optimize supply efficiency. It is not highly 
necessary to orient such a supply pipeline towards responsiveness but rather towards efficiency. A supply to 
stock or a supply to forecast/need decoupling point is useful in such circumstances, corresponding to a 
continuous-flow or efficient strategy respectively. 
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Appendix E: SME input analysis 
questionnaire 
A google form was used to present the semi-structured interview and SMEs were informed that they 
were regarded as experts in public healthcare and/or supply chain management and/or the Visibility 
Analytics Network (VAN) strategy. As such, they were kindly requested to give their input on the 
preliminary product categorization framework developed, to which a pre-reading document, 
presented in Appendix D, was provided prior to the assessment. The assessment first assessed the 
design requirements established and employed in the development of the product categorization 
framework and subsequently, the construct of the framework itself was assessed.  
The responses were ranked from strongly agree to strongly disagree, so it was requested that SMEs 
provide the extent to which they agree with the questions posed. The assessment was postulated to 
take about 8 minutes. 
Please provide your name and surname: 
 
Please provide a brief description of your professional background and experience: 
 
Please provide your frequently used email address for follow-up on responses provided: 
 
FUNCTIONAL REQUIREMENTS [F]: Parameters 
These are the parameters by which the framework provides a clear mechanism for categorizing 
products according to their attributes. Products should be categorized according to the established 
PDCL2 product attributes classification. PDCL2 = Product; Demand; Cost to the supply chain; Lead 
time to deliver; and Life cycle. 
1. Do you think the established PDCL2 product attributes taxonomy is a clear mechanism for 
categorizing pharmaceutical products according to their attributes? 
Strongly agree Agree Neutral Disagree Strongly disagree 
O O O O O 
If you disagreed, please kindly provide some more information explaining why: 
 
Stellenbosch University https://scholar.sun.ac.za
 Page | 159  
 
2. Do you think the product attributes can be practically used to categorize pharmaceuticals 
effectively and efficiently? 
Strongly agree Agree Neutral Disagree Strongly disagree 
O O O O O 
If you disagreed, please kindly provide some more information explaining why: 
 
3. Do you think the recommended approach for defining thresholds between the binary gradations for 
provinces in the South African public healthcare is reasonable? 
Strongly agree Agree Neutral Disagree Strongly disagree 
O O O O O 
If you disagreed, please kindly provide some more information explaining why: 
 
USER REQUIREMENTS [U]: Outputs 
The framework must support supply planning decisions at different operational levels e.g. the national 
and provincial levels, by recommending an appropriate supply chain strategy for each pharmaceutical 
product. Each supply chain strategy, contextualized to the VAN strategy, should dictate an 
appropriate sourcing plan and replenishment plan based on its affiliated decoupling point. 
The framework must also provide a decision-making approach in special cases e.g. vaccine supply or 
delivery site restrictions and limited storage capacity. The framework’s output, which identifies as 
output of a supply plan, should be usable as input to a distribution plan. The employed supply chain 
strategies framework, based on Perez (2013), consists of: continuous-flow; efficient; fast; custom-
configured; agile; and flexible supply chain strategies. 
4. Do you think the supply chain strategies employed, based on Perez (2013), i.e: continuous-flow; 
efficient; fast; custom-configured; agile; and flexible supply chain strategies, are appropriate? 
Strongly agree Agree Neutral Disagree Strongly disagree 
O O O O O 
If you disagreed, please kindly provide some more information explaining why: 
 
5. Do you think these supply chain strategies coupled with their respective decoupling points can be 
used effectively in a VAN-enabled public healthcare supply chain? 
Strongly agree Agree Neutral Disagree Strongly disagree 
O O O O O 
Stellenbosch University https://scholar.sun.ac.za
 Page | 160  
 
If you disagreed, please kindly provide some more information explaining why: 
 
6. Do you think the interpolated meanings ascribed from the generic decoupling points are reasonable 
for an informed push model and public healthcare service supply planning? 
Strongly agree Agree Neutral Disagree Strongly disagree 
O O O O O 
If you disagreed, please kindly provide some more information explaining why: 
 
7. Can the recommended supply chain strategies for each pharmaceutical product support supply 
planning decisions at different operational levels e.g. the national and provincial levels? 
Strongly agree Agree Neutral Disagree Strongly disagree 
O O O O O 
If you disagreed, please kindly provide some more information explaining why: 
 
DESIGN RESTRICTIONS [R]: Inputs 
The pharmaceuticals restricted to the demand plan product portfolio which describe the Essential 
Medicine List (EML) should be used as input to the supply plan product categorization framework. 
If products are bundled based on their inherent characteristics, the medicine schedules bundles S0-S4 
and S5-S8 should be used. 
8. Do you think the bundling up of pharmaceutical products based on their schedules, the first bundle 
being S0-S4 and the second being S5-S8, is reasonable?  
Strongly agree Agree Neutral Disagree Strongly disagree 
O O O O O 
If you disagreed, please kindly provide some more information explaining why: 
 
9. Do you think the use of these two medicine schedules bundles to describe the two gradations of 
the 'product' attribute in the PDCL2 product attributes taxonomy is reasonable?  
Strongly agree Agree Neutral Disagree Strongly disagree 
O O O O O 
If you disagreed, please kindly provide some more information explaining why: 
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BOUNDARY CONDITIONS [B]: Controls 
The framework’s output, in the form of recommendations for managing the public healthcare 
pharmaceutical supply chain, must align with the principles that underpin the Visibility and Analytics 
Network strategy, most importantly the concept of informed push. The framework’s output, in the 
form of recommendations for determining supply planning’s sourcing and replenishment plans, must 
contribute to determination of supplier collaboration constraints (contracts and tenders) within the 
funding limitations. The framework’s output, in the form of recommendations for managing the 
public healthcare pharmaceutical supply chain, must align with the principles that underpin the South 
African Constitution. 
10. Do you agree with the boundary conditions which define the product categorization framework 
design’s preferred solution space?  
Strongly agree Agree Neutral Disagree Strongly disagree 
O O O O O 
If you disagreed, please kindly provide some more information explaining why: 
 
ATTENTION POINTS [A]: Enablers 
The framework’s recommendation for managing supply chain strategies should ideally incorporate 
the direct delivery and depot system that are already operational in the South African public 
healthcare pharmaceutical supply chain. 
11. Do you agree with the acknowledging of the direct delivery and depot system attention points?  
Strongly agree Agree Neutral Disagree Strongly disagree 
O O O O O 
If you disagreed, please kindly provide some more information explaining why: 
 
THE PRODUCT CATEGORIZATION FRAMEWORK 
The design requirements are synthesized to develop the product categorization framework, based on 
the systems engineering input-output transformation process. The product categorization framework 
entails the organization of pharmaceutical products into categories according to shared attributes (the 
PDCL2 product attributes) which influence the selection of an appropriate supply chain strategy and 
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associated decoupling point. The framework aims to enhance sustainable availability and access to 
medicines in the public healthcare.  
12. Do you think the logic that governs the decision tree which underpins the product categorization 
framework is appropriate?   
Strongly agree Agree Neutral Disagree Strongly disagree 
O O O O O 
If you disagreed, please kindly provide some more information explaining why: 
 
13. Do you think 'the product categorization framework special cases index' is useful in aiding 
framework decision-making under stated special cases?  
Strongly agree Agree Neutral Disagree Strongly disagree 
O O O O O 
If you disagreed, please kindly provide some more information explaining why: 
 
14. Do you think the decision-making philosophy employed in the product categorization framework 
is reasonable?  
Strongly agree Agree Neutral Disagree Strongly disagree 
O O O O O 
If you disagreed, please kindly provide some more information explaining why: 
 
15. Do you think the incorporation of the product categorization framework in the context of the VAN 
strategy for the South African public healthcare pharmaceutical supply chain is beneficial?  
Strongly agree Agree Neutral Disagree Strongly disagree 
O O O O O 
If you disagreed, please kindly provide some more information explaining why: 
 
16. To what extent do you agree that the product categorization framework can be used to categorize 
pharmaceuticals to enhance sustainable availability of medicines in a public healthcare 
pharmaceutical supply chain?  
Strongly agree Agree Neutral Disagree Strongly disagree 
O O O O O 
If you disagreed, please kindly provide some more information explaining why: 
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17. Are there any comments/additions/subtractions to the construct of the framework that you would 
like to make? 
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Appendix F: Product categorization 
framework—Case study application 
By: Newton Mapowo 
Foreword 
This document serves as a fact sheet with data that details the description of pharmaceutical products for use within the 
PDCL2 product attributes taxonomy, the Product Categorization framework as a whole and the Product Categorization 
framework special cases index. This information will be used to conduct a case study in conjunction with the pre-read 
framework document. The case study shall follow the overarching process flow of the Product Categorization framework 
as given in Figure 3.2 (page 14) of the pre-read document. The aim of the case study is to show the operability and 
applicability of the Product Categorization framework, hence three pharmaceutical products with distinct and different 
behaviour in the public healthcare pharmaceutical supply chain will be chosen as examples for demonstration. In the use 
of the PDCL2 product attributes taxonomy, data for the product attributes e.g. cost to the supply chain data; lifecycle data; 
lead time data etc was not readily available and could not be used at the time of the case study. Hence, hypothetical 
description of the product attributes was established (informed by the public healthcare Master Procurement Catalogue 
(MPC)) which enable participants to determine the thresholds for gradations of these attributes e.g. stable vs volatile; 
expensive vs affordable etc based on the said hypothetical but practicable descriptions. Hypothetical but practicable 
descriptions were also given for the facilities to which the medicine can be supplied. These descriptions give an overview 
of the pre-existing conditions or characteristics of the selected pharmaceuticals and facilities before the Product 
Categorization framework can be applied to test operability and applicability.  
Pharmaceutical drugs employed in the case study 
Three medicines were selected for the purpose of the case study, namely: Dolutegravir 50mg x 30 tablets; Vaccine: 
Influenza (inactivated) injection (0.5ml prefilled syringe antigenicity); and Alprostadil, 0.5mg/ml, 1ml injection. These 
medicines can give a clearer view of the operability and applicability of the Product Categorization framework as one is 
a chronic (ARV) medicine, the other is a vaccine (seasonal) medicine, and the other is a specialized psychotic medicine 
thus they have distinct and different behaviour in the public healthcare pharmaceutical supply chain. The distinction 
between the gradations of the product attributes can be distinguished as provided in Table 2.1 (page 6) of the pre-read 
document. A more entailing description/dataset of the selected medicines together with their characteristics within the 
PDCL2 product attributes taxonomy is given in the succeeding sections. 
1.1 ‘Product’ attribute 
Dolutegravir 50mg x 30 tablets is part of the Essential Medicine List (EML) in the MPC from the medicine schedules 
bundle S0-S4 (standard). It falls under the ARV therapeutic category and is administered in the form of tablets.  
Vaccine: Influenza (inactivated) injection (0.5ml prefilled syringe antigenicity) is also part of the EML from the medicine 
schedules bundle S0-S4 (standard). It falls under the vaccines therapeutic category and is administered in the form of an 
injection. 
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Alprostadil, 0.5mg/ml, 1ml injection is part of the EML from the medicine schedules S5-S8 (special). It falls under the 
psychiatric agents therapeutic group and is administered in the form of an injection.  
 1.2 ‘Demand’ attribute  
Volatility which entails the variation in product demand over a period of time can be determined using the standard 
deviation calculation. Standard deviation is the degree to which the volume varies from the average (mean) over the given 
period of time. Variability of the products can be determined using the variance which depicts measure of the dispersion 
of the data (volume) around the mean.  
❖ If the monthly demand in volume together with percentage monthly volume change of the Dolutegravir 50mg x 30 
tablets is as given below: 
 
Month January February March April May June 
Demand volume (units) 60 000  65 000 63 000 61 000 64 000 62 000 
% monthly change  8.33% -3.08% -3.17% 4.92% -3.13% 
Using Excel formulae, the monthly standard deviation is 5.48% which represents the monthly volatility of the 
Dolutegravir 50mg x 30 tablets and the variance is 0.30% which represents the variability of the Dolutegravir 
50mg x 30 tablets.  
❖ If the monthly demand in volume together with percentage monthly volume change of the Vaccine: Influenza 
(inactivated) injection (0.5ml prefilled syringe antigenicity) is as given below: 
Month January February March April May June 
Demand volume (units) 1500 3000 2000 6000 13000 17000 
% monthly change  100.00% -33.33% 200.00% 116.67% 30.77% 
Using Excel formulae, the monthly standard deviation is 88.56% which represents the monthly volatility of the 
Vaccine: Influenza (inactivated) injection (0.5ml prefilled syringe antigenicity) and the variance is 78.43% which 
represents the variability of the Vaccine: Influenza (inactivated) injection (0.5ml prefilled syringe antigenicity). 
❖ If the monthly demand in volume together with percentage monthly volume change of the Alprostadil, 0.5mg/ml, 
1ml injection is as given below: 
Month January February March April May June 
Demand volume (units) 500 510 570 500 550 550 
% monthly change  2.00% 11.76% -12.28% 10.00% 0.00% 
Using Excel formulae, the monthly standard deviation is 9.58% which represents the monthly volatility of the 
Alprostadil, 0.5mg/ml, 1ml injection and the variance is 0.92% which represents the variability of the Alprostadil, 
0.5mg/ml, 1ml injection. 
 
1.3 ‘Cost to the supply chain’ attribute 
Order line values, frequency of order lines and order line weights can be used to determine between expensive and 
affordable cost based on the procurement cost, holding cost, obsolescence cost and distribution cost. An order line is a 
part of an order on a bill which can be made up of one item or multiples of an item. The order line weight represents the 
number of order line items due for dispatch. 
NB: The distribution cost quoted excludes the transport cost. 
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❖ In the procurement catalogue, if the price/unit is R60 with 15% price VAT being R9; minimum order quantity (MOQ) 
being 150 units; holding cost/unit = R2.10 at a facility; obsolescence cost/unit= R66; distribution cost/unit=R3 of the 
Dolutegravir 50mg x 30 tablets and the stated cost/MOQ compared to the expected performance benchmarked to the 
best practices of ISO 13485 is as given below: 
 
 Procurement 
cost/MOQ 
Distribution 
cost/MOQ 
Holding 
cost/MOQ 
Obsolescence 
cost/MOQ=Total cost 
Currently R9000 R450 R315 R9 900 
Expected performance benchmarked 
to the best practices of ISO 13485 
R9 000 R400 R300 R9700 
❖ In the procurement catalogue, if the price/unit is R50 with 15% price VAT being R7.50; minimum order quantity 
(MOQ) being 100 units; holding cost/unit = R3 at a facility; obsolescence cost/unit= R58; distribution cost/unit=R5 
of the Vaccine: Influenza (inactivated) injection (0.5ml prefilled syringe antigenicity) and the stated cost/MOQ 
compared to the expected performance benchmarked to the best practices of ISO 13485 is as given below: 
 
 Procurement 
cost/MOQ 
Distribution 
cost/MOQ 
Holding 
cost/MOQ 
Obsolescence 
cost/MOQ = Total cost 
Currently R5 000 R500 R300 R5 800 
Expected performance benchmarked 
to the best practices of ISO 13485 
R5 000 R480 R300 R5 780 
❖ In the procurement catalogue, if the price/unit is R7 000 with 15% price VAT being R1 050; minimum order quantity 
(MOQ) being 10 units; holding cost/unit = R2 at a facility; obsolescence cost/unit= R7 005; distribution cost/unit=R3 
of the Alprostadil, 0.5mg/ml, 1ml injection and the stated cost/MOQ compared to the expected performance 
benchmarked to the best practices of ISO 13485 is as given below. 
 
 Procurement 
cost/MOQ 
Distribution 
cost/MOQ 
Holding 
cost/MOQ 
Obsolescence 
cost/MOQ = Total cost 
Currently R70 000 R30 R20 R70 050 
Expected performance benchmarked 
to the best practices of ISO 13485 
R60 000 R25 R15 R60 040 
1.4 ‘Lead time to deliver’ attribute 
Pharmaceutical products that cannot be sourced nor replenished rapidly based on the supply cycle time, supply takt time 
and time service levels can constitute the long lead time, while the opposite is true for a short lead time. The Master 
Procurement Catalogue (MPC) usually provides the lead times to deliver for each product based on tenders, contracts and 
distribution plans. Therefore, each pharmaceutical product can be benchmarked against the median (quantity lying at the 
midpoint of a frequency distribution values) lead time of the rest of the products in the MPC. 
❖ Consider that the Dolutegravir 50mg x 30 tablets has a lead time to deliver of 21 days and the median lead time of 
the rest of the products in the MPC is 14 days. 
❖ Consider that the Vaccine: Influenza (inactivated) injection (0.5ml prefilled syringe antigenicity) has a lead time of 
7 days and the median lead time of the rest of the products in the MPC is 14 days. 
❖ Consider that the Alprostadil, 0.5mg/ml, 1ml injection has a lead time to deliver of 10 days and the median lead time 
of the rest of the products in the MPC is 14 days. 
 
1.5 ‘Lifecycle’ attribute 
Products that require a short end-to-end pipeline, rapid time to market and have short shelf life and life time can be 
considered to have a temporal life cycle, with the opposite being true for a lasting life cycle. 
❖ Consider that the Dolutegravir 50mg x 30 tablets has an expiry date (lifetime) of 24 months from manufacture date 
and does not require a short end-to-end pipeline and rapid time to market.  
❖ Consider that the Vaccine: Influenza (inactivated) injection (0.5ml prefilled syringe antigenicity) has a shelf life of 
12 months at 2 - 8°C and would require a short end-to-end pipeline and rapid time to market. 
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❖ Consider that the Alprostadil, 0.5mg/ml, 1ml injection has a shelf life of 12 months and would not require a short 
end-to-end pipeline and rapid time to market. 
 
Please indicate the gradations of the described medicines as per the PDCL2 product attributes taxonomy using an (x). 
 
 
Medicine 
Product Demand Cost to supply chain Lead time Lifecycle 
S0-S4 S5-S8 Volatile Stable Expensive  Affordable Short Long Temporal Lasting 
Dolutegravir 50mg x 30 
tablets 
          
Vaccine: Influenza 
(inactivated) injection 
(0.5ml prefilled syringe 
antigenicity) 
          
Alprostadil, 0.5mg/ml, 
1ml injection 
          
After determining the gradations of the PDCL2 product attributes taxonomy, follow the overarching process flow of the 
Product Categorization framework as given in Figure 3.2 (page 14) of the pre-read document. Examine the supply chain 
profile recommended for each respective route of the medicines in question. 
 
The conditions at the facilities to which the medicines are to be supplied are: 
❖ Facility A: A district hospital with low storage capacity (though it is easily accessible). 
❖ Facility B: A district hospital with high capacity and easily accessible. 
❖ Facility C: A remote clinic not easily accessible, though the storage capacity is high. 
❖ Facility D: A remote clinic not easily accessible and the storage capacity is low. 
Questions: 
3. Do you think the use of the Product categorization Framework and its tools is robust and sustainable for the 
South African public healthcare pharmaceutical supply chain in the context of the VAN supply planning? 
Strongly Agree Agree Neutral  Disagree Strongly Disagree 
     
4. Do you think the use of the Product categorization Framework and its tools is beneficial in enhancing sustainable 
availability of medicines in the South African public healthcare pharmaceutical supply chain in the context of 
the VAN supply planning? 
Strongly Agree Agree Neutral  Disagree Strongly Disagree 
     
 
 
 
Participant’s name: ……………………………………………………………………  Date:..…/……/…  
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